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Introduction, aim and scope of thesis 
	
	







o Idiosyncratic drug-induced liver injury remains a major problem in drug discovery, 
safety assesment and clinical practice 
o Host factors, including immune system activation, play an increasingly recognized role 
in the etiology of idiosyncratic drug-induced liver injury 
o In this thesis, we asses hepatocyte proinflammatory TNFα signaling mechanistically 
and in applied in vitro testing systems 
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Idiosyncratic drug-induced liver injury (DILI) remains one of the major challenges in drug 
development, safety assessment and clinical practice. Increased mechanistic 
understanding and improved toxicity testing strategies are essential to predict DILI hazard 
for specific compounds and patients. In this thesis, we studied possible mechanisms of 
drug-induced liver toxicity, with a focus on TNFα signaling in hepatocytes. Furthermore, we 
developed a model to monitor drug-induced cellular stress responses and predicted DILI 
hazard of a set of compounds. Here we will introduce the liver, liver specific immune 
regulation and the role of TNFα in DILI. Furthermore, we will discuss how immune signaling 
currently can be assessed with recent liver toxicity models. 
 
The liver 
The liver is an essential organ in maintaining both metabolic and immunological 
homeostasis in the human body. In agreement with this diverse function, the structure of 
the liver is very complex. The functional units of the liver are the hexagonal liver lobules 
(Fig. 1A). Oxygen-rich blood enters the liver via the hepatic artery. Nutrient-rich blood 
arrives via the portal vein, together with the bile duct situated in the portal triad. The portal 
vein collects blood from both spleen and intestines, making the blood rich in antigens from 
food, toxic substances and pathogens. Blood from the artery and vein mix inside the 
sinusoids, and is relatively long exposed to and detoxified by hepatocytes. Due to this 
process the amount of specific molecules, including metabolites, toxic substances and 
oxygen, differ over the length of the sinusoidal axis (Fig. 1C). Among other mechanisms, 
oxygen responsive transcription factors mediate the expression of specific metabolic 
enzymes, thereby regulating the metabolic zonation. Toxicity is most seen in the periportal 
region, warranting a different classification of liver regions in periportal, pericentral and 
midlobular zones (Fig. 1A)1,2.  
In general, fenestral liver sinusoidal cells (LSEC) surrounded by stellate cells line 
up between the sinusoid and the hepatocytes, forming the perisinusoidal space (Fig. 1B). 
The diffusion rate into the perisinusoidal space is regulated by the hepatic stellate cells, 
which also store the body’s main stock of vitamin A3. To facilitate the clearance and efficient 
transport of specific molecules to the hepatocytes, LSECs are specialized in endocytosis 
and transcytosis4. The liver resident macrophages, Kupffer cells (KCs), travel through the 
liver sinusoids and eliminate large antigens. Together with a relatively large fraction of 
natural killer cells they form the resident liver immune cell population. When activated, the 
Kupffer cells can differentiate into the proinflammatory M1 phenotype or in the alternative 
M2 phenotype. In contrast to the M2 phenotype, M1 macrophages express high 
proinflammatory cytokines, including TNFα, and low IL10 levels. This differentiation process 
depends on the activation signal, the environmental context and the genetic background of 
the individual5. However, not only the immune cells affect inflammation. Also the stellate 
and LSEC have recognized immunomodulatory functions, which have recently been 
reviewed3,6. Hepatocytes are the most abundant cell type in the liver, responsible for most 
metabolic and homeostatic functions. These parenchymal cells produce bile to aid in the 
digestion, which is transported via the bile canaliculi and collected in bile ducts, lined by 
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cholangiocytes. Logically, liver failure is in the end always a result of malfunctioning 
hepatocytes. However, the interplay between hepatocytes and non-parenchymal cell 




Fig 1. Structure of the liver A) The liver lobule is schematically represented. The different zones are indicated. The 
portal triad consists of a bile duct, hepatic vein and a hepatic artery. The bile duct and bile canaliculi are indicated in 
green, the arterial blood flow is indicated in red and the venal blood flow in blue. B) An enlargement of A, the sinusoid 
lined with hepatocytes. The different cell types are indicated and the bile canaliculi are visualized in green. C) Part of 
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Drug-induced liver injury and inflammatory stress 
Drug-induced hepatotoxicity is a common adverse drug reaction, raising problems in drug 
development and clinical practice. The unpredictability and low incidence of idiosyncratic 
DILI (iDILI) makes it difficult to detect in expensive clinical trials. Furthermore, the risk on 
iDILI for few patients leads to black box warnings and inhibits prescription of an, for most 
patients, effective drug therapy.  
 
Fig 2. Etiology of idiosyncratic drug-induced liver injury in hepatocytes Different processes and factors are 
represented in this overview of risk factors for idiosyncratic drug-induced liver injury. Host factors are visualized in the 
inner circle and cellular processes in hepatocytes in the outer circle. Going clockwise, drug exposure will lead to 
cellular stress. Host factors as pharmacokinetics and drug metabolisms can diverge between individuals due to 
genetic variability, and thereby modulate DILI liability in a specific individual. Upon cellular stress, immune activation 
and mitochondrial impairment can be regulated by genetic and environmental factors (including concurrent therapies 
and diseases). Combined, these processes can lead to apoptosis or necrosis of the hepatocyte. The liver can restore 
after some injury, called clinical adaptation. However, in some cases hepatotoxicity levels will increase and lead to 
liver failure. In this thesis, cytokine secretion is mimicked by manual addition of proinflammatory cytokines.   
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To predict which drugs are going to induce iDILI in specific people from in vitro and in vivo 
studies, we have to understand the interaction of drug properties with both general and 
drug-induced cellular signaling. One reoccurring host factor involved in DILI is activation of 
the innate immune system (Fig. 2).  
In vivo, mimicking viral or bacterial infection, for example by poly I:C or LPS 
exposure, concurrent to exposure of a non-toxic dose of certain drugs lead to synergistically 
increased hepatotoxicity7–10. For trovafloxacin toxicity upon LPS exposure, this synergism 
has been proven to be dependent on TNF receptor and TNFα expression11. TNFα is a 
proinflammatory cytokine, in the liver mainly produced by KCs or invading immune cells 
upon damage or inflammation-induced chemotaxis. Drug-induced signaling in the KC itself 
can lead to proinflammatory cytokine production, including TNFα production12. However, 
recognition of pathogen-associated molecular patterns or damage-associated molecular 
patterns secreted by drug-treated liver cells can evoke KC activation and cytokine 
production as well. TNFα produced by KCs can signal to hepatocytes via the TNF receptor 
(TNFR). Healthy hepatocytes are not sensitive for TNFα-induced cell death. However, 
excessive and long-term hepatic inflammation characterized by chronic high levels of TNFα, 
can lead to massive hepatotoxicity and is associated with several hepatic diseases13. 
Currently, it is unknown how TNFα stimulation together with drug exposure can induce 
synergistic cell death in hepatocytes in only few individuals. The role of MAP kinases and 
cellular stress response pathways have been studied before14–16. In chapter 5 we detect 
several known regulators of the TNF receptor signaling pathway that play important roles in 
drug/TNFα synergistic apoptosis. 
 
TNFα signaling pathway 
Upon binding of TNFα, trimerization of the TNFR leads to recruitment of the TNFR signaling 
complex. The TNFR signaling complex activates the IKK kinase complex and subsequently 
induces NF-κB transcriptional activity. NF-κB activation protects hepatocytes from TNFα-
induced cytotoxicity17. Besides NF-κB activation, also MAPK pathways JNK and p38 are 
activated via the TNFR signaling complex. The induction of antioxidant proteins via NF-κB 
transcriptional activity prevents prolonged JNK activation and cell death18,19. Furthermore, 
NF-κB induces general anti-apoptotic protein expression and these dissociate the TNFR 
signaling complex. Without NF-κB activity induced anti-apoptotic protein expression, the 
TNFR signaling complex progresses into complex II, inducing cytotoxicity17. TNFα-induced 
apoptosis is characterized by caspase 8 activation and necroptosis by RIPK3 activation. 
The exact TNFα-induced cell death mechanisms have recently been reviewed by Brenner 
et al.20.  
The NF-κB transcription factor family consists of 5 proteins: RelA (p65), RelB, 
cREL, p50/p105 and p52/p100. All proteins share a Rel homology domain for dimerization 
and DNA binding, but only RelA, RelB and cREL have a c-terminal transactivation domain. 
RelB forms the core of the non-canonical NF-κB pathway. This pathway is activated by 
cytokines including CD40 and lymphotoxin beta, and characterized by stabilization of NIK 
(MAP3K14) and IKKα activity21. Precursors p105 and p100 need processing, before taking 
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their active DNA binding form. For p100, this process is regulated by phosphorylation by 
active IKKα, while p105 is constantly processed. Several different homo- and hetero-dimers 
can be formed. Homodimers from p50 and p52 are thought to be transcriptionally inactive 
and inhibit active NF-κB dimer DNA binding by competitive binding22. The best-
characterized NF-κB signaling heterodimer is RelA-p50, which becomes transcriptionally 
active upon TNFα signaling. 
Upon TNFα stimulation, NF-κB translocates into the nucleus and transcribes its 
own inhibitors IκBα and A20 (TNFAIP3). By this negative feedback loop NF-κB itself 
regulates its oscillatory nuclear phenotype upon stimulation23,24. The reason behind and 
physiological result of this oscillatory phenotype is largely unknown. Currently, the major 
belief is that this oscillatory phenotype translates into differentially regulated functional gene 
transcription patterns25–27. However, the function of this relation between transcription factor 
oscillations and subsequent transcription profiles is not well understood. NF-κB regulates 
the transcription of around 600 target genes. These genes are expressed in many 
functional and three temporally differentiated groups; early, middle and late28. NF-κB target 
genes function in many cellular processes, including inflammation, cell growth, cell cycle 
and cell survival29. In chapter 3 and chapter 4, we studied the regulation of TNFα-induced 
NF-κB nuclear oscillation and the effect of drug exposure on its target gene induction, 
respectively.  
 
Drug toxicity hepatocyte models 
Cell death of hepatocytes is the hallmark feature of hepatotoxicity. Therefore, most hepatic 
drug safety testing systems include hepatocytes at the core of their model. However, as all 
models do, they limit the complexity of the human liver. For example, metabolic zonation of 
the liver forms a factor not often reflected. Interactions between hepatocytes themselves, 
the different cell types and the extracellular matrix and blood stream is another feature that 
is difficult to capture in in vitro models. The attempts to reflect all these layers of complexity 
in 3D models and artificial liver ‘on a chip’ approaches have been extensively reviewed 
elsewhere2,30.  
Reliable co-culture, or co-exposure methods of hepatocytes and KCs have 
recently been developed and increase the predictive power for specific immune related 
toxicants12,31,32. However, the need for glucocorticoids to stabilize CYP expression in the 
hepatocytes has a clear anti-inflammatory effect on the Kuppfer cell31. Besides some of 
these technical drawbacks, co-culture models using donor-specific Kupffer cells and 
hepatocytes can add major mechanistic insight into the role of the innate immune system 
and the individual susceptibility of certain patients herein. Furthermore, once optimized and 
validated, they can form a testing platform for early detection of possible immune-related 
DILI. Trovafloxacin-mediated toxicity can be detected in Kupffer cell and hepatocyte co-
culture31. Interestingly, this increased hepatocyte toxicity can also be detected in a 
hepatocyte only model with the manual addition of TNFα33. 
Separate hepatocyte and immune cell culture methods can provide mechanistic 
understanding, distinguishing between hepatocyte and Kupffer cell signaling in the process 
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of developing DILI. For example, IκBα phosphorylation in 7 day old mice is regulated by 
TRAF2 expression in liver and spleen, but not in lung and muscle34. Also, ketoconazole 
treatment did lead to NF-κB pathway activation in HepG2 cells, but not in the macrophage 
cell line THP-135. These studies underline that the specific cellular background is of major 
importance for mechanistic research and the design of fit-for-purpose studies, especially 
concerning immune signaling.  
The golden standard in hepatocyte toxicity screening are currently freshly isolated 
primary human hepatocytes (PHH). The variety of PHH models, including 3D culture, co-
culture and precision-cut liver slices have been reviewed extensively by Godoy et al.1. As 
fresh hepatocytes are difficult to use due to their unpredictable availability, cryopreservation 
is a good alternative. None of the hepatocyte cell lines HepG2, Upcyte or HepaRG, are 
currently able to mimic PHHs in metabolic enzyme expression and activity36. However, also 
PHHs quickly lose their metabolic capacity upon isolation and culturing37. Adjusting the 
culture methods to low glucose medium, 3D cultures or co-culture systems can improve 
hepatic function1.  
One of the difficulties in using PHHs for hepatocyte inflammatory signaling 
research is the possible contamination with a minority of immune cells during the isolation 
procedure. These few immune cells can excrete massive amounts of signaling mediators 
when activated, shifting the homeostasis within a “hepatocyte only” culture massively. 
However, even pure hepatocyte cultures seem to activate an inflammatory disease 
phenotype37. In addition, the preferred PHH culture medium includes a glucocorticoid, both 
inducer of CYP enzyme expression and NF-κB inhibitor. This could inhibit the inflammatory 
response in primary hepatocyte cultures. However, as hormones as hydrocortisone are also 
present in the human body, it is unknown if these additives result in non-physiological 
behavior of hepatocytes. A final consideration on the use of PHH cultures is that donor 
differences can be major. As some donors are not plateable, we probably underestimate 
the donor variability based upon available data1,38. 
For early toxicity screening in the pharmaceutical industry, the HepG2 cell line is 
still routinely used. HepG2 cells have retained many hepatocyte specific functions, but have 
in general very low expression of drug and bile transporter proteins and phase I metabolic 
enzymes. These levels can differ between separate batches39. Simple endpoint studies 
performed with the same clone at different companies showed stark differences in outcome, 
although HepG2 cells are generally viewed as a very stable cell line40. Both in PHHs and 
HepG2 cells co-exposure of drug and cytokines, including TNFα, can lead to synergistic 
apoptosis33,41. To increase the fit-for-purpose applicability of the easy-to-handle HepG2 cell 
in toxicity screening, their relation to primary human hepatocytes should be more precisely 
determined. Including cytokines as co-stimulation would also increase usability. In chapter 
6, we predicted DILI liabilities of marketed compounds using a HepG2 stress response 




Aim and scope of this thesis 
In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells 
can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a 
synergistically increased sensitivity for TNFα-induced apoptosis42. We have also shown that 
synergistic drug/ TNFα-induced cell death is dependent on concurrent cellular stress 
responses16,43. To monitor these stress responses, we have developed a fluorescent 
protein stress response reporter platform, feasible for high throughput approaches44. In this 
thesis, we focus on an in vitro HepG2 cell model, in which the addition of TNFα reflects 
inflammatory stress (Fig.2). We studied inflammatory signaling, both for use in improved in 
vitro testing approaches and to gain mechanistic understanding of TNFα-induced signaling 
in hepatocytes. In Chapter 2, the current knowledge on the role of TNFα signaling during 
iDILI and several models in which TNFα signaling could be reflected in vitro have been 
summarized. In Chapter 3, we used a siRNA-mediated screen approach, detecting 
regulators of the TNFα-induced RelA oscillatory phenotype. We studied their regulation of 
A20 expression and synergistic drug/TNFα cytotoxicity. We revealed CDK12 (CRK7) as a 
novel regulator of TNFα-induced RelA oscillation, A20 expression and synergism. In 
Chapter 4, we systematically evaluated drug effects on TNFα-induced NF-κB nuclear 
translocation and target gene induction. Interestingly, drug exposure by itself induced TNFα 
target gene induction, including RelB, CCL5 and IL8. RelB expression showed strong 
correlation with oxidative stress response induction and was independent of RelA 
transcriptional activity. The drug-induced expression of chemokines CCL5 and IL8 was 
RelA-dependent, but also negatively regulated by NF-κB family members RelB and cRel. In 
Chapter 5, we studied known TNF receptor pathway components and their role in 
carbamazepine/TNFα synergism towards apoptosis by a siRNA-mediated approach, 
revealing 24 candidate genes. We determined 3 out of 124 drugs that acted synergistically 
towards apoptosis with TNFα (colchicine, griseofulvin and valproic acid). The candidate 
genes consisted of both specific and generic drug/TNFα synergism regulators (e.g. A20, 
PHF5A) The effect of candidate gene knockdowns on drug/TNFα synergism were 
correlated with drug-induced cellular stress responses. We detected two separate branches 
of the oxidative stress and DNA damage response pathways that were strongly correlated 
with certain candidate gene effects. For Chapter 6, a HepG2 cell line harboring a 
fluorescent TNFα responsive ICAM1 gene has been generated and used as part of the 
stress response fluorescent reporter platform to predict DILI potential in humans. We 
predicted DILI hazard with a sensitivity of 60% and a specificity of 75%. Finally, in Chapter 
7 I summarize all findings in this thesis and provide an overview and future perspective on 
the implications of these studies. 
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Chapter 2 
o Idiosyncratic drug-induced liver injury, including diclofenac-induced liver injury, 
is associated with derailed proinflamamtory (TNFα) signaling 
o In vitro testing methods for liver toxicity liability do not often include immune-related 
tests 




For new candidate drugs the liability towards idiosyncratic drug-induced liver injury 
(DILI) remains difficult to predict from preclinical in vitro and in vivo studies. The 
DILI-inducing potential of a drug is generally only detected in the clinical testing 
phase or once on the market. In the last decades, research on the interaction of host 
factors and drug-dependent processes has produced valuable insights into the 
mechanisms of idiosyncratic DILI. Continued development of screening methods and 
prediction models has led to improved prediction of DILI. However, the immune 
component involved in many drug-induced toxicities is notoriously difficult to 
characterize. In this review, we will discuss the interaction of innate inflammatory 
signaling, thereby focusing on TNFα-signaling, and drug-induced processes leading 
to hepatotoxicity. In general, there is a clear interaction between liver-resident innate 
immune cells and hepatocytes during the onset of DILI. At a mechanistic, 
intracellular level this involves interaction of drug-induced general adaptive stress 
response activation and cytokine-mediated signaling, and this interaction provides a 
basis for hepatocyte cytotoxicity. Understanding of these complex mechanistic 
interactions in human idiosyncratic DILI will allow development of tailored in vitro 
screening approaches. 
	
Keywords: diclofenac, drug-induced liver injury, hepatotoxicity, in vitro models, LPS, stress 
response, TNFα 
	
Introduction to drug-induced liver injury 
Drug-induced Liver Injury (DILI) is a complex condition with difficult diagnosis and 
prediction, since it displays a broad array of symptoms that resemble other chronic or acute 
liver conditions. In the most recent prospective studies in the US and Iceland, it was found 
that around 11 % of all idiosyncratic acute liver failure cases were caused by drugs45 and 
that the incidence rate of DILI in the general population was 19.1 cases per 100.000 
inhabitants per year46. Currently, DILI remains one of the major concerns in both clinical 
and drug developmental practices. Since 1997, no drugs were approved by the Food and 
Drug Administration that had to be withdrawn later due to DILI, indicating raised awareness 
and improved detection of DILI in clinical trials47. However, to prevent the enormous costs 
that accompany clinical studies for a drug with DILI-potential, the emphasis of current 
research lies with better prediction of DILI from animal and in vitro approaches.  
Over the last decade, the over-simplified classification of DILI in intrinsic and 
idiosyncratic has developed in a less distinctive mapping. Acetaminophen, the classical 
example of intrinsic DILI, causes most acute liver failure cases in the U.S. in a 
predominantly dose-dependent fashion. However, the prognosis for acetaminophen-toxicity 
outcome seems to be dose-independent, pointing to general mechanisms starting to act the 
moment the threshold for toxicity is reached48. Furthermore, a study in the U.S. published in 
2005 found around 8% of the cases developed by therapeutic dosing, suggesting 
mechanistic explanations that are rather associated with idiosyncratic DILI49. In this review, 
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idiosyncratic mechanisms of toxicity are defined as involvement of specific host factors 
interacting with the drug, its metabolites or responses induced by either, inducing 
hepatotoxicity in a few individuals. 
Even when excluding acetaminophen hospitalization, drug treatment remains the 
major cause for acute liver failure in the U.S. Of these drug-induced cases of hepatotoxicity, 
most are considered idiosyncratic being relatively dose-independent and occurring in a yet 
unpredictable minority of people treated with the culprit drugs50. Risk factors include a high 
daily dose and drug-characteristics, including lipophilicity and metabolism, but more 
importantly the personal environmental factors like age, pre-existing liver disease, obesity 
and ethnicity, all of which has been summarized in a recent review51. One reoccurring and 
very interesting risk factor is gender. Although on first glance the ratio of DILI incidence 
might seem similar for females and males, the percentage of patients that develops severe 
acute liver failure is significantly higher for women45,51. Furthermore, genetic association 
studies have identified various defined HLA allele variants that are associated with 
idiosyncratic DILI52,53. The fact that gender background and in particular the HLA genotype 
are regarded as risk factors for DILI might point towards the immune system as one of the 
causal factors of DILI, since there are differences in immune reactions between males and 
females in various fields, as described in this review54. Observations that strengthen this 
hypothesis are that autoimmune hepatitis upon drug exposure is rarely seen in males and 
that the injury pattern of DILI seems to change in females above 60 compared to younger 
women. However, gender has not been detected as a risk factor for DILI in all studies and 
has been suggested to be drug-specific51. In mice, both halothane-induced injury and Con 
A-induced liver injury were more severe in females. This was regulated by sex hormones 
inducing an altered cytokine response and thereby modulating the subsequent adaptive 
immune response55,56. Taken all together, these data suggest that the modulation of the 
immune system is a critical factor in developing DILI and progression to severe 
hepatotoxicity. 
This review will discuss the role of the innate immune system in the onset and 
progress of idiosyncratic DILI. The central part of this review will discuss the archetypical 
idiosyncratic drug diclofenac and the involvement of lipopolysaccharide (LPS) and tumor 
necrosis factor alpha (TNFα) signaling in DILI. This will be followed by an overview of the 
progress in the application of in vitro cell systems for the mechanistic understanding and 
prediction of DILI that involve innate immune signaling. 
 
Liver immunology and drug-induced inflammatory response 
Immune system in the liver  
The liver has a unique immunological build-up; this is essential since it is situated at the 
portal vein with continuous exposure to gut-derived antigens and cellular debris from the 
blood stream. As peripheral immunotolerant organ, it contains a population of liver resident 
immune cells as Kupffer cells (KC), natural killer cells (NK) and dendritic cells (DC) that are 
skewed to inducing tolerance, therefore called tolerogenic6,57. Together with hepatocytes, 
liver sinusoidal endothelial cells (LSEC) and stellate cells, they form an environment in 
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which it is difficult to invoke a tissue-damaging pro-inflammatory response (see for 
details3,4,58). To sustain this tolerogenic environment, antigen presentation, clonal deletion 
of antigen-specific T cells and the shift from a Th2 favored response to a Th1 response 
must be strictly controlled by direct and paracrine signaling (reviewed by59,60). Many of the 
signaling pathways in the liver that lead to tolerance mechanisms are altered and skewed 
towards inflammation by exposure to DILI drugs. One of the main pathways leading to 
activation of the innate immune system is the Toll-like receptor 4 (TLR4) signaling pathway, 
driven by LPS, an endotoxin from the outer membrane of Gram-negative bacteria.  
 
Toll-like receptor signaling in drug-induced liver injury 
In the liver, TLR4 is expressed on KCs, hepatic DCs, NK cells, LSECs, stellate cells and 
hepatocytes61,62. Signaling by TLR4 is remarkably inhibited in a healthy liver, sustaining the 
tolerogenic environment. The continuous low exposure to LPS is essential for maintaining 
tolerance by affecting KCs and LSECs in a negative feedback-loop regulating expression of 
several proteins, miRNAs and IL10 signaling61,63–65. Indeed, administering low doses of LPS 
protects against D-galactosamine/LPS and ischemia-reperfusion liver injury by 
downregulation of TLR4-mediated signaling66,67. Interestingly, in many chronic liver 
diseases and obesity, often named risk factors for DILI, TLR4 signaling is upregulated61,68. 
Furthermore, it is generally accepted that antimicrobials are amongst the drugs that most 
frequently and severely induce DILI69. Altered TLR signaling might explain this DILI 
inducing potential. Antimicrobials change the gut microbiome, thereby increasing the 
transfer of commensal bacteria across the gut epithelium. Translocated bacteria can induce 
inflammatory responses via TLR signaling70. Increased LPS translocation together with 
inflammatory signaling from the gut environment could lead to increased pro-inflammatory 
signaling in the liver. Combined, these data suggest a role of the gut environment and 
altered LPS leakage to the liver as an possible mechanism in the development of 
antimicrobial-induced hepatotoxicity. Finally, TLR4 signaling is involved in the several 
rodent models that show a synergistic increase in hepatotoxicity with co-exposure of LPS 
with well-known DILI drugs including diclofenac, trovafloxacin, sulindac, and 
chlorpromazine. In these studies, LPS was administered at different time points ranging 
from 2 hours pre-treatment to 16 hours post-treatment8,9,71–73. It would be relevant to 
determine whether repeated low-dose LPS exposure would be able to prevent 
hepatotoxicity of the combined LPS/drug exposures in these animal models, as it would 
confirm the importance of inhibition of TLR4 signaling in the protection against aberrant 
inflammation during drug exposure.  
The function and signaling cascades induced by TLR4 activation in the different 
cell types in the liver are much debated. Here, we will discuss the effects of LPS on KCs 
and hepatocytes. TLR4 signaling in other liver cell types is reviewed in these 
publications62,65. Via the portal vein the blood enters the liver, rich in nutrients, metabolites 
and potentially toxic compounds. From the hepatic artery, oxygen rich blood joins this 
mixture. This blood mixture contains many antigens that have to be cleared from the blood 
before it enters the systemic circulation. The clearance of gut-derived LPS from the blood 
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stream in non-inflammatory conditions depends on both hepatocytes and KCs74,75 and is 
based on receptor-dependent endocytosis and phagocytosis, respectively76. In 
hepatocytes, binding of LPS and subsequent clearance seems to induce TLR4-induced 
signaling, although not via the classical MyD88 pathway but via p38/MAPK signaling77. 
Furthermore, TLR4-mediated LPS clearance activates adaptive stress response pathways, 
like p62-regulated autophagy and the Nrf2-mediated oxidative stress response78. Non-
endocytosed LPS on the other hand, signals via the classical TLR signaling pathway, 
inducing NF-κB and MAPK signaling. This leads to low levels of pro-inflammatory cytokine 
production and induction of metabolic activity by regulation of CYP enzyme expression in 
hepatocytes79,80. The induction of CYP enzyme expression upon TLR4 stimulation 
contradicts many studies that show an LPS-induced decrease of CYP enzyme expression 
and metabolic activity, both in vivo and in vitro81,82. This downregulation of CYP enzymes 
seems to be dependent on LPS-induced cytokine production, amongst which are IL6 and 
TNFα. The function of down-regulated CYP enzyme expression during inflammation is 
currently much debated, as is discussed in this review83. 
In a recent elegant mouse study, cell-type specific TLR4 knockouts were used in a 
model for sepsis. TLR4 expression in the myeloid cell population (KCs and neutrophils) is 
essential for efficient bacterial clearance and determines the level of inflammation and liver 
injury in a high bacterial load model. However, in a low bacterial load model, TLR4 
expression on the hepatocytes was essential to prevent LPS-induced pro-inflammatory 
cytokine production by KCs and hepatotoxicity, measured by increased plasma ALT 
levels84. This data shows that both hepatocyte and KC TLR4 signaling is essential in 
clearance of LPS during sepsis. This might suggest a role for hepatocytes in LPS clearance 
in healthy, steady state liver as well.  
LPS is not the only TLR4 ligand present upon hepatocyte dysfunction. High 
mobility group box-1 (HMBG1), a nuclear factor that is released from sites of hepatocellular 
stress, activates TLR4 signaling in the liver85. HMBG1 resembles LPS in that pre-
conditioning with repeated low levels of HMBG1 can protect against ischemia/reperfusion 
(I/R)-induced liver injury86. TLR4-dependency of different cell type specific knockouts in 
mice was studied in a model of sterile inflammation caused by I/R as well. In this model, no 
LPS was present to stimulate TLR4 signaling.. However, liver injury was dependent on 
effective TLR4 signaling in both KC and hepatocyte population, while the TLR4 signaling in 
the DC population was protective based on IL10 secretion. Furthermore, TLR4 signaling in 
hepatocytes was necessary for neutrophil recruitment, and via c-Jun N-terminal kinase 
(JNK) activation also for the excretion of HMBG187. Altogether these studies point to a 
cooperative mechanism of activated KCs and hepatocytes in the induction of both 
endotoxin-mediated and sterile inflammation, which could lead to liver injury. 
Activated KCs upregulate the secretion of pro-inflammatory cytokines (TNFα, IL1), 
eicosanoids, and chemokines (e.g. CCL3, CCL4, CCL5, and CCL12)88–90. While the exact 
effect of individually upregulated cytokines and chemokines on different liver cell types and 
hepatotoxicity is unclear, they are involved in pro-inflammatory processes as for example 
recruitment of immune cells, the acute phase response and increased cell death, as well as 
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in repair processes91. For instance TNFα, as is described below, induces hepatocyte 
apoptosis when drugs interfere with TNFα-induced cytoprotective signaling. In contrast, the 
expression of the TNFα receptor and in some cases TNFα itself, are required for liver 
regeneration92. 
 
Drug-induced idiosyncratic liver injury 
Diclofenac-induced idiosyncratic liver injury 
An archetypical drug that can induce idiosyncratic DILI is the common anti-inflammatory 
painkiller diclofenac. Currently, diclofenac is still prescribed and even sold without 
prescription in the UK and Europe as nonsteroidal anti-inflammatory drug (NSAID). Among 
the class of NSAIDs, diclofenac is one of the drugs with the highest risk on DILI93. In the 
most recent study on NSAID-induced liver injury with data from the Drug-Induced Liver 
Injury Network in the U.S., diclofenac-induced liver injury was most frequent and most 
severe94. Diclofenac-induced liver injury is in most cases hepatocellular, and in a minority of 
the cases cholestatic95. This correlates with the genetic variants found in drug excretion 
proteins, for example in MRP2 (ABCC2), that were associated with diclofenac-induced liver 
injury96. Latency times range from 6 days to a year, and the disease can present itself in 
some cases with an immunoallergic phenotype with symptoms like fever and rash or with 
the production of autoimmune antibodies94,95. 
 
Diclofenac metabolism  
Diclofenac-induced liver injury is slightly dose dependent, the risk increasing by daily doses 
higher than 150 mg97. The major diclofenac metabolites are 4′-OH diclofenac mainly formed 
by CYP2C9, 5-OH diclofenac by CYP3A4, CYP2C8 and CYP2C19 and diclofenac acyl-
glucuronide mainly by UGT2B793. Of these, especially the reactive 5-OH diclofenac-derived 
quinone imines and acyl-glucuronides are implicated in diclofenac-induced toxicity. Genetic 
variants of UGT2B7 and CYP2C8 have been correlated to diclofenac-induced 
hepatotoxicity96. Furthermore, comparison between metabolically active HepaRG cells and 
metabolically less active HepG2 cells showed less toxicity in the HepaRG cells, pointing 
towards protection by increased detoxifying processes in HepaRG cells. In both cell types, 
TNFα stimulation was able to increase cytotoxicity98. Interestingly, the exposure of HepG2 
cells to 4′-OH diclofenac in combination with TNFα showed increased cytotoxicity, in 
contrast to the 5-OH diclofenac and diclofenac acyl-glucuronide99. In conclusion, it is still 
unclear if drug metabolism actually protects against synergistic induction of cell death or 
plays a role in the induction of TNFα-induced cytotoxicity. 
 
Diclofenac-induced immune activation 
Autoimmune and immunoallergic presentation of diclofenac-induced liver injury as stated 
earlier, points to the activation of the adaptive immune system. The question how drug-
induced activation of the immune response can occur has inspired many theories, including 
the hapten hypothesis, the p-i concept, and the danger hypothesis. The hapten hypothesis 
states that a drug on itself cannot induce an adaptive immune response unless covalently 
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bound to proteins in plasma or liver. Diclofenac-derived acyl-glucuronides can form 
metabolite adducts by binding to target proteins. These adducts can act as haptens and are 
mainly found in liver zone 3.In diclofenac-induced liver injury, zone 3 necrosis is a common 
finding94, although the relation between these two observation is unclear. Indeed, acyl-
glucuronide and acyl-glucuronide-induced adduct formation are found in human plasma in 
diclofenac users100,101. However, antibodies recognizing diclofenac-induced protein adducts 
were detected in the majority of the diclofenac users that did not demonstrate DILI102. This 
finding implicates adaptive immune responses towards acyl-glucuronide-induced protein 
adducts are not the single causative reason for idiosyncratic diclofenac-induced liver injury. 
The p-i concept states that drugs by itself can be recognized as antigens by specific T cell 
clones. Although shown for several drugs including carbamazepine103, this seems not to be 
the case for diclofenac104. The danger hypothesis claims that absence of danger-related 
signals will lead to tolerance by hapten-presentation. The danger signals necessary to 
mount a full immune response are the interaction of the processed hapten with the T-cell 
receptor, an independent interaction of co-receptor with a stimulatory molecule and 
polarizing cytokine signaling105. The timing and ratio of danger signals likely determines the 
activation profile of cytotoxic T cells106. Since polymorphisms in the tolerance-inducing 
cytokines IL10 and IL4 were associated with diclofenac hepatotoxicity 102 and activated 
cytotoxic CD8+ T cells seems to be mainly involved in DILI107, it is likely this theory is at 
least partially applicable on diclofenac-induced liver injury.  
 
Animal models of inflammation in drug-induced liver injury 
Immune-dependent latency in a mice model  
An interesting observation in clinical studies is the apparent clinical adaptation of patients 
with mild DILI under continuation of the drug. In these cases, patients that take the drug 
develop mildy abnormal liver function values. However, these abnormalities disappear while 
the patients continue taking the culprit drug. Very few of these patients progress towards 
severe DILI. This suggests that the cases of severe DILI have disturbed clinical adaptation 
processes, leading to severe hepatotoxicity59. A mouse model in which this adaptation 
process is reflected has been generated by Methusi et al., in which amodiaquine treatment 
in PD1-/- mice induced mild liver injury, resolving despite continuous treatment. However, 
co-treatment with CTLA4 antibody, blocking the tolerogenic signaling induced by CTLA4, 
induced severe liver injury108. Although CD8+ T cells were the most abundant in this model 
of severe injury, NK cells seem to play a more important role in the development of the mild 
injury upon treatment in PD1 knockout mice109. This points to a role for the innate immune 
system in the early processes in drug-induced liver injury. It would be interesting to see the 
effect of treatment with diclofenac or other idiosyncratic DILI drugs in this model. This mice 
model nicely shows the cumulative effect of several signaling cascades that is necessary to 
break the tolerance and develop severe liver injury instead of adaptation. However, how 





Animal models on the inflammatory response in diclofenac-induced liver injury 
The application of rodents to understand the mechanisms of immune-related mechanisms 
of diclofenac toxicity shows that small non-toxic doses of LPS can greatly enhance 
diclofenac-induced hepatotoxicity8,99. Although neutrophils are recruited and correlated to 
injury, they seem to play a minor causative role in the hepatotoxicity in LPS/diclofenac-
induced injury110. To mimic human treatment, Ramm et al. treated rats with very low doses 
of diclofenac for seven days. On the seventh day, a small non-toxic dose of LPS was 
administered. Significant toxicity of combined LPS/diclofenac treatment was seen 
compared to diclofenac or LPS treated rats. Glutathione depletion and drug metabolism 
were not enhance by LPS/diclofenac treatment compared to diclofenac treatment.However, 
combined diclofenac/LPS treatment induced upregulation of cellular stress responses, 
including the oxidative stress response, the NF-κB response and hypoxic stress response. 
Taken together with an upregulation of pro-inflammatory cytokines and danger-associated 
molecules, this could lead to the hepatotoxicity seen in diclofenac-induced liver injury99,111. 
Interestingly, the highest upregulation of stress responses and protein production of TNFα 
and HMGB1 was detected in the only two animals that died from co-treatment of LPS and 
diclofenac99.  
In vivo studies into other DILI-inducing drugs, trovafloxacin and sulindac, have 
showed the importance of TNFα-signaling in LPS/drug-induced liver injury. The 
replacement of LPS with TNFα showed a similar pattern of hepatic injury. In both cases, the 
increased hepatotoxicity was dependent on prolonged elevated plasma TNFα levels and 
altered TNFα-receptor (TNFR) signaling10,11. Moreover, the neutralizing TNFα antibody 
Etanercept clearly diminished LPS-induced trovafloxin- or sulindac-mediated liver injury in 
rodents9,72. However, in both human and mouse precision-cut liver slices, diclofenac 
downregulated LPS-induced TNFα production upon co-exposure112,113, contradicting the 
trovafloxin/sulindac research. What this downregulation of LPS-induced TNFα exactly 
means in the context of diclofenac-induced toxicity is not clear. 
 
Role of TNFα signaling in diclofenac-induced liver injury 
Upon LPS stimulation in the liver, TNFα is mainly produced by KCs and less by other liver 
resident cells114. In acetaminophen-induced liver injury in mice, the removal of KCs 
abolished the TLR4-dependent upregulation of TNFα, and led to significantly less liver 
injury115.However, it should be noticed that the removal of KCs and their role in 
acetaminophen-induced liver injury has revealed contradictory results, as described in this 
review116. Signaling by the pleiotropic cytokine TNFα regulates many processes in target 
cells, including proliferation, production of pro-inflammatory cytokines, cell death and cell 
survival. These contradictory processes are regulated by an intricate web of signaling 
proteins and post-translational modifications, leading to well-known key players as the 
transcription factors NF-κB, c-Jun, AP-1 and cell death modulators like RIP1, RIP3 and 
caspase-8. These complex signaling pathways leading to cell death or survival are quite 
recently discussed in this review by Brenner et al20, and the role of these pathways in 
inflammatory processes by Wallach117. In short, TNFα stimulation leads to conformational 
Drug-induced liver injury and TNFalpha signaling	
	 19	
changes of the TNFR, assembling an receptor signaling complex. This complex contains 
TAK1, a kinase that can activate MAPK signaling cascades including JNK, and the IKK 
complex. The IKK complex phosphorylates IκBα, the cytoplasmic inhibitor of NF-κB. Upon 
subsequent proteosomal breakdown of IκBα, NF-κB translocates into the nucleus and 
induces signaling. Maturation of the TNFR complex based on the status of RIP1 
ubiquitination can lead to formation of cell death complexes, inducingapoptosis, necrosis or 
necroptosis20.  
In in vitro cell culture models using HepG2 cells, primary human or rat 
hepatocytes, diclofenac synergizes with TNFα to induce apoptosis41,42. This synergism has 
been shown to be dependent on JNK activation, inhibition of NF-κB nuclear translocation 
and an activated mitochondrial apoptotic pathway42. In addition, diclofenac/TNFα-induced 
synergism has been shown to be increased by concomitant IFNγ exposure. This increased 
synergism is dependent on ERK-dependent STAT1 activation14. Activation of the 
endoplasmic reticulum (ER) stress response is essential for induction of diclofenac-
mediated TNFα-induced cytotoxicity. Expression of ER-stress response-related genes 
including transcription factor CHOP is enhanced upon diclofenac exposure alone in HepG2 
cells, primary human hepatocytes (PHH) and human precision-cut liver slices. Subsequent 
siRNA-mediated knockdown of CHOP and its upstream translational regulator EIF4A1 in 
HepG2 cells confirmed the role of ER-stress in TNFα-induced hepatotoxicity16.  
The role of the ER-stress response in different liver diseases has recently been 
reviewed118. In HepG2 cells, diclofenac-induced increase in intracellular calcium was 
increased by both TNFα and IFNγ, leading to activation of JNK and ERK and subsequent 
cytotoxicity15. Interestingly, ER-stress in HepG2 cells seems to induce ER-stress in THP-1 
macrophages via both soluble and insoluble factors. ER stress in macrophages leads to a 
reduction in pro-inflammatory cytokine secretion and is thereby providing a negative 
feedback loop for drug-induced inflammation119. Also trovafloxacin-mediated TNFα-induced 
cell-death was characterized by ERK activation and prolonged JNK activation. However, in 
this case activation of these signaling pathways was mediated by DNA replication 
stress33,120. Furthermore, oxidative stress and heat shock responses have been shown to 
interact with TLR4 and TNFα-induced signaling and NF-κB activation121. Several DILI-
inducing drugs that synergize with TNFα activate oxidative stress responses by 
themselves43. Inhibition or aberrant activation of these oxidative stress responses in HepG2 
cells by siRNA-mediated knockdown enhances or inhibits this TNFα-induced cytotoxicity, 
respectively16. Together, these data suggest that several drug-induced adaptive stress 
response pathways can interfere with TNFα-induced hepatotoxicity. 
 
Idiosyncratic drug-induced liver injury prediction by in vitro approaches 
It is clear that the cause of idiosyncratic DILI is in all cases multifactorial. Drug-specific 
responses make it difficult to predict the effect of novel drug-candidates on the many host 
factors involved in the development of DILI. However, using improved prediction models on 
clinical trial results led to majorly improved prediction of DILI hazard47. Currently used in 
	
	20	
vitro methods have been extensively reviewed1,122,123. In this review, we will focus on the 
incorporation of inflammatory signaling in in vitro models. 
DILI is characterized by massive hepatocyte cell death. Therefore, hepatocyte only 
models are much-used in the pharmaceutical industry to test for the hepatotoxic potential of 
novel compounds. For these models, PHHs are the golden standard, besides having some 
serious drawbacks in for example donor variability and low availability. The quite recently 
established hepatoma cell line HepaRG forms hepatocyte-like cells surrounded by biliary 
epithelial-like cells upon differentiation. This cell line is relatively easy to handle and shows 
enhanced metabolic capacity and hepatic transporter function, giving better prediction of 
especially drug-induced cholestasis124. Immortalized cell lines, for instance HepG2, are 
much used for their easy handling, high availability and stable phenotype. However, 
severely decreased drug-metabolism capacity makes this model less applicable in cases of 
drug metabolite-induced toxicity. Functionality and phenotypes of these cell lines for toxicity 
research have been frequently compared and the results are not conclusive125,126, 
introducing the pragmatic “fit for purpose” approach1,127,128. PHHs, HepaRG cells and 
HepG2 cells have all been shown to greatly improve their hepatocyte phenotype by 
sandwich culture or 3D culture, together with prolonged sustainability and the possibility of 
repeated dosing. However, high-throughput screening, especially with other than endpoint 
measurements, remains difficult with this culture method1, although some progress has 
been made (unpublished data;129). Mimicking activated liver immune cells in hepatocyte 
only cultures occurs mainly by manual addition of effector proteins or cytokines. This 
approach can be used in high-throughput screening methods and in prediction models 
(unpublished data;41,130). 
Co-culture models with non-parenchymal cell types in 2D and 3D systems greatly 
improve hepatocyte function and phenotype1. In 2D, KC and hepatocyte co-culture showed 
in general upregulated hepatocyte CYP enzyme expression and drug metabolism in 
hepatocytes, and increased KC cytokine production and concurrent hepatotoxicity12,31,32,35. 
 
Fig. 1. The applicability of experimental model systems for hepatotoxicity screening and understanding 
cytokine-induced hepatocyte toxicity Model systems used to detect immune signaling in human idiosyncratic drug-
induced liver injury are assessed, both on the reflection of the human immune response in the model system and the 
possibility to detect specific hepatocyte signaling on immune activation. All depicted cell model systems can be 
implemented with either cell lines or pri- mary cells. The models are evaluated on the complexity level of immune 
signaling that is possible, the hepatocyte phenotype, the donor variability, the possibility of hepatocyte-specific 
measurements, the possibility of genomic interference, the availability of the model for high-throughput approaches, 
the sustainability of the cell culture model over time, and the possibility of interfer- ence of the system (in, for instance, 
measuring or adding a specific cytokine). Specifically mentioned is the possibility to use fluorescent reporter cell lines 
in complex models as 3D models and cocultures of cell lines. The use of these fluorescent reporters is extensively 
reviewed in Wink et al. (2014); the use of these reporter cell lines confers the possibility to detect hepatocyte-specific 
immune signaling on the mentioned models, increasing model value for mechanistic and predictive toxicity research. 
LPS, lipopolysaccharide; PHHs, primary human hepatocytes. Color images available online at 
www.liebertpub.com/aivt 
  







Culture systems in which the proximity of KCs and hepatocytes can be controlled, as is the 
case in micropatterned culturing methods, have demonstrated an increased hepatocyte 
function compared to random co-culture1. Furthermore, it has been shown that the ratio of 
KCs to hepatocytes, cell-cell contact and the relative proximity between these cell types 
determine the functionality of hepatocytes131. However, to our best knowledge, no co-
exposure experiments with LPS and drugs have been performed in this model. However, 
co-culture of KCs with hepatocytes in a 3D culture model, shows that KC activation by LPS 
decreased the cytotoxicity threshold for trovafloxacin threefold compared to only 
trovafloxacin treatment132. Taken together, these co-culture models show promising results 
for the assessment of inflammatory stress in high throughput approaches. 
Another, more complex, multicellular approach eventually feasible for low/medium 
throughput purposes are human precision-cut liver slices. This model can show LPS-
induced synergistic cytotoxicity and can be used to classify hepatotoxicants, although it has 
to be further developed for screening purposes112,113,133. A general overview of the most-
used cell culture methods in toxicity screening and their applicability for the detection of 
inflammation-induced signaling and hepatotoxicity is displayed in figure 1. Advantages and 
disadvantages of each model are listed, clearly showing that these models have their own 
restricted values. The advantages and shortcomings of each model make serious 
consideration of the purpose of the screening or mechanistic study essential in choosing a 
fitting model system. Currently, the most exciting progress in model development in the 
idiosyncratic DILI research field is made with human-induced pluripotent stem cells. These 
cells can be developed into donor-specific hepatocytes, enabling the research on donor-
specific cells from DILI-susceptible donors1,134. Once the induction of stem cells into 
hepatocytes and especially in non-parenchymal cells is optimized, this model will 
revolutionize toxicity research.  
The models described above can be used not only for screening and prediction 
purposes, but also to gain mechanistic understanding. Fluorescent HepG2 reporter cell 
lines allow the quantitative, time-resolved detection of adaptive stress response activation 
on a single-cell basis135. These data, in combination with phosphoproteomics130, genomics 
approaches16, and co-culture system proteomics35 point towards the important role of 
adaptive stress responses interfering with cytokine-induced signaling. These insights in 
cytokine-induced toxicity from in vitro models might help unravel human DILI. They also 
show how immune/cytokine signaling is reflected, or lacks, in in vitro high throughput 
predictive models when compared to human and animal in vivo data.. 
 
Summary and future perspective 
Idiosyncratic DILI remains one of the most unpredictable adverse drug reactions, often 
leading to discontinuation of drug development or restricted use of effective drugs. In this 
review, the inflammatory signaling as a host factor that increases DILI potential has been 
discussed, highlighting the recent progress in this field. This with a main focus on the role of 
TNFα signaling, TLR4 signaling, and diclofenac. Taken together, these data suggest that 
drug-induced adaptive stress response pathways in hepatocytes and non-parenchymal 
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cells could sensitize cells to drug-independent host factors. It would explain the 
idiosyncratic nature of many drug-induced liver injury, since a critical amount of host factors 
would be involved in both drug-dependent and -independent cellular adaptive processes. 
The typically unpredictable length of latency time suggests that many processes are 
involved in the adaptive processes before the threshold is reached for induction of 
hepatotoxicity. Furthermore, the clinical adaptation of most of the mild DILI cases despite 
continuation of drug treatment implies inherent negative feedback signaling. Finally, 
understanding idiosyncratic DILI in human, together with the understanding of the potential 
and limitations of our in vitro screening approaches will lead to improved prediction of 
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Chapter 3 
o siRNA-mediated screening of TNFα-induced nuclear NF-κB oscillation identified 46 
regulators 
o Several of these regulators modulate A20 expression and drug/TNFα synergistic 
cytotoxicity 
o CDK12 is revealed as a novel modulator of TNFα-induced NF-κB oscillation, 
synergistic apoptosis signaling and A20 expression 
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NF-κB signaling is critical in normal homeostasis and disease progression. Tumor 
necrosis factor-alpha (TNFα) triggers nuclear oscillation of the dimeric transcription 
factor NF-kappaB (NF-κB). In the nucleus, NF-κB directs transcription of target genes 
involved in diverse biological programs and its own response inhibitors, 
IkappaBalpha (IκBα) and the ubiquitin-editing enzyme A20. To unravel the signaling 
programs that regulate the TNFα-induced NF-κB oscillatory response, we applied a 
live-cell imaging-based siRNA screen to identify individual kinases, (de)ubiquitinases 
and sumoylases that control the temporal NF-κB oscillatory response using liver 
HepG2 cells as a model. We identified 46 candidate genes that either positively or 
negatively regulate the oscillatory behavior of NF-κB. These include a majority of 
previous uncharacterized NF-κB regulators, for instance the kinases CDK12, ADCK2, 
TTK, MAPK4 and AATK, and (de)ubiquitinases USP8, FBXW5 and TRIM50. A 
characteristic delay in TNFα-induced NF-κB oscillation generally protected against 
TNFα-induced cytotoxicity in combination with drugs with established liability for 
hepatotoxicity. For several candidate regulators the cytotoxicity protection was 
associated with enhanced expression of A20, a negative regulator of TNFα-mediated 
apoptotic signaling. Depletion of the cellular stress-related kinase CDK12 delayed 
TNFα-induced NF-κB oscillation, which was concurrent to upregulation of TNFα-
induced A20 expression. Moreover, CDK12-depleted cells are partially protected 
against drug/TNFα-dependent cytotoxicity, suggesting a relationship between these 
effects of CDK12 knockdown. Overall the work provides a refined repository of TNFα 
signaling components that control the TNFα-induced spatio-temporal activity of NF-
κB and A20 expression. These signaling components may contribute to novel 
therapeutic strategies to modulate disease status involving TNFα-mediated NF-κB 
activation.  
 
Keywords: NF-κB signaling, RNAi screening, systems microscopy, apoptosis, CDK12, A20 
 
Introduction 
The dimeric transcription factor nuclear factor-κB (NF-κB) plays a central role in normal 
physiological homeostasis as well as disease onset and progression136,137. Transcriptionally 
active NF-κB is crucial in the host-pathogen response by inducing pro-inflammatory gene 
expression and thereby activating the innate and adaptive immune response138. In addition, 
erroneous regulation of NF-κB has been associated with disease states such as cancer, 
chronic inflammatory, autoimmune diseases and adverse drug reactions13,29. 
The best-characterized proinflammatory cytokine that induces NF-κB 
transcriptional activity is tumor necrosis factor-α (TNFα). Targeting TNFα-signaling with 
TNFα and TNF-receptor specific antibodies has become a regular therapy for NF-κB-
related inflammatory auto-immune diseases such as arthritis and psoriasis, but can also 
induce unexpected and remarkably severe side effects20,139. TNFα exerts pleiotropic effects 
upon effector cells, including cell survival or cell death. These effects are dependent on cell 
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type and homeostatic status of these cells20. The transcriptional activity of NF-κB seems 
crucial in prevention of TNFα-induced hepatocyte cell death, by inducing anti-apoptotic 
gene expression17. These anti-apoptotic NF-κB target genes block the progression of the 
initial TNF receptor complex to the so-called TNF receptor complex II. As TNF receptor 
complex II is formed this leads to cell death, including apoptosis20,140. Post-translational 
modification, including phosphorylation but specifically ubiquitination, are the most 
important regulators of signaling from both TNF receptor complexes141. Genetic mice and 
biochemical studies all underline the importance of the enigmatic ubiquitin-editing enzyme 
A20 (or TNFAIP3) in inflammatory and auto-immune diseases142,143. A20 exhibits E3 ligase, 
ubiquitin-binding and de-ubiquitinases (DUB) function and its expression is induced by NF-
κB transcriptional activity. Upon induction, A20 also inhibits NF-κB activation, functioning as 
a negative feedback loop. Furthermore, A20 activity forms a switch between NF-κB 
signaling and cell death complex formation by ubiquitination and deubiquitination of TNFR 
complex subunits142,144. 
The TNFα-induced signaling pathways that control the transcriptional activity of 
NF-κB have been well-studied. Recent gain- and loss-of-function screens based on NF-κB 
luciferase reporter constructs or fixed immunostaining of NF-κB, were performed using 
cDNA145, RNA-interference146–150, or miRNA screens151. While these screens unraveled 
many upstream regulators, these primarily focused on TNFα-induced NF-κB translocation 
or transcriptional activity on a specific time point, and the luciferase constructs determine 
one particular NF-κB target gene response. Since NF-κB has many target genes 
(http://www.bu.edu/nf-kb/gene-resources/target-genes) with very distinctive temporal 
patterns of activation152,153, the coverage of signaling modalities that modulate NF-κB 
signaling are likely incomplete.  
To avoid the specificities of a particular target gene and time point, we examined a 
general feature of NF-κB transcriptional activation: nuclear translocation. Nuclear 
translocation of NF-κB is a key characteristic of activation and has been linked to NF-κB 
induced target gene expression on single cell level27,154. Translocation detection has been 
previously used for screening purposes, however this was on fixed time points150. The 
nuclear translocation of NF-κB is an oscillatory response that is controlled by negative 
feedback mechanisms and varies between individual cells and different cell types24,155.This 
oscillatory phenotype might determine NF-κB target gene expression levels and kinetics25–
27. 
To discover novel regulators of critical NF-κB transcriptional activity in survival 
signaling pathways, we established an automated high-throughput assay to follow TNFα-
induced NF-κB oscillation over time156. We and others demonstrated that the anti-
inflammatory liver toxic drug diclofenac disturbed the cytokine-induced NF-κB nuclear 
oscillation and amplified the TNFα-induced cytotoxicity in liver cells42. Here, we used 
diclofenac to facilitate the RNAi-based discovery of novel positive and negative regulators 
of the TNFα-induced dynamics of the nuclear translocation of NF-κB subunit RelA. We then 
determined the role and mechanism of several of these regulators in the regulation of TNFα 
signaling and the onset of liver TNFα/drug-induced cytotoxicity. We identified, for the first 
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time, a key role for CDK12 in modulation of TNFα-induced A20 expression, NF-κB 
oscillation and cytotoxicity.  
 
Material and Methods 
Reagents and antibodies 
Human recombinant TNFα was acquired from R&D Systems (Abingdon, UK). Diclofenac 
sodium, carbamazepine, and the antibody against tubulin were from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). AnnexinV-Alexa633 and AnnexinV-Alexa561 were in house 
generated as previously described (20). The antibody against IκBα was from Cell Signaling 
(Bioké, Leiden, The Netherlands), A20 was from Santa Cruz (Tebu-Bio, Heerhugowaard, 
The Netherlands), UFD1L was from BD Transduction Laboratories (Breda, the 
Netherlands), caspase-8 was from Cell Signaling (Bioké, Leiden, The Netherlands) and 
cleaved-PARP was from BioLabs (Ipswich, UK). The bromo phenol blue lysis buffer was 
from Merck (Merck Millipore, Amsterdam, The Netherlands). 
 
Cell culture 
Human hepatoma HepG2 cells were obtained from American Type Culture Collection 
(clone HB-8065, ATCC, Wesel, Germany). HepG2 cells stably expressing GFP-p65 (NF-κB 
subunit RelA) were created by 400 µg/ml G418 selection upon pEGFP-C1-p65 transfection 
using Lipofectamine™ 2000 (Invitrogen, Breda, Netherlands). HepG2 BAC A20-GFP cells 
were generated by bacterial artificial chromosome (BAC) recombineering44,157. Upon 
validation of correct C-terminal integration of the GFP-cassette by PCR, the BAC-GFP 
construct was transfected using Lipofectamine™ 2000. Stable HepG2 BAC A20-GFP cells 
were obtained by 500 µg/ml G418 selection. For all experiments the cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine 
serum (FBS), 25 U/ml penicillin, and 25 µg/ml streptomycin between passages 5 and 25. 
 
RNA interference experiments 
Transient knockdowns of individual target genes were achieved using siGENOME 
SMARTpool siRNA reagents in the primary screen or single siRNA sequences in the 
secondary deconvolution screen (50 nM; Dharmacon GE Healthcare, Landsmeer, 
Netherlands) and other experiments. HepG2 cells were transfected using INTERFERin 
siRNA transfection reagent according to the manufacturer’s procedures (Polyplus 
transfection, Leusden, Netherlands) and medium was refreshed after 16 hours of 
incubation. The cells were used at 72 hours after siRNA transfection to achieve maximal 
knockdown before treatment. The negative controls used were mock transfection of 
INTERFERin without siRNA, siGENOME non-targeting pool #1 and siGFP, all from 
Dharmacon (GE Healthcare, Landsmeer, Netherlands). 
 
Exposures and live cell imaging of GFP-p65 and A20-GFP in HepG2 Cells 
Prior to imaging, nuclei were stained with 100 ng/ml Hoechst 33342 in complete DMEM for 
45 minutes or overnight. The cells were exposed to diclofenac 500 µM, carbamazepine 500 
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µM, or DMSO 0.2% for 8 hours. The cells were then challenged with human TNFα (10 
ng/ml) addition to the compound medium.The GFP-p65 nuclear translocation response 
upon 10 ng/ml human TNFα challenge was followed for a period of 6 hours by automated 
confocal imaging every 6 minutes (Nikon TiE2000, Nikon, Amstelveen, Netherlands). 
Quantification of the nuclear/cytoplasmic ratio of GFPp65 intensity in individual cells was 
performed using an algorithm for ImageJ 156. A20-GFP accumulation was measured in live 
cells using automated confocal imaging every hour (Nikon TiE2000, Nikon, Amstelveen, 
Netherlands). Quantitative analysis was performed with Cell Profiler version 2.1.1158 with an 
in house developed segmentation module159. Data analysis was performed with an in house 
developed data analysis package H5CellProfiler (Wink et al., manuscript in preparation) 
using R.  
 
Translocation response class definition and hit definition statistics 
For the primary screen, the amplitudes of the individual translocation response tracks were 
normalized to their intrinsic response maxima (=1) and minima (=0) to be able to compare 
the timing of the nuclear translocation events versus the plate average. For the secondary 
screen, non-normalized data were used. Four different classes were defined according to 
the type of nuclear p65 oscillation response: increased, no oscillation, decreased and 
different compared to the oscillation observed with control siRNA. Each class used a 
different set of five specific parameters (Fig. 1A). For each targeted gene, a Pearson's chi-
squared cumulative statistic was calculated from the set of five parameters of each class 
and p-values were obtained by comparing the value of the statistic to a chi-squared 
distribution. Targeted genes obtaining a p-value lower than or equal to 0.001 were 
considered as hits. 
 
Apoptosis measurements 
Apoptosis was determined by the live cell apoptosis assay previously described160. The 
relative Annexin V fluorescence intensity per image was quantified using Image Pro (Media 
Cybernetics, Bethesda, MD) and normalized to the number of nuclei. 
 
Western Blot 
Cells were harvested in sample buffer (6 times diluted bromophenol blue solution, with β-
mercaptoethanol). The samples were subjected to protein separation, blotted on 
Immobilon-P (Millipore, Amsterdam, The Netherlands). Phosphorylated IκBα was detected 
using the Tropix Western-Star kit™ (Applied Biosystems) following manufacturer’s protocol. 
For tubulin, A20, UFD1L and IκBα, the membranes were blocked for 1h at room 
temperature in milk powder 5% (w/v) in Tris-buffered saline/Tween 20 (TBS-T). Primary 
antibody incubation was done overnight at 4°C followed by incubation with cy5-labeled 
secondary or horseradish peroxidase-conjugated antibodies (Jackson Immunoresearch, 
Newmarket, UK) in 1% BSA in TBS-T for 1 h at room temperature. Protein signals were 
detected with ECL (GE Healthcare Diegem, Belgium) followed by film detection, by 
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visualization on the Typhoon 9400 imager (GE Healthcare, Diegem, Belgium), or by 
detection on an ImageQuant LAS 4000 (GE Healthcare, Diegem, Belgium). 
 
Statistical procedures 
All numerical results are expressed as mean ± standard error of the mean (SEM). Statistical 
significance was determined by GraphPad Prism/R using an unpaired t-test, * P≤0.05, ** 
P≤0.01, *** P≤0.001. Heatmap representations and hierarchical clustering (using Pearson 
correlation) were performed using the Multiple Experiment Viewer (MeV) software. For 
statistical analysis of the screen results, see above. 
 
Results 
NF-κB nuclear oscillation phenotype siRNA screening in HepG2 cells 
Stimulation with TNFα initiates oscillatory nuclear translocation of NF-κB in various cell 
types, including HepG2 cells42,155. We established HepG2 cells with GFP-tagged RelA to 
follow the dynamics of NF-κB using time-lapse confocal microscopy. TNFα stimulation 
induced transient nuclear translocation of RelA-GFP, followed by a dampened oscillation at 
defined time intervals. Under control conditions the translocation peaks at 30 minutes after 
TNFα stimulation, followed by a second and third peak at 150 and 270 minutes, 
respectively (Fig. 1A, top). The maximum oscillation response was seen at 10 ng/mL 
TNFα135. For unbiased hit detection we required the quantitative classification of the four 
oscillatory phenotypes: normal oscillation, increased oscillation, decreased oscillation and 
no oscillation. Normal oscillation was determined as the DMSO, mock-transfected control 
condition. The ubiquitin editing enzyme A20 (TNFAIP3) has a negative feedback on the 
activity of the IKK complex and suppresses NF-κB activation161. Knockdown of A20 slightly 
decreased the time-interval between oscillations, leading to faster oscillation (increased 
oscillation). In contrast, knockdown of well-known NF-κB inhibitor IκBα almost completely 
inhibits NF-κB oscillation (no oscillation). This inhibition was associated with enhanced 
levels of A20 expression (Fig. 1A, middle and Suppl. Fig. S1). Treatment of hepatocytes 
with the hepatotoxic drug diclofenac increases the susceptibility for TNFα-induced 
apoptosis41,42 and increases the time interval between NF-κB oscillation peaks (decreased 
oscillation) (Fig. 1A, bottom). We established a pipeline of automated image segmentation 
and GFP-RelA nuclear/cytoplasmic ratio quantification for all individual cells within one 
time-series, followed by extraction of 32 distinct oscillation features156. We classified the 
phenotypes based on the direction versus control for at least 5 oscillation features, e.g. 
number of peaks, time between peaks and amplitude of peaks (Fig. 1A). If more than 5 of 
the 32 measured oscillation features were distinct from control and the oscillation 
phenotype did not match any of the other categories, the response was marked as 
“different oscillation”.  
	 	




Fig. 1: NF-κB oscillation phenotype siRNA screening in HepG2 cells (A) Representative images of RelA-GFP 
translocation after TNFα (10 ng/mL) challenge in HepG2 cells by automated confocal microscopy. Insets: zooms of 
single cells with an average response in respect to the imaged population. The nuclear translocation events are 
marked by yellow boxes and the numbers indicate the time in minutes after TNFα exposure. The nuclear translocation 
track of each cell was quantified and normalized to its own highest nuclear-to-cytoplasmic ratio (value of 1) and its 
lowest ratio (0). The average response of the total cell population is presented in the middle panel. The features and 
their directions that define the response classes (different, increased, decreased and no oscillation) compared to 
control are shown in the panel to the right. (B) Flowchart of the siRNA screen. (C) Representation of the siRNA 
distribution between respective libraries in the primary screen compared to the final hit selection. Some candidate 
genes are represented in several libraries, as the TNFR/TLR library also contains kinases and (de)ubiquitinases. 
MAP3K14 and MAP3K8 are in both kinase and TNFR/TLR library, while CYLD is in both deubiquitinase and 
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Having established an automated system to track, segment and categorize the NF-κB 
oscillation pattern in individual cells, we used siRNA screening to identify genes that define 
the timely activity of the NF-κB response (Fig. 1B). We screened 779 kinases, 107 de-
ubiquitinases and sumoylases, 580 ubiquitin ligases and 123 players in the TNFR/TLR-
driven NF-κB response. We screened under control (DMSO) and 8 hr diclofenac (DCF) pre-
treatment conditions. AnnexinV-Alexa633 labeling of the cells allowed identification and 
exclusion of genes that upon knockdown affect cell viability during screening. TNFα-
induced oscillation of NF-κB was followed for 6 hours at 6 minute intervals for all individual 
knockdowns, directly after TNFα stimulation. Then, we normalized the nuclear/cytoplasmic 
GFP intensity ratio and independently analyzed the data for both treatment conditions. For 
each condition, we considered those genes a candidate hit at a p-value below or equal to 
0.001. Within this p-value cut-off we could trace back the effect most of the A20 knockdown 
plate controls (76% and 92%, control and diclofenac treatment, respectively) and of the 
IκBα knockdown plate controls (94% and 100%, control and diclofenac, respectively) 
(Suppl. Fig. S2). Visual inspection of the oscillatory responses defined another 42 
candidate genes, leading to in total 115 regulator genes detected from initial screening; 25 
candidate genes were discarded due to limited number of cells or onset of cell death (Fig. 
1). Using the same strategy, we performed a subsequent validation screen targeting the 
initial 115 candidate genes. For this we used 4 single siRNAs that were part of the initial 
smartpool siRNA mix in the primary screen. Then, 46 genes were confirmed to affect the 
GFP-RelA oscillation with 2 or more single siRNAs in addition to the pooled siRNAs in 
either or both DMSO and DCF conditions (see Supplementary movies S1-S6). We 
identified 17 kinases, 27 (de)ubiquitinases, and 8 genes that are known members of the 
TNFR/TLR signaling pathway. Knockdown of PHF5A and UCHL1162,163 decreased 
oscillation; knockdown of AGTR2164–167, MAPK4, MAPKAPK2168, SENP2169, TNFAIP3142,170, 
RELA and TNFRSF17171 increased oscillation; knockdown of CDK12, RBX1172, USP8, 
TNFRSF18173, ADCK2, CUL1174, FBXW11175, FBXW5, IKBKG176, MAP3K14177, MAPK8178, 
RAPSN, RNF126, TNFRSF1A, TRIM27179, TRIM50, TRIM8180,181, TTK, UBOX5 and 
UFD1L182 stopped oscillation; knockdown of TSKS, MLL2183, AATK, CYLD184,185, NTRK3186, 
BAHD1, MVK, TTBK1, UNK, FBXW9, MAP3K8187, OTUB2188, UBE3A, PHF19, STRADA, 
MASTL and USP15189 have a miscellaneous effect on oscillation (Fig. 1C; Table 1). Several 
validated candidate genes are known to affect the NF-κB signaling pathways (IKBKG, 
MAP3K14, CYLD), while others that showed a strong effect are novel (CDK12, PHF5A, 
TTK). Similar to NF-κB activity, CDK12 polymorphisms have been associated with cancer 
progression190, as has TTK expression levels191.  
 
Candidate NF-κB signaling modifiers affect the single cell oscillation behavior 
Our screening approach enabled the analysis of the dynamics of the NF-κB response at a 
single cell level within an entire population of cells, which allows measurement of the 
population dynamics upon knockdown of our candidate genes (Fig. 2A and 2B). Under 
control conditions 57 % of the cells showed at least three nuclear translocation events in a 
6 hour period. As expected, around 70 % of the cells showed no or only one shallow 
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oscillation upon knockdown of genes that blocked oscillation. This is for instance true for 
knockdown of TNFR1 and IKKγ, that are both well-characterized as essential for NF-κB 
activation. (Fig. 2Bi). 
 
 
Fig. 2: Population statistics of candidate genes (A) The population distribution of NF-κB oscillations in HepG2 
RelA-GFP cells upon indicated siRNA treatments. (B) Examples of how each phenotypic class is distributed in relation 
to the number of translocation peaks in single cell data. (C) The translocation features that define the different 
classes: “no oscillation” (Ci), “decreased” (Cii) and “increased”(Ciii) are exemplified by their representative siRNAs in 
the control DMSO condition.  
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For the decreased oscillation phenotype a drastic shift occurred for cells with 2 oscillations 
from 15% under control to around 50%, for example for CDK12 and PHF5A knockdown 
(Fig. 2Bii). The ‘increased phenotype’ clearly demonstrated an increase in the percentage 
of cells with 4 oscillations as observed for TNFAIP3 (A20) knockdown (Fig. 2Bii). Extraction 
of quantitative descriptors of the oscillatory response allowed further insights in the 
oscillatory phenotype. For the no oscillation phenotype the number of peaks was vastly 
reduced and any observable translocation event occurred later than in control cells, at lower 
amplitude and with a reduced nuclear entry slope. Within the remaining fraction of cells 
(~30%) that showed more than one nuclear translocation event, the peaks remained 
shallow, reflected by reduced dampening between the peaks and lower amplitude (Fig. 
2Ci). For the candidate genes CDK12, RBX1, PHF5A and USP8 that caused a decreased 
oscillation phenotype upon knockdown, the overall duration and time of the first peak were 
extended while the second peak occurred later than in control conditions (Fig. 2Cii). Finally, 
knockdown of TNFAIP3 (A20), MAPKAPK2, AGTR2 and MAPK4 induced an increased 
oscillation phenotype, hallmarked by an increase in the number of oscillations. They 
showed a decreased time interval between peaks, associated with an overall increase in 
the amplitude of TNFα-induced NF-κB nuclear translocation (Fig. 2Ciii).  
 
Functional and phenotypic classification of the siRNA screen hits that control NF-κB 
oscillation 
Next, we classified our 46 validated candidate genes and defined their role in the control of 
NF-κB oscillatory behavior (Fig. 3A and B and summary Table 1). Under control conditions 
7 genes increased the oscillation upon knockdown, including AGTR2, MAPKAP2 and 
MAPK4. Another 5 genes decreased the oscillation upon knockdown, including USP8, 
CDK12 and PHF5A. A majority of 24 genes blocked oscillation upon knockdown, including 
UFD1L, RNF128 and TRIM8. Furthermore, knockdown of TSKS, MLL2 and TNFRSF17 
also significantly affected NF-κB oscillation based on our statistical analysis, but these did 
not fall within the previous three categories. Overall, diclofenac pretreatment allowed 
identification of the same candidate genes (Fig. 3B and 3C and Table 1). However, several 
additional genes were identified that enhanced the diclofenac-delayed oscillation upon 
knockdown, including MAP3K8, OTUB2 and UBE3A. Other genes further shifted the effect 
from decrease to full suppression of the oscillatory behavior upon knockdown, as observed 
for CDK12, RBX1 and USP8 (Fig. 3B and Table1).  
 
Fig. 3: Functional and phenotypic profiling of the siRNA screen candidates that control NF-κB oscillation (A) 
Typical non-normalized NF-κB oscillation averages acquired in the deconvolution screen, including examples of 
knockdowns that led to a phenotype similar to the classification controls; siA20, diclofenac (DCF) and siIκBα. The 
“different” class is defined by having five or more features significantly different from the siControl. (B) Heatmap of the 
SMARTpool classification P-values for the hits confirmed by 2 or more single siRNAs in the deconvolution screen, 
clustered for their corresponding classification on the right. The overlap of the hits under DMSO and DCF conditions 
are additionally presented in (C). (D) Overview of functional properties of the candidate genes involved in regulation of 
NF-κB translocation phenotype under DMSO and DCF conditions. Candidate proteins were classified with PANTHER 
analysis. Statistical analysis is explained in the material and methods section. 
  







PANTHER functional analysis of the candidate genes showed that most were kinases, 
ubiquitin ligases and hydrolases (Fig. 3D and 3E). Knockdown of hydrolases led to a 
predominantly ‘increased oscillation phenotype’, while knockdown of kinases and ligases in 
general led to ‘no oscillation phenotype’. 
 
Effect of knockdown of candidate genes on drug/TNFα-mediated cell death 
Transcriptional activity of NF-κB is cytoprotective against TNFα-induced apoptosis in 
hepatocytes 17. Previously we hypothesized a key role for NF-κB signaling in the control of 
liver cell death in the context of drug-induced liver toxicity by diclofenac 42. Here, we further 
explored the role of our candidate regulators of NF-κB nuclear translocation in the cytotoxic 
effect of drug/TNFα exposure. We focused on the 20 genes with the strongest phenotype, 
the ones that fully inhibited the oscillation upon knockdown (Table 1). Treatment with 
diclofenac or carbamazepine for 8 hours induced some cytotoxicity (Fig. 4B, 4Ci and Cii, 
upper, most left panel). While knockdown of most candidate genes did not affect drug-
induced cytotoxicity compared to control knockdown, most remarkable, knockdown of 
TNFRSF1A enhanced the cell death for both diclofenac and carbamazepine conditions 
(Fig. 4A). Subsequent TNFα exposure vastly enhanced the cell death by diclofenac and 
carbamazepine (Fig.4B, lower panel). This effect was reduced by TNFR1 knockdown and 
strongly inhibited by caspase-8 knockdown (Fig. 4Ci and Cii, middle panel). In general, 
knockdown of the candidate genes caused a protection against drug/TNFα-induced cell 
death. Only knockdown of IKBKG increased TNFα-induced cell death significantly (Fig. 4C), 
demonstrating that direct and severe inhibition of NF-κB activation increases drug-induced 
cytotoxicity. Knockdown of CDK12 and UFD1L most strongly inhibited the TNFα-induced 
cytotoxic response without inducing significant changes in cytotoxicity upon diclofenac or 
carbamazepine treatment alone (Fig. 4A and C, Suppl.Fig.3). This indicates that CDK12 
and UFD1L are strong modifiers of both TNFα-induced NF-κB nuclear translocation and 
drug-mediated TNFα-induced cytotoxicity. 
 
Several candidate genes modulate both TNFα-induced NF-κB oscillation phenotype and 
A20 expression 
Knockdown of A20 strongly increased the TNFα-induced nuclear oscillation phenotype of 
NF-κB (Fig. 1). A20 is a direct target gene of NF-κB and acts in a negative feedback loop to 
modulate TNFR1 downstream signaling and suppress NF-κB activation. Besides regulating 
NF-κB activity, A20 is also an important modifier of TNFα-induced apoptosis and 
necroptosis20,24,141. As such, A20 regulates tissue homeostasis143,144,192. Indeed, 
hepatocyte-specific knockdown of A20 increases TNFα-induced toxicity192. On the other 
hand, hepatocyte-specific upregulation of A20 protects against D-Gal/LPS-mediated liver 
injury, also under high TNFα-levels193. We reasoned that knockdown of our candidate 
genes could be modulating the expression of A20, delaying the NF-κB oscillatory 
phenotype and simultaneously altering the cytotoxic potential of TNFα stimulation during 
diclofenac and carbamazepine exposure. To monitor A20 expression using live cell 
imaging, we established a BAC-GFP A20 HepG2 reporter cell line.  
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Fig. 4: Effect of modulators of NF-κB oscillation phenotype on TNFα/drug-induced cytotoxicity Live apoptosis 
imaging of parental HepG2 cells with knockdowns resulting in a “no oscillation” phenotype after 500 µM diclofenac or 
500 µM carbamazepine pre-incubation for 8 hours followed by stimulation with TNFα (10 ng/mL) for 16 hours. The 
amount of AnV is normalized to the number of cells. A) Apoptosis after only drug-exposure of eight hours in cells with 
candidate knockdown, where the AUC is presented as a fold change of mock/siGFP condition. B) The upper panel 
reflects the ratio of AnV staining and number of nuclei after 8 hours drug exposure. The lower panel shows the 
increase of cell death upon TNFα-stimulation over time. C) Representative examples of AnV staining in control 
conditions in the left panel, quantified in the middle graphs. In the right panel, the increase of apoptosis upon TNFα 
with or without candidate gene knockdown has been depicted in AUC, normalized to the mock/siGFP condition. All 
data is represented as the mean +/- SEM. Diclofenac data are three independent experiments, carbamazepine data 
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In this cell line, we could monitor the expression of A20-GFP that is controlled by an 
endogenous promoter. Only carbamazepine pre-treatment suppressed A20-GFP 
background expression significantly (Fig.5A). We then evaluated the effect of knockdown of 
our 20 candidate genes that inhibit NF-κB translocation. Knockdown of CDK12 and TTK 
slightly increased background A20-GFP expression levels, while TRIM50 decreased A20 
expression significantly; this was unaffected by diclofenac or carbamazepine treatment 
(Suppl. Fig. 4). Stimulation with TNFα strongly increased the expression of A20-GFP; this 
response was significantly inhibited by pre-treatment with either diclofenac or 
carbamazepine (Fig.5Aii). Importantly, KD of TNFR1 and IKBKG (NEMO/IKKγ) inhibited the 
A20-GFP induction by TNFα, confirming that the upregulation of A20 is likely TNFα-induced 
NF-κB signaling dependent. Knockdown of ADCK2, RAPSN and TRIM50 also strongly 
inhibited TNFα-induced A20-GFP induction. On the other hand, knockdown of CDK12, 
TRIM8, TTK and USP8 increased TNFα-mediated A20-GFP induction. While 
carbamazepine had a limited influence on the KD effects, diclofenac exposure increased 
the variability and in general suppressed the effect of knockdown conditions upon TNFα-
induced A20-GFP expression (Fig. 5B). While both knockdown of CDK12 and UFD1L were 
most effective in inhibiting TNFα-induced cell death under diclofenac and carbamazepine 
conditions (Fig. 4), only siCDK12 and not siUFD1L enhanced TNFα-induced A20-GFP 
expression (Fig. 5). This effect of CDK12 knockdown was maintained in drug-treated 
conditions (Fig.5C). 
 
A20 expression is essential for both delayed TNFα-induced NF-κB oscillation and the 
protective effect of both CDK12 and UFD1L knockdown in diclofenac pre-treated cells 
Next, we investigated the functional relationship between CDK12, UFD1L and regulation of 
A20 expression, in the context of TNFα-induced cytotoxicity. For this purpose, we 
performed siRNA-mediated knockdown of A20 together with the knockdowns of CDK12 or 
UFD1L. Double knockdown retained robust reduction in protein expression (Suppl. Fig. 5). 
Single knockdown of A20 strongly enhanced the cytotoxic potential of TNFα upon 
diclofenac or carbamazepine pre-exposure (Fig. 6A). While knockdown of CDK12 or 
UFD1L alone inhibited TNFα/compound cytotoxicity, this effect was partially reversed to 
mock-GFP knockdown levels by additional A20 knockdown. However, knockdown of 
CDK12 or UFD1L did still inhibit mock/GFP + A20 knockdown toxicity (Fig. 6B). Together, 
these data suggest a functional dependency between UFD1L, CDK12 and A20 in 
TNFα/diclofenac-induced cytotoxicity. Finally, we tested whether the delayed TNFα-induced 
NF-κB oscillation phenotype induced by CDK12 or UFD1L knockdown was also dependent 
on A20 expression. For this purpose, RelA-GFP cells were transfected with siRNA leading 
to a double knockdown for the candidate gene and A20.  
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Fig. 5: Several modulators of NF-κB oscillatory response affect A20 expression strongly Live confocal imaging 
of A20-GFP BAC reporter cell line upon 500 µM diclofenac or 500 µM carbamazepine treatment followed by 
stimulation with TNFα (10 ng/mL) for 16 hours. Ai) Examples of TNFα-induced A20 expression under DMSO, 
diclofenac or carbamazepine treatment, with the 8h pre-treatment conditions quantified. Aii) Quantification of the A20-
GFP time-response dynamics after TNFα-addition, and the representation in AUC values normalized to the DMSO 
control condition. B) AUC of the A20-GFP response after TNFα-addition, normalized to mock/siCtrl1 conditions per 
compound pre-treatment. Ci) Visualization of the effect of two candidate genes and controls on A20-GFP expression. 
Cii) Representative examples of the quantification of the response in Ci. All data is from three independent 
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This was followed by stimulation with TNF and live cell imaging. The oscillation phenotype 
of single knockdown of A20 was similar to double knockdown of CASP8/A20. Moreover, 
knockdown of the TNF receptor and A20 fully abolished oscillatory NF-κB responses, thus 
confirming the functionality of double knockdowns in the assessment of the oscillatory 
response (Fig. 6C). A20 knockdown partially reversed the delay in TNFα-induced NF-κB 
oscillation caused by siUFD1L, and more pronouncedly reversed the delay by siCDK12 
(Fig. 6C). This CDK12 knockdown reversal led to a normal population distribution of the 
oscillatory response, with more than 50 % of the cells demonstrating three NF-κB 
translocation events. This suggests that CDK12 exerts regulation of NF-κB oscillation 
partially via A20. 
 
 
Fig. 6: Functional interplay between CDK12, UFD1L and A20 in TNFα-induced NF-κB oscillation and 
cytotoxicity (A) Live apoptosis imaging of parental HepG2 cells with an A20 knockdown after 500 µM diclofenac or 
500 µM carbamazepine pre-incubation for 8 hours followed by stimulation with TNFα (10 ng/mL) for 16 hours. B) Live 
apoptosis imaging of wild type HepG2 with A20 or GFP knockdown together with knockdown of the candidate genes. 
After 500 µM diclofenac or 500 µM carbamazepine pre-incubation for 8 hours, cells were imaged upon stimulation 
with TNFα (10 ng/mL) for 16 hours. All data is the mean from three independent experiments +/- SEM. Significance is 
defined with a two-tailed student’s t-test where * P≤0.05, ** P≤0.01 and ***P≤0.001. C) Live imaging of GFP-p65 cells 
with A20 or GFP knockdown together with knockdown of the candidate genes upon TNFα stimulation (10 ng/mL) for 6 
hours. Right panel reflects the population distribution of the number of peaks of the single cell p65 oscillatory 
phenotype. Data is the mean from two independent experiments.   
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In summary, these data imply interaction of both CDK12 and UFD1L with A20 
function, whereby A20 levels are partially responsible for modulating NF-κB activation as 
well as the apoptotic response. We anticipate that CDK12-induced regulation of TNFα-
induced responses is partially due to direct modulation of A20 expression levels.  
 
Discussion 
In this study we report the systematic discovery of cell signaling components that control 
the TNFα-induced NF-κB nuclear translocation dynamics. From in total 1567 genes that 
cover kinases, (de)ubiquitinases and several mediators of TNF-receptor and Toll-like 
receptor signaling, we identified 46 candidate genes that modulate NF-κB oscillatory 
behavior. Of these, 24 genes have previously been described to affect NF-κB activity, 
including well- characterized components of TNFR signaling pathway IKKγ (NEMO), NIK 
(MAP3K14), A20 (TNFAIP3) and CYLD (Table 1). Known inhibitors of NF-κB activation 
indeed enhanced the oscillatory behavior upon knockdown in our screening setup. In line 
with the validity of our NF-κB reporter model, knockdown of previously established 
activators of NF-κB nuclear translocation led to a block of NF-κB oscillation. Our live cell 
imaging screen discovered 22 not previously described regulators of TNFα-induced NF-κB 
oscillation: 3 genes that increased the NF-κB oscillatory phenotype (MAKP4, UBE3A and 
MASTL) and 17 genes that decreased or blocked the NF-κB oscillatory phenotype (PHF5A, 
CDK12, USP8, ADCK2, RAPSN, RFN126, TRIM50, TTK, UBOX5, AATK, BAHD1, MVK, 
TTBK1, and UNK) (Table 1). 
Upon TNFα stimulation, cytoplasmic NF-κB translocates to the nucleus, thereby 
inducing transcription of genes that are involved in cell survival and inflammatory 
processes. In many cell types, this translocation has been found to be oscillatory upon tonic 
TNF stimulation155. Several studies have established the relation between the oscillatory 
phenotype of NF-κB translocation and target gene transcription upon TNFα stimulation, 
both on population level and single cell level 26–28,154,194. Very low or pulse-wise stimulation 
of cells increases the fraction of cells with only one initial NF-κB nuclear translocation, 
which affects the expression of especially late TNFα target genes, while early target gene 
expression remains relatively unaffected28,194. Several candidate genes demonstrated a 
reduced amount of oscillatory peaks and/or a delay of the second peak of NF-κB 
translocation on population level upon TNFα stimulation. We anticipate that this will affect 
the expression of downstream target genes, which in turn will determine the biological 
outcome of NF-κB activity, including the onset of apoptosis.  
Inhibition of NF-κB activity enhances TNFα-induced cytotoxicity17. Several drugs 
that have a high liability for idiosyncratic drug-induced liver injury, including diclofenac and 
carbamazepine, delay TNFα-induced NF-κB oscillation42,43. Therefore, we focused on 
genes that inhibit TNFα-induced NF-κB oscillatory behavior upon knockdown. CDK12 and 
UFD1L were among the strongest effectors of TNFα/drug-induced cytotoxicity (Fig. 4C). 
Interestingly, CDK12 knockdown also had a strong inducing effect on TNFα-induced A20 
expression; this was not observed for UFD1L knockdown (Fig. 5B and C). The moderate 
cytoprotective effect of CDK12 knockdown under drug exposure conditions likely depends 
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on this enhanced A20 upregulation, as double knockdown of CDK12/A20 reversed the 
cytotoxicity of drug/TNFα partially. Several other modulators of NF-κB oscillatory behavior 
and TNFα-induced cytotoxicity also affected A20 upregulation, albeit less pronounced than 
knockdown of CDK12. In summary, this study demonstrates a critical role for various 
signaling components in NF-κB activity and cytotoxicity, possibly via the modulation of A20 
expression. 
We here demonstrate for the first time that knockdown of the stress activated 
kinase CDK12 induces a major increase in TNFα-induced A20 expression. CDK12 interacts 
with many proteins involved in RNA processing, including splicing factors195. However, the 
best-characterized function of CDK12 is the phosphorylation of Ser2 on the C-terminal 
domain of RNA Pol II196,197. Interestingly, CDK12 kinase function has been implicated in 
cellular stress response pathways, by upregulating the transcription of specific stress-
induced target genes of p53 and Nrf2198,199. In our system, the expression of A20 induced 
by diclofenac and carbamazepine was slightly enhanced by CDK12 knockdown and the 
TNFα-induced A20 expression was more than 2-times enhanced by CDK12 knockdown 
(Fig 5). Together these data indicate that CDK12 acts as a suppressor of drug-induced A20 
upregulation. In general, A20 expression is quickly upregulated upon TNFα stimulation. The 
pre-formed transcription elongation complex containing A20-specific elongation factors 
ensures the rapid transcription of the gene and subsequent splicing and capping of the pre-
mRNA200,201. Ser2 phosphorylation plays an important role in this process, as it is essential 
for the elongation process to proceed. Although the common Ser2 kinase CDK9 dissociates 
quickly after the initiation of transcriptional activity of RNA Pol II, Ser2 levels are maintained 
during elongation of A20 RNA transcripts200. We hypothesize that CDK12 suppresses 
TNFα-induced A20 expression through direct modulation of transcriptional activity of RNA 
Pol II.  
Our data demonstrate that UFD1L is essential in the NF-κB oscillatory behavior 
and onset of TNFα/drug-induced cytotoxicity; yet, UFD1L knockdown did not enhance 
TNFα-induced A20 upregulation. Together with Npl4, UFD1L acts as an adaptor complex 
for AAA+ ATPase VCP/p97 to bind ubiquitinated proteins targeted for proteasomal 
degradation202. This complex has been reported to facilitate the degradation of the inhibitor 
of NF-κB, IκBα, upon TNFα stimulation182. However, in our hands, knockdown of UFD1L did 
not abolish the phosphorylation and breakdown of IκBα, indicating normal function of the 
IKK-complex (Suppl. Fig. 6). Other characterized functions of UFD1L in human cells 
converge on protection of the cellular homeostasis. UFD1L is involved in ER-associated 
degradation, cell cycle progression and mitosis203,204. Interestingly, the downregulation of 
endogenous UFD1L induces cell cycle arrest by upregulation of p27 in tunicamycin-induced 
ER stress205. Our previous work demonstrated a key role for ER stress in executing and 
modulating TNFα/drug-induced cell death16. We hypothesize that the depletion of UFD1L 
might affect ER stress and hence modulate TNFα/drug-induced cytotoxicity and NF-κB 
oscillation.  
In the past years, the function of A20 in the regulation of TNFα-induced NF-κB 
activation and apoptosis has received much attention. We observed that A20 is a critical 
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determinant in NF-κB oscillatory behavior as well as the onset of TNFα/drug-induced 
cytotoxicity. Liver-specific up- or downregulation of A20 shows respectively protective or 
detrimental effects on TNFα-induced toxicity in vivo192,193. We anticipate that our candidate 
genes that affect A20 expression will also affect the susceptibility of liver cells to apoptosis 
onset under in vivo circumstances. Thus, we report here for the first time that besides 
CDK12 also TRIM8, TTK and USP8 strongly enhance A20 upregulation upon knockdown; 
reversely, knockdown of receptor-associated molecule RAPSN and E3-ligase TRIM50 
strongly downregulate A20 expression (Fig. 5B). Since this involves different signaling 
molecules, this provides insight in the complexity of A20 modulation and hence modulation 
of NF-κB activity and TNFα-induced cytotoxicity.  
In conclusion, our study determined novel key regulators of the TNFα response, as 
detected by live-cell imaging of NF-κB oscillation, A20 expression and modulation of 
cytotoxicity. Acute liver failure caused by drug-induced toxicity is a major challenge and its 
outcome is linked to an exacerbated inflammatory phenotype in patients206. We anticipate 
that our candidate genes are critical players in the regulation of inflammatory responses in 
the onset of idiosyncratic drug-induced liver injury.  
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Suppl.Fig.1: siRNA-mediated knockdown is successful in wildtype and GFP-p65 HepG2 cells 50 nM siRNA 
SMARTpool transfection on positive controls, siA20 and siIκBα, results in successful knockdown using INTERFERin 
tranfection reagent, as determined by western blotting. In RelA-GFP cells the knockdown of IκBα results in higher 
IκBα levels after 72 hours of knockdown, since knockdown of this inhibitor leads to enhanced p65 activity during this 
period and thereby increased IκBα transcription. 
	
Suppl.Fig.2: P-value distribution of the hits and the positive and negative controls P-values of the positive 
control IκBα represented among all screen results. Under DMSO conditions the true discovery rate was 0.94 and 0.76 
for siIκBα and siA20 respectively while the false discovery rate was 0.04. Under DCF conditions the corresponding 
values were, 1, 0.92 and 0 respectively. 4.5% of the screened genes were found to have an effect on the oscillation 
under DMSO conditions while 4.7% were determined to give a significant effect after DCF pre-exposure.	
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Suppl.Fig.3: Drug/TNFα mediated caspase-8 and PARP cleavage is decreased in candidate gene knockdown 
conditions Western-blot analysis of cleaved PARP and caspase-8 in wild-type HepG2 cells with indicated 
knockdowns of candidate genes or controls. Cells were treated with 500µM diclofenac, with or without TNFα (10 





Suppl.Fig.4: Several candidate gene knockdowns affect A20 expression Live confocal imaging of A20-GFP BAC 
reporter cell line upon DMSO, 500µM diclofenac or 500µM carbamazepine treatment. AUC of over time quantification 
is normalized to mock/siCtrl1 condition. Data is from three independent experiments, +/- SEM. Significance is defined 
with a two-tailed student’s t-test where * P≤0.05, ** P≤0.01 and ***P≤0.001. 
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Sup.Fig.4 Herpers et al. 2016




Suppl.Fig.5: siRNA-mediated double knockdown is retains robust knockdown efficiency Western-blot analysis 




Suppl.Fig.6: Knockdown of UFD1L does not impair TNFα-induced IκBα degradation Western-blot analysis of 
IκBα and UFD1L levels of cells with UFD1L knockdown. Cells were pre-treated with 500 µM diclofenac or DMSO and 
stimulated with TNFα (10 ng/mL) for 15 minutes, as indicated. Quantification is the mean normalized expression of 
three independent experiments with error bars representing SEM. The results were not significant according to a two-
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Chapter 4 
o Drug exposure enhances TNFα-induced target gene expression, independent of either 
kinetic gene expression profile of the target gene or liver toxicity hazard of the drug 
o Drug exposure itself enhances gene expression typical for TNFα 
o Drug-induced gene expression is negatively regulated by oxidative stress-induced NF-
κB family members RelB and cREL, and induced by RelA 
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Drug-induced liver injury (DILI) complicates drug-development and clinical practice. 
Activation of the immune system has been increasingly recognized as an important 
host factor in the etiology of DILI. Previously, we and others showed that hepatocyte 
stimulation with the abundant pro-inflammatory cytokine TNFα together with drugs 
can culminate in synergistic hepatotoxicity. Here, we systematically evaluated the 
interaction of ten severe or less severe DILI drugs with the temporal TNFα-induced 
expression of NF-κB target genes, using high throughput transcriptomics of 44 
target genes. The DILI compounds included diclofenac, carbamazepine, nefazodone, 
troglitazone, tolcapone, entecapone, pioglitazone, flucoxacillin, acetaminophen and 
metformin. TNFα caused the anticipated differential temporal induction of both early, 
middle and late NF-κB target genes in HepG2 cells. DILI compounds caused a 
significant enhancement of TNFα-induced target gene expression, with metformin, 
diclofenac, carbamazepine and nefazodone giving he strongest responses. 
Interestingly, DILI compound exposure alone also induced expression of target 
genes typically induced by TNFα. Drug-induced expression of several NF-κB 
subunits, notably RelB and NFKB2, did correlate with oxidative stress responses. 
Drug-induced NF-κB target gene expression was largely dependent on NF-κB subunit 
RelA expression, while RelB and cRel acted as suppressors. Altogether these data 
indicate a critical role for DILI compound-induced cellular perturbations on the 
modulation of the TNFα-induced inflammatory response. Such responses may have 
impact on the etiology and progression of DILI. 
 
Keywords: liver toxicity, drug-induced liver injury, TNFα, NF-κB, oxidative stress 
 
Introduction 
Drug-induced liver injury (DILI) remains a major problem in both drug development and 
clinical practice. Most DILI responses are rare and only observed in large population 
settings, and often missed during clinical trials. There has been an urge to improve the 
mechanistic understanding of DILI and implement this knowledge in improved in vitro 
testing systems to detect the DILI liability of a novel compound in an early development 
phase207. 
A critical factor in DILI is the activation of both the innate and adaptive immune 
system208. Subtle immune modulations in both in vitro and in vivo experimental systems can 
invoke severe hepatotoxicity of otherwise harmless drugs209. For trovafloxacin, this 
synergism between the drug and non-toxic doses of LPS in mice is dependent on TNF-
receptor signaling11. Also, in a repeated dose model of diclofenac in rats, the severity of 
hepatotoxicity upon LPS exposure is associated with the expression of TNFα99. We have 
shown that diclofenac and TNFα cause synergism in liver cells, which is directly related to a 
decreased NF-κB nuclear translocation behavior and transcriptional activity42. The current 
literature suggests specific interactions between DILI compounds and TNFR signaling, yet 
a systematic examination on NF-κB target gene activation in relation to DILI 
compound/TNFα co-treatment has been lacking so far. 
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The NF-κB transcription factor family consists of five different genes: RelA (p65), RelB and 
cRel as the DNA binding subunits with an activation domain, and NFKB1 (p50) and NFKB2 
(p52) as DNA binding subunits without activation domain. NFKB1 and NFKB2 are first 
expressed as precursors p105 and p100. p105 is constantly processed. In contrast, the 
processing of p100 is dependent on post-translational phosphorylation. Upon extracellular 
cytokine stimulation (including TNFα) or internal cellular signals, NF-κB heterodimers 
migrate to the nucleus. This is due to the disassociation from their inhibitory binding 
partners. The family of inhibitory IκB proteins includes IκBα (NFKBIA), IκBε (NFKBIE) and 
precursors as p100 (NFKB2)210.  
TNFα binding to the TNFR induces formation of the TNF receptor complex, 
recruiting TRADD, TRAF2, RIP1, A20, the LUBAC complex and TAK1, among others. 
TAK1 activates the IKK complex and several MAP kinase signaling pathways. Activated 
IKK complex phosphorylates IκBα, marking it for proteosomal degradation. Dissociation of 
the cytoplasmic RelA-p50 causes it to translocate into the nucleus and activate gene 
transcription. Which target genes are activated depends on the interaction of other signaling 
pathways with RelA transcriptional activity and varies greatly among different (co-)stimuli 
and cell types20. Currently, the spatio-temporal nuclear translocation dynamics of NF-κB is 
considered as one of the critical determinants of target gene expression26,27. Among the 
critical target genes are chemokines and cytokines that modulate the inflammation 
responses, as well as anti-apoptotic proteins that protect cells against cell death13,211. 
However, the dynamics of TNFα-induced NF-κB target gene expression in liver hepatocytes 
remain unclear.  
Here, we systematically characterized the TNFα-induced NF-κB signaling 
dynamics in the context of adverse drug reactions, using the liver hepatocyte HepG2 cell 
line. We used high throughput analysis of TNFα target gene expression to assess DILI drug 
exposure effects kinetically16,53,212. We detected many drug-induced changes in TNFα-
induced target gene expression, which was not directly correlated to the drug-mediated 
delayed TNFα-induced RelA oscillatory response. Interestingly, several drug exposures 
induced expression of specific subsets of NF-κB target gene, including CCL5 and IL8. Their 
drug-induced gene expression was predominantly dependent on RelA transcriptional 
activity, but was inhibited by RelB and cRel expression. Drug-induced oxidative stress 
induction correlated strongly with drug-induced expression of RelB. This shows that drug 
exposure can both induce and regulate TNFα target gene expression via separate NF-κB 
family members. Together, these data show the complex nature of DILI compound-induced 
pertubations of immune signaling pathways and underlines the importance of NF-κB 
signaling in understanding DILI. 
 
Material and Methods 
Cell culture 
Human hepatoma HepG2 cells were acquired from ATCC (clone HB8065). HepG2 RelA 
(p65) BAC GFP reporter cell line was generated and characterized as described 
previously44. HepG2 wild type and BAC GFP reporter were maintained and exposed to 
 
	52	
drugs in DMEM high glucose supplemented with 10% (v/v) FBS, 25U/mL penicillin and 
25µg/mL streptomycin. The cells were used between passage 5 and 25.  
 
Reagents 
Most compound chemicals were acquired through the MIP-DILI consortium (AstraZeneca). 
Carbamazepine was from Sigma-Aldrich (Zwijndrecht, The Netherlands). Before use, the 
compounds were freshly dissolved in DMSO; except for metformin and acetaminophen, that 
were dissolved in DMEM and subsequently spiked with DMSO. TNFα was acquired from 
R&D Systems (Abingdon, UK). The final treatment concentration contained 0.2% v/v 
DMSO. AnnexinV (AnV) was prepared in house as described before42. All primers were 
purchased from Sigma Aldrich (Zwijndrecht, The Netherlands). For the splicing 
experiments, primers were designed based on the FASTA sequence of the most abundant 
splicing variant. Criteria for the measurement of unspliced transcripts described by Hao and 
Baltimore213 were met. For mRNA expression experiments KiCqStart SYBR Green primers 
were purchased. All primer sequences can be found in Suppl. table 2. All primers were 
tested for linearity and efficiency. 
 
Live cell imaging 
Accumulation and position of GFP levels and Hoechst staining was monitored using a 
Nikon TiE2000 confocal laser microscope (lasers: 488nm and 408nm). The microscope 
was equipped with an automated stage and perfect focus system at 37 degrees Celsius 
with humidified atmosphere and 5% CO2/air mixture. Before imaging at 20x magnification, 
HepG2 cells were stained for 45 minutes with 50 ng/mL Hoechst33342 to visualize the nuclei. 
The Hoechst medium was replaced with exposure medium containing the drug or control 
DMSO. After 8 hours pre-exposure to compound only, the medium was spiked with TNFα 
(1:20 dilution in 96-well-plate (RelA)) up to a final concentration of 10ng/mL . To prevent a 
delay in response in the oscillations of the RelA-GFP reporter, was added at the 
microscope per well, directly upon imaging of the first image(t=0). 
 
Immunofluorescence of primary human hepatocytes 
Three donors of cryopreserved PHH (KaLy-Cell, Plobsheim, France) (Suppl. Fig. 4) were 
thawed in KaLy-Cell thawing medium (KLC-TM; proprietary formulation) and next 
centrifuged at 168 x g for 20min at room temperature. The cell pellets were resuspended in 
KLC-washing medium (KLC-WM; proprietary formulation), followed by centrifugation at 100 
x g for 5 minutes at room temperature. The cell pellets were resuspended and cultured in 
KLC- seeding medium (KLC-SM) which was composed of Williams’ Medium E (Life 
Technologies, Paisley, UK) supplemented with 10% heat inactivated foetal calf serum 
(FCS, Life Technologies), 1 µM dexamethasone (Sigma-Aldrich, St Louis, Missouri), 4 µg/ 
ml insulin (Life Technologies) and 10 U penicillin/10 mg streptomycin (Life Technologies). 
The attachment efficiency of cryopreserved hepatocytes varied between donors with cell 
densities ranging between 50000 and 70000 cells per well (96-well plate). KLC-seeding 
medium was replaced with exposure medium, consisting of William’s Medium E and 10 U 
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penicillin/10 mg strepto- mycin (Life Technologies). Cells were treated with TNFα (10ng/mL) 
(1:20 dilution in 96 well plate) at indicated timepoints. After fixation in 4% of 
paraformaldehyde, samples were stained with RelA antibody (SantaCruz). Samples were 
measured by confocal microscopy using a Nikon TiE2000 confocal laser microscope 
(lasers: 488nm and 408nm). 
 
Real-time PCR 
RNA from compound-treated cells was isolated using the Machery Nagel NucleoSpin 
(Düren, Germany) kit according to the manufacture’s protocol. cDNA synthesis was 
performed using the RevertAid H Minus First Strand cDNA synthesis kit from ThermoFisher 
Scientific (Waltham, USA). Real time PCR analysis was performed on the 7900HT Fast 
Real-time PCR system from Applied Biosystems (Carlsbad, USA) or QuantStudio 6 Flex 
Real-Time PCR System from ThermoFisher Scientific (Waltham, USA). Primer sequences 
can be found in Suppl. table 2. Quality control was done based on the amplification and 
dissociation curves.  
 
Real-time high throughput PCR 
cDNA samples were prepared as described above. High throughput Fluidigm PCR data 
was collected by ServiceXS (Leiden, The Netherlands). Real-Time PCR analysis was 
performed at ServiceXS using the 96.96 BioMark™ Dynamic Array for Real-Time PCR 
(Fluidigm Corporation, San Francisco, CA, U.S.A), according to the manufacturer’s 
instructions. Before use on the BioMark array, the cDNA was first subjected to 14 cycles of 
Specific Target Amplification using a 0.2X mixture of all Taqman Gene Expression assays 
in combination with the Taqman PreAmp Master Mix (Applied Biosystems), followed by 5-
fold dilution. Thermal cycling and real-time imaging of the BioMark array was done on the 
BioMark instrument, and Ct values were extracted using the BioMark Real-Time PCR 
analysis software. Quality control performed by ServiceXS was taken into account with 
analysis of these results, discarding flagged samples and using only Ct values within 5 -35 
cycles. The Fluidigm RT-PCR array genes were selected based on previous experiments16. 
Primer sequences can be found in Suppl. table 2. Six housekeeping genes (HMBS, 
GAPDH, TBP, PSMB6, ACTB, MDH1) were taken along, based on their expression in 
HepG2 cells in literature214–216. The average of these genes was used to generate deltaCt 
values. For clustering of the HepG2 response on TNFα stimulation, timepoint 0 was 
substracted and responses were filtered on a fold change of 2 or higher on any timepoint 
compared to timepoint 0. To focus on the kinetics, responses were scaled between 0 and 1 
and clustered using the hclust function in the package pheatmap with clustering method 
Ward2, specifying the amount of clusters as 7. The oxidative stress genes were selected 
upon 2 times upregulation after exposure with 100 µM diethylmaleate or 30 nM CDDO-me 
(bardoxolone methyl) on one of the selected time points (7 and 24 hours). The upregulated 
oxidative stress genes were used to rank the compounds by their average drug-induced 
upregulation. Linear correlation was determined by Pearson’s correlation function in base 
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R. Annotation of protein function is based on literature and focused on liver biology (Suppl. 
table 1). 
 
Fluorescence reporter image quantification and statistics 
Qantitative image analysis was performed with CellProfiler version 2.1.1158 with an in house 
developed module implementing the watershed masked algorithm for segmentation159. 
Image analysis results were stored as HDF5 files. Data analysis, quality control and 
graphics was performed using the in house developed R package H5CellProfiler (Wink et 
al., 2017, manuscript in preparation). 
 
Data management and representation  
Data was managed with R, using packages plyr, dplyr, tidyr and reshape2217,218. Data 




Unless stated otherwise, P-values were calculated using a t-test. All errorbars reflect the 
standard deviation (SD). For the Fluidigm PCR results, a two-way ANOVA was conducted 
that examined the effect of compound treatment and time of TNF treatment on gene 
expression levels. There were statistically significant interaction effects between the effects 
of time of TNF treatment and compound treatment on gene expression. Next, a Tukey post 
hoc test for the TNF responses over time under DMSO conditions compared to treatment 
conditions revealed significant differences. All analysis was done using the stats package in 
R220. P-value < 0.05 is *, P-value < 0.01 is **, P-value < 0.001 is ***.  
 
Results 
Dynamics of TNFα-induced NF-κB target gene expression 
In hepatocytes, both increased NF-κB activity by knockout of A20 as well as inhibition of 
NF-κB activity lead to increased hepatotoxicity17,192. Various drugs with liver toxicity liability 
affect NF-κB signaling dynamics induced by TNFα; we have studied this previously in the 
liver hepatocyte cell line HepG242,43. The dynamics of TNFα-induced target gene 
expression have been well characterized in mouse embryonic fibroblasts (MEFs). Here, we 
determined similarity of the TNFα-induced target gene kinetics between MEFs and HepG2 
cells. According to literature, TNFα-induced target gene expression is temporally regulated, 
clustering in three well-characterized groups (early, middle and late) of gene transcription28 
(Fig. 1Ci). These kinetics are in MEFs largely defined by delayed RNA splicing kinetics and 
mRNA stability152,213. Using specific primers for non-spliced and spliced RNA transcripts of 
NFKBIA (IκBα; early), TNFAIP3 (A20; early), ICAM1 (middle), RELB (middle) and SLC2A6 
(late), we characterized the TNFα-induced gene expression and splicing process in HepG2 
cells (Fig. 1Bi).    
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Fig. 1: Characterization of TNFα-induced NF-κB signaling in HepG2 cells A) Overview of TNFα-induced NF-κB 
signaling pathway. Bi) Schematic overview of detection of spliced transcripts. Pre-mRNA is visualized with green 
introns and blue exons. Pre-mRNA primers bind within an exon and within an intron (green). mRNA primers bind in 
exons with intermittent introns, ensuring transcription only when the gene is spliced (blue). Bii) RNA expression data 
of NF-κB target genes upon TNFα exposure. Pre-mRNA transcription is displayed in green and on the left y-axis, 
spliced mRNA is visualized in blue and on the right y-axis. Error bars represent the standard deviation over three 
independent experiments. C) Example of literature based TNFα-induced target gene kinetics. Clustering of target 
gene RNA transcription based on kinetics only (scaled between 0 and 1 and an average of three independent 
experiments). Cluster 1, 2, and 3 are respectively early, middle and late TNFα-induced target gene expression. Gene 
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Fig. 2: DILI compound exposure delays TNFα-induced RelA translocation and enhances NF-κB target gene 
expression A) Time scale overview of experiments. Bi) HepG2 RelA-GFP oscillatory responses upon TNFα 
stimulation (10 ng/mL). At the top panel, the control DMSO response is visualized as both a line graph and density 
plot. The nuclear/cytoplasm GFP ratio data is scaled between 0 (white) and 1 (blue). Exact concentrations, and arrow-
indicated concentrations used for further experiments can be found in the supplementary data (Suppl. Table 3). 
*Crystal precipitation of pioglitazone hampered analysis. B.ii RelA-GFP oscillatory responses with the concentration 
used in further experiments, non-scaled data. Green indicates DMSO treated conditions, blue drug-treated conditions. 
Error bars represent the standard deviation over three independent experiments. C) Cell death responses over time. 
Ratio of AnnexinV staining and nuclear area are depicted. Red shading is the standard deviation of two independent 
experiments. D) TNFα-induced target gene responses with drug exposure, depicted as negative delta Ct values. The 
drugs are ranked on disruptive RelA-GFP oscillation effects, the numbers correspond to the compound. Colors depict 
functional annotation as in suppelmentary table 1. The genes are grouped at cluster. The shaded region represents 
the standard deviation over three independent experiments. 
 
All TNFα-induced genes started with a similar early peak of pre-mRNA, with NFKBIA and 
TNFAIP3 being slightly faster. NFKBIA and TNFAIP3 mRNA kinetics followed the unspliced 
transcript dynamics closely, whereas RELB, ICAM1 and SLC2A6 had a clear delay in the 
mRNA kinetics compared to their unspliced RNA expression (Fig.1B).  
Next we applied high throughput RT-PCR to evaluate the dynamics of a larger set 
of TNFα-induced genes in HepG2 cells. We selected genes based on previous 
transcriptomics data in human primary human hepatocytes and literature16. Of these, 44 
were upregulated more than 2-fold upon TNFα exposure. The target genes followed 
different temporal dynamics representing subsets of early, mid and late expression profiles 
(Fig. 1C). These individual profiles closely mimicked responses observed in MEFs152,213. 
Together, these data suggest that HepG2 cells present dynamics of TNFα-induced target 
gene expression similar to MEFs.  
 
Effect of drugs with liver toxicity liability on NF-κB signaling 
Several drugs with a liability for drug induced liver injury (DILI) act in synergy with TNFα, 
inducing cytotoxicity. Therefore, we studied the effect of DILI compounds on TNFα-induced 
NF-κB signaling. We focused on a selected panel of 10 drugs, based on the Innovative 
Medicine Initiative MIP-DILI project, each with a different level and mechanism of DILI 
liability212. To determine the optimal compound concentration for high throughput RT-PCR, 
we evaluated the effect of DILI compounds on TNFα-induced NF-κB nuclear translocation 
behavior. For this the RelA-GFP BAC HepG2 reporter cells were pre-treated for 8 hours 
with different concentrations of DILI compounds followed by stimulation with TNFα (Fig. 2A 
and Suppl. Fig. 5). Most DILI compounds affected the TNFα-induced oscillatory RelA-GFP 
response at a certain concentration, with metformin, diclofenac, nefazodone and 
carbamazepine being most potent (Fig. 2B). Based on disruption of RelA-GFP oscillation 
and toxicity, concentrations were chosen for further research (Suppl. table 3). At these 
concentrations not much cytotoxicity was observed for exposure to only DILI compounds. 
Only diclofenac and carbamazepine caused a synergistic cytotoxic response with TNFα 
(Fig. 1C). Next we determined the effect of pre-treatment on the TNFα-induced temporal 
gene expression (Fig. 2D). We observed enhanced TNFα target gene expression for most 
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DILI compounds; this was observed for early, middle and late target genes. Some target 
genes did not show enhanced induction, including TNFAIP3 and NFKBIA. There was no 
coherent correlation between RelA oscillatory response disruption and altered target gene 
expression. While metformin, diclofenac, nefazodone and carbamazepine all induce a clear 
disruption of TNFα-induced RelA oscillatory kinetics, each caused a different modulation of 
TNFα-induced target gene dynamics (Fig. 2D). 
 
DILI compounds activate specific NF-κB target genes 
DILI compounds can activate many cellular stress signaling pathways including ER stress 
and oxidative stress responses16. Oxidative stress, ER stress and DNA damage can directly 
modulate NF-κB signaling13,19. We therefore reasoned that ongoing stress responses 
caused by DILI compounds could affect NF-κB signaling, and thereby enhance the TNFα-
induced NF-κB signaling. To study this, we compared peak TNFα responses versus the 
peak DILI compound-induced target gene expression. Interestingly, some TNFα target 
genes were induced by drug exposure itself (Fig. 3A, and see results of all DILI compounds 




Fig. 3: Effect of DILI compounds on TNFα target genes expression A) Peaks of drug-induced and TNFα-induced 
expression (negative deltadeltaCt values to DMSO treated control) are depicted. Shapes relate to the drug exposure 
and colors represent the protein function of the target genes. B) The temporal drug-induced response compared to 
the TNFα-induced response. The pre-exposure with drugs started 8 hours before the first timepoint (0). The data is 
displayed as the negative deltadelta Ct values to the DMSO-treated control. The shades or error bars represent the 
standard deviation over three independent experiments.  
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The target genes most affected by compound exposure alone included CXCL3, CCL20, 
IER3, IL8, ELF3, CCL5 and CD44. Diclofenac induced extensive expression of CXCL3, 
which was also strongly induced by TNFα. In contrast, CCL5 was strongly induced by 
nefazodone but only mildly induced by TNFα.  
 
 
Fig. 4: Relationship between DILI compound-induced RelB expression and oxidative stress response A) 
Graph displays the genes of which the drug-induced expression correlates positively with oxidative stress. The x-axis 
groups the genes to their TNFα kinetic clusters. The colors depict the protein function in TNFα signaling. B) The drug-
induced expression values (the fold change to the control DMSO values) are scaled between 0 and 1. The drugs are 
ranked based on their oxidative stress induction. The correlation is printed on the graph. Colors reflect the different 
drug treatments and the grey line shows the linear correlation. C) qPCR based values (Fold change to control 
samples) per target gene. The colors correspond to the drug exposure. The error bars show the standard deviation. 
D) The drug-induced expression (Fold change to control samples) is shown on the x-axis versus the drug-induced 
expression in RelB knockdown cells on the y-axis. The colors reflect drug exposure, data is the average of three 
independent experiments and the error bars show the standard deviation. Values on the y=x line are not changed 
upon knockdown. E) Expression of IL8 (Fold change of control) upon drug exposure and with different knockdowns. 
Dashed line is a fold change of one. The colors show different drug-exposures and error bars reflect the standard 
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Relationship between DILI co pound-induced RelB expression and oxidative stress response 





























Visualization of the temporal expression of these genes in response to DILI compound 
exposure compared to the TNFα-induced response showed the induction of many typical 
NF-κB target genes (Fig. 3B, Suppl. Fig. 1). Overall, the drug-induced expression of TNFα-
induced target genes was not associated with DILI hazard in humans, a specific kinetic 
cluster or protein function. 
 
Correlation of NF-κB target gene expression and oxidative stress 
Previously, we demonstrated that carbamazepine- or diclofenac-induced Nrf2 activation 
plays a protective role in the TNFα-mediated synergistic cell death in HepG2 cells16 and 
that TNFα-induced NF-κB activation can be inhibited by DILI compounds43. The 
bidirectional interaction between ROS formation and TNF signaling has been long 
recognized19. Therefore, we evaluated the relationship between DILI compound-induced 
oxidative stress and compound-induced TNFα target gene expression. First, we ranked the 
compounds on their oxidative stress response profile. The relevance of the candidate 
oxidative stress genes included in the Fluidigm PCR array was assessed by treatment with 
two prototypical Nrf2 activators, diethylmaleate and CDDO-me (Suppl. Fig. 3A). The 
oxidative stress response ranking of DILI compounds was determined by the average 
induction of these oxidative stress genes per compound (Suppl. Fig. 3B). Next, we studied 
the correlation between drug-induced oxidative stress and target gene expression for each 
individual TNFα target gene. (Fig. 4A and Suppl. table 4). Interestingly, the NF-κB family 
members RelA, RelB and NFKB2 were amongst the target genes that correlated most 
strongly with the oxidative stress response (Fig. 4B). RelB and NFKB2 were also strongly 
induced by TNFα (Suppl. Fig. 3C). However, the compound-induced expression of RelB 
and NFKB2 was not dependent on RelA expression (Suppl Fig. 3F). RelB was induced in 
similar levels as by TNFα stimulation (Suppl Fig. 3F and Suppl. Fig. 2). We reasoned that 
RelB might contribute to DILI compound-induced target gene induction.  
To assess this, we first confirmed the DILI compound-induced expression of 
CCL20, CCL5, CD44, CXCL3, ELF3, IER3, and IL8 by standard RT-qPCR (Fig. 4C). While 
neither knockdown of RelB nor cREL did affect the DILI compound-induced transcription of 
most genes (Fig. 5D and Suppl. Fig. 3E), compound-induced expression of IL8, CCL5 and 
CD44 was significantly increased by RelB and/or cREL knockdown (Fig. 4D and E, and 
Suppl. Fig. 3E). Together these data suggest that compound-induced RelBexpression is 
associated with oxidative stress responses, independently of RelA transcriptional activity. 
Both RelB and cREL act rather as suppressors than as enhancers of the expression of 
drug-induced, typical TNFα-regulated target genes. 
 
RelA affects DILI compound-induced TNFα target gene expression 
We anticipated a role for RelA during the induction of some of the TNFα-induced target 
genes by DILI compounds. Indeed, knockdown of RelA did decrease drug-induced 
expression of several TNFα target genes, most notably CCL20 and IER3 under diclofenac 
and nefazodone conditions, and partly CCL5 and IL8 (Fig. 5A). In contrast, siRelA 
knockdown enhanced ELF3 expression. While diclofenac-induced IL8 expression was 
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inhibited by RelA knockdown, nefazodone-induced IL8 expression was not. This role of 
RelA was not related to substantial nuclear translocation at the exposure concentration 
used in aforementioned experiments, determined by our RelA-GFP reporter. However, 
diclofenac itself caused significant translocation of RelA-GFP upon higher concentrations 
(Fig. 5B). An overview of the experimental designs and key messages of this study can be 
found in Suppl. Fig. 5.  
 
Discussion 
Here we demonstrate that concurring signaling events induced by various DILI compounds 
affect the final outcome of TNFα-induced NF-κB target gene expression. This effect is 
mediated through the direct compound-induced activation of NF-κB transcriptional and 
regulational activity. This occurs likely in close relationship to the onset of oxidative stress 
responses and is regulated by RelA as well as by RelB and cRel NF-κB family members. 
While TNFα induces an oscillatory nuclear translocation of NF-κB subunit RelA, such a 
spatio-temporal behavior is not observed for DILI compound-induced RelA nuclear 
translocation. 
  Cellular survival signaling in hepatocytes is critical during DILI onset and TNFα-
induced NF-κB signaling is a well-characterized survival pathway. In addition, several 
TNFα-induced NF-κB target genes are proinflammatory cytokines or chemokines, 
regulating the dynamics of the inflammatory response at organ or even systemic levels. Our 
data demonstrate that DILI compounds impact the dynamics of TNFα-induced target gene 
expression substantially. As inflammation is a hallmark of DILI, these compounds might 
influence the inflammatory process and thereby DILI progression under in vivo 
circumstances. HepG2 cells indicates that TNFα signaling in HepG2 cells generally mimics 
TNFα responses in MEFs. We evaluated TNFα-induced nuclear oscillation of RelA, splicing 
of mRNA as an important regulator of mRNA target gene kinetics, and clustering of target 
genes in three similar kinetic groups23,152,213. Thus, we are confident that HepG2 cells 
represent a normal, MEF-like physiological response to TNFα.  
To extend our analysis of TNFα-induced NF-κB signaling in hepatocytes, we 
assessed TNFα-stimulated RelA translocation in primary human hepatocytes (PHH). 
Unexpectedly, we were unable to induce a reproducible TNFα response in three 
independent cryo-preserved PHH donors (Suppl. Fig. 4). Before stimulation with TNFα, 
there was already RelA present inside the nucleus. The nuclear RelA levels were higher 
than those in unstimulated wild type HepG2 cells (Suppl. Fig. 4). These high levels made 
the induction of RelA translocation by TNFα less intense and the detection more difficult. To 
our best knowledge, the TNFα-induced translocation dynamics of RelA in PHHs have not 
been researched before. Furthermore, in our hands, we found that TNFα target gene 
transcription in cryopreserved hepatocyes was difficult to detect, had major donor 
differences and was in general lower than expected (data not published). These 




Fig. 5: Drug-induced gene expression depends largely on RelA expression Ai) Drug-induced gene expression 
(Fc to control) is plotted on the x-axis, while the drug-induced gene expression with siRNA mediated knockdown is 
plotted on the y-axis. The colors represent the pre-exposure drugs. The y=x line shows where the knockdown has no 
effect on the drug-induced gene expression. Aii) The data from Ai for IER3 and IL8 is represented in a bar graph. a = 
p-value > 0.05 compared to the mock control with the same treatment. The data is the average of three independent 
experiments and the error bars reflect the standard deviation. B) RelA-GFP reporter upon drug exposure. The ratio of 
nuclear divided by cytoplasmic GFP is shown. The bold numbers are the concentrations used in the PCR experiments 
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Previously, we have published TNFα-stimulated PHH gene expression data from the TG-
GATES database, in which TNFα target gene induction was clearly seen in cryopreserved 
PHHs43,221,222. On one hand, this inconsistency could point to (polymorphic) donor 
differences in TNFα signaling pathways, leading to fundamentally different outcomes. On 
the other hand, technical issues, including hepatocyte purity levels and plating techniques, 
could also lead to different results. In 2016, Godoy et al. showed that the purity of isolation 
and plating procedure of PHHs is of major importance, especially for inflammation research. 
Inpurity, including the remains of a few KCs in the samples, induces inflammatory disease 
phentoypes. 
They also show that improving isolation and culturing methods could diminish, but 
not fully prevent a disease-like inflammatory PHH phenotype37. Therefore, our observations 
in cryopreserved PHHs, but also observations and conclusions by others relating to 
inflammatory signaling in primary human hepatocytes should be treated with utmost care. 
Further research into the nature of inflammatory signaling in HepG2 cells and PHHs in vitro 
in comparison to PHHs in vivo, however difficult, is recommended. At last, the observed 
donor variations detected in our assay warrant further assessment of TNFα signaling in 
PHHs of different donors, as this may impact individual susceptibility to the interaction 
between DILI compound exposure and TNFα-induced signaling. 
Our results demonstrate that the different DILI compounds show a plethora of 
interferences with the TNFα-induced expression of many temporally regulated genes. This 
underscores the complexity of interpreting single target gene responses. Some DILI 
compounds, including diclofenac, carbamazepine and nefazodone, demonstrate a strong 
effect on the RelA nuclear translocation oscillatory behavior induced by TNFα and also 
strong modulation of TNFα-induced target gene expression. However, these compounds 
did not affect the same target genes in a similar manner. Therefore, we conclude that the 
drug-induced delay in RelA oscillation does not directly reflect the alterations in gene 
expression. The relation between RelA oscillation and target gene induction is very 
complex. Recent data using knock-in GFP-RelA MEFs showed that pulse-wise TNFα 
stimulation leads to pulse-wise target gene expression, at least when the time in between 
pulses is sufficient. Pulse-wise gene expression reflected the pulsatile nuclear RelA 
localization and was much more pronounced for early genes than for middle and late TNFα-
induced gene expression27. However, we do not detect specific early gene effects by drug-
mediated TNFα-induced gene expression. In addition, other DILI compounds with limited 
effect on RelA oscillation also enhanced TNFα-induced target gene expression (for 
example entacapone). Therefore, we conclude that other drug-induced signaling pathways 
likely modulate TNFα-induced gene expression.  
Most DILI compounds induced upregulation of TNFα target gene expression in the 
absence of TNFα (Suppl. Fig. 1). Of relevance, some of the compound-induced target gene 
inductions were correlated to the relative activation of the oxidative stress response by our 
compounds. As expected, these included antioxidants MAFF and SOD2. Both MAFF, 
exhibiting Nrf2 pathway regulation, and SOD2, exhibiting mitochondrial ROS regulation are 
central in diminishing the oxidative stress load upon TNFα stimulation19,223. Oxidative stress 
 
	64	
is central in many types of liver injury in vivo and concurrent to TNFα signaling. Both 
oxidative stress and TNFα signaling induce JNK activation224. The prolonged activity of JNK 
is crucial in TNFα/diclofenac-induced cell death in vitro and in GalN/LPS induced liver 
failure in vivo14,42,225. Also in TNFα-stimulated mouse fibroblasts, oxidative stress inhibits 
MAP kinase phosphatases and thioredoxin reductase, inducing prolonged JNK activation 
and cell death18. The relationship between ROS and JNK signaling is complex, as the 
mutual interaction is often bidirectional, localization dependent, cell type dependent and 
contains many feedback loops19,226,227. Well-timed TNFα-induced expression of antioxidants 
is essential to prevent over-activation of JNK and subsequent apoptosis19. As our data 
demonstrate, TNFα-induced expression of antioxdiants is skewed upon previous drug 
exposure. The exact mechanistic relationship between oxidative stress, NF-κB target gene 
activation by DILI compounds and subsequently TNFα warrants further investigations. 
Oxidative stress induction positively correlated with drug-induced RelB and NFKB2 
expression as well. In recent years, the so-called non-canonical NF-κB signaling has been 
emerging as an important player in the regulation of RelA transcriptional activity and vice 
versa. Interestingly, we showed that compound-induced RelB expression is not RelA-
dependent (Suppl Fig. 3F). Taken together, this suggests that drug-mediated RelB 
expression is mediated by oxidative stress. 
Nuclear RelB can induce specific RelB target gene expression as MMP3 and p53 
in non-immune cells, but is foremost known for its inhibitory effect on RelA transcriptional 
activity228,229. RelB can bind directly to, and thereby inhibit RelA. The affinity of the binding 
is affected by phosphorylation of both RelA and RelB230,231. In non-hepatic cells, Ser276 
phosphorylation of RelA is inhibited by HMOX1 expression reducing oxidative stress and 
increased by oxidative stress induced ATM activation232,233. However, in our study HMOX1 
expression is only minorly affected by TNFα and drug exposure (Suppl Fig. 3C). In addition, 
RelB together with p100 (NFKB2) can effectively capture RelA in a large complex and 
inhibit RelA transcriptional activity in TNFα stimulated MEFs231,234. Either way, inhibition of 
RelA transcriptional activity by RelB expression is consistent with our data. RelB 
knockdown did increase RelA dependent drug-induced gene expression, especially from 
the well-described IL8 and CCL5 (Fig. 5D).  
The NF-κB target genes IL8 (also named CXCL8) and CCL5 are both chemokines 
that are produced in the diseased liver. IL8 recruits mainly neutrophils, CCL5 is involved in 
liver fibrosis, recruits monocytes and activates NK cells235. In vivo, lower expression of 
these chemokines would decrease proinflammatory signaling. Indeed, silencing of RelB has 
a protective effect on ischaemia/reperfusion-induced oxidative stress and TNFα-dependent 
liver injury236. In addition, forced activation of the non-canonical pathway in in vivo mouse 
liver (by stabilized NIK expression) induced massive hepatotoxicity. This hepatotoxicity was 
dependent on increased oxidative stress induction and hepatocyte-induced activation of 
macrophages237. These studies, in combination with our presented data, show the potential 
consequences of enhanced expression of TNFα-induced CCL5 and IL8 by DILI compounds 
on local inflammatory and pathological responses in the liver. 
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In summary, we here studied drug affected TNFα-induced NF-κB responses in HepG2 
cells. We show that RelB expression was induced by compounds in a RelA-independent 
manner and correlated positively with oxidative stress formation. Most drug-induced TNFα 
target genes were RelA dependent, but well-timed and well-regulated expression of for 
example IL8 and CCL5 was also dependent on both RelB and cREL-mediated inhibition. 
Together, these results emphasize the complexity of interactions between drug and TNFα-
induced NF-κB family signaling in hepatocytes.  
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Suppl. Table 1 
 
 
Cluster Kinetic group variable protein function protein function 
group 
 
Gene symbol general 
in TNFα signaling 
(focus on liver biology) 
2a middle CXCL5 cytokine/chemokine pro-inflammatory238 
2a middle IL23A cytokine/chemokine pro-inflammatory239 
2a middle FSTL3 cytokine/chemokine unknown function240 
2a middle SDC4 receptor anti-inflammatory241 
2a middle NFKB2 signaling protein NFKB subunit22 
2a middle BIRC3 signaling protein anti-apoptotic13 
2a middle TNFAIP3 signaling protein anti-apoptotic192 
2a middle TNFAIP3 signaling protein anti-inflammatory143,242 
2a middle CCL20 cytokine/chemokine pro-inflammatory243 
2a middle LTB cytokine/chemokine anti-apoptotic244 
2a middle NFKBIE signaling protein IkB subunit245 
2a middle BCL2A1 signaling protein anti-apoptotic246 
2a middle ICAM1 adhesion molecule pro-inflammatory247 
2a middle VCAM1 adhesion molecule pro-inflammatory248 
2a middle TNFRSF9 receptor pro-inflammatory249 
2b middle IER3 transcription factor anti-apoptotic/pro-apoptotic250 
2b middle MAFF signaling protein oxidative stress251 
2b middle MAFF signaling protein anti-apoptotic252 
2b middle CSF1 cytokine/chemokine pro-inflammatory253,254 
2b middle CX3CL1 cytokine/chemokine pro-inflammatory255 
2b middle TRAF1 signaling protein anti-apoptotic256 
2b middle PLAU signaling protein anti-apoptotic257,258 
2b middle IL8 cytokine/chemokine pro-inflammatory259 
2c middle NFKBIA signaling protein IkB subunit245 
2c middle TNFAIP2 signaling protein anti-apoptotic260 
2c middle CXCL10 cytokine/chemokine pro-inflammatory261,262 
2c middle ELF3 transcription factor pro-inflammatory263,264 
2c middle NFKBIZ signaling protein pro-apoptotic265 
2c middle CSF2 cytokine/chemokine pro-inflammatory266 
2c middle CXCL2 cytokine/chemokine pro-inflammatory259,267 
2c middle BCL3 signaling protein anti-inflammatory268 
2c middle BCL3 signaling protein anti-apoptotic269,270 
3a late CCL5 cytokine/chemokine pro-inflammatory271 
3a late SLC7A11 transporter anti-apoptotic272 
3a late C3 secretable factor liver recovery273,274 
3a late LCN2 signaling protein anti-inflammatory275 
3a late LCN2 signaling protein anti-apoptotic275 
3a late CD44 adhesion molecule pro-inflammatory276 
3a late SOD2 superoxide scavenger oxidative stress277 
3b late TNIP1 signaling protein anti-apoptotic278 
3b late SLC2A6 transporter unkown function279 
3b late RELB transcription factor NFKB subunit280 
3b late IL15 cytokine/chemokine pro-inflammatory281 
1 early CSF3 cytokine/chemokine pro-inflammatory282 
1 early CXCL3 cytokine/chemokine pro-inflammatory283 
1 early CXCL1 cytokine/chemokine pro-inflammatory267 
1 early SELE adhesion molecule pro-inflammatory284 
1 early IRF1 transcription factor pro-inflammatory285 
1 early IRF1 transcription factor pro-apoptotic286,287 
NA Decreasing INHBA cytokine/chemokine pro-inflammatory288 
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Suppl. Table 2  
KiCq	Start	primers Taqman	Gene	Expression	Assays	(Applied	BioScience)
Gene	symbol Forward	(F)/Reverse(R) Sequence Gene	Symbol Assay	ID Context	Sequence
RELA F GCAGAAAGAGGACATTGAG ADH1A Hs00605167_g1 ATTCTTGGTGGCTTTAAAAGTAAAG
RELA R GTGCACATCAGCTTGC CXCL5 Hs01099660_g1 AAATTTTGGACGGTGGAAACAAGGA
NFKB1 F GACAACTATGAGGTCTCTGG IER3 Hs04187506_g1 TCTACCCTCGAGTGGTCCGGCGCCA
NFKB1 R ATCACTTCAATTGCTTCGG NFKBIA Hs00355671_g1 TGTCAATGCTCAGGAGCCCTGTAAT
NFKB2 F CCATGACAGCAAATCTCC UGT2B15 Hs00870076_s1 GAAGGAAAATGTGAACATGGAAACA
NFKB2 R TAAACTTCATCTCCACCCC BLNK Hs00179459_m1 ATGACTTTGACAGCGACTATGAAAA
IL8 F TGTAAACATGACTTCCAAGC CXCL6 Hs00605742_g1 GGAAGTGGTAGCCTCCCTGAAGAAC
IL8 R AAAACTGCACCTTCACAC IFRD1 Hs00912593_m1 ATTGGCCAGAGGAATAGAGAGTGAC
CXCL3 F CATCAAACATAGCTCAGTCC OSGIN1 Hs00203539_m1 AGAAGAAGCGAAGAGGTCTTCGCAA
CXCL3 R CCCTGTCATTTATCAAGGTG CASP4 Hs01031951_m1 ATTGAAAATGGAAGCCACAAGCAGC
ELF3 F CTCTATTTAGAGCCGGGTAG F3 Hs01076029_m1 TCAAATAAGCACTAAGTCAGGAGAT
ELF3 R GTTGCTAATCTCACAGGTTG IL23A Hs00900828_g1 ACAACAGTCAGTTCTGCTTGCAAAG
cREL F AAAGACAACTCTGCTTTTCC REL Hs00968440_m1 TATGACAACCGTGCTCCAAATACTG
cREL R CTTCCTTCTCCAATTGAACC CCL5 Hs00982282_m1 CTGCCTCCCCATATTCCTCGGACAC
CCL20 F TATATTGTGCGTCTCCTCAG FSTL3 Hs00610505_m1 GGCCGCTGCCGCAAGTCCTGTGAGC
CCL20 R GCTATGTCCAATTCCATTCC TNFAIP2 Hs00196800_m1 CCTCTACCCCAATGACATCATCAAC
TNF F AGGCAGTCAGATCATCTTC SDC4 Hs00161617_m1 GCCGAGTCGATCCGAGAGACTGAGG
TNF R TTATCTCTCAGCTCCACG CDC34 Hs00362082_m1 AGACATCATCCGGAAGCAGGTCCTG
IER3 F AAGTAGGAGAAGAAATGGGG GADD45G Hs02566147_s1 GCAGGAGCGTGAAGGACTTAGCCGA
IER3 R AGAAGATGGAAGGATCTCAC TNIP1 Hs00374581_m1 CCTCCATTCTGCAGACCCTGTGTGA
NFKBIZ F CACGTTCCTTCATATTGCTG SLC2A6 Hs01115485_m1 CCTGCCAGTGGTGAGCACCTTCGGC





Splicing		primers ACTB Hs01060665_g1 CCCAGGCACCAGGGCGTGATGGTGG
Gene	symbol Forward	(F)/Reverse(R) Sequence Exon/Intron MDH1 Hs00936497_g1 GGGAGAATTTGTCACGACTGTGCAG
TNFAIP3 M1_F AGTTTTGTCCTCAGTTTCGGG exon SLC7A11 Hs00921938_m1 ATGCAGTGGCAGTGACCTTTTCTGA
TNFAIP3 M1_R TTCCTCAGTACCAAGTCTGTG exon CXCL10 Hs01124251_g1 CCACGTGTTGAGATCATTGCTACAA
TNFAIP3 M2_F CAGCACGCTCAAGGAAACAGACA exon HMBS Hs00609296_g1 GTCCCTGCCCAGCATGAAGATGGCC
TNFAIP3 M2_R GCCAGTGGAGAGGCAAGTAA exon NFKB2 Hs01028901_g1 CTATCCCACTGTCAAGATCTGTAAC
TNFAIP3 J2_F GCCAAAAGGACAGAAGAGCA exon ELF3 Hs00963881_m1 GCTGAGCCGGGCCATGAGGTACTAC
TNFAIP3 J2_R TTGGAGGTAGCATTTCGGAC intron RELB Hs00232399_m1 GCCCGCCATCGAGCTCCGGGATTGT
TNFAIP3 J3_F GGACGTTTCTGTCTGGGTTTT exon ABCA1 Hs01059118_m1 GAACAACATGAATGCCATTTTCCAA
TNFAIP3 J3_R AGACACGAAAGGAGCAAAGC intron CXCL3 Hs00171061_m1 AAAAGATACTGAACAAGGGGAGCAC
NFkBIA M5_F TCCTCAACTTCCAGAACACC exon NOD2 Hs00223394_m1 TTCTTGGCATTGAGGCTGGGGAATA
NFkBIA M5_R ACAGCCAGCTCCCAGAAGT exon CSF1 Hs00174164_m1 AGCATGACAAGGCCTGCGTCCGAAC
NFkBIA M6_F CTACACCTTGCCTGTGAGCA exon HAMP Hs00221783_m1 TCCCACAACAGACGGGACAACTTGC
NFkBIA M6_R TGACACCAGGTCAGGATTTTG exon CFB Hs00156060_m1 AATGATCGATGAAAGCCAGTCTCTG
NFkBIA J4_F GAGGATGAGGAGAGCTATGACAC exon GCLM Hs00157694_m1 CGCACAGCGAGGAGCTTCATGATTG
NFkBIA J4_R TAGTTAGAGCGCCGAAGGAG intron G6PD Hs00166169_m1 GGGTGCATCGGGTGACCTGGCCAAG
NFkBIA J5_F ATCGTGGAGCTTTTGGTGTC exon KEAP1 Hs00202227_m1 AATCTACGTCCTTGGAGGCTATGAT
NFkBIA J5_R GCTTATGGCTGCATTTGGAA intron CX3CL1 Hs00171086_m1 GCTGGCTGGACAGCACCACGGTGTG
ICAM1 M1_F GCTGAGCTCCTCTGCTACTCA exon PTX3 Hs00173615_m1 ACTGAGGACCCCACGCCGTGCGCCT
ICAM1 M1_R GGCTATCTTCTTGCACATTGCT exon SLC10A1 Hs00161820_m1 GGACATGAACCTCAGCATTGTGATG
ICAM1 M2_F CATAGAGACCCCGTTGCCT exon PI3 Hs00160066_m1 GCAGCTGTCACGGGAGTTCCTGTTA
ICAM1 M2_R GCAGCGTAGGGTAAGGTTCTTG exon CXCL1 Hs00605382_gH GATGCTGAACAGTGACAAATCCAAC
ICAM1 J1_F GCAACCTCAGCCTCGCTAT exon C3 Hs00163811_m1 CAAGAAAGGGATCTGTGTGGCAGAC
ICAM1 J1_R TCCCATAAACAGCTACCTAAGCA intron BIRC2 Hs01112284_m1 GCTGACCCACCAATTATTCATTTTG
ICAM1 J2_F ATCACCATGGAGCCAATTTC exon FABP1 Hs00155026_m1 AAGGCAATCGGTCTGCCGGAAGAGC
ICAM1 J2_R CATTGCAGGATACCCCACC intron BIRC3 Hs00985031_g1 GAAGATGTTTCAGATCTACCAGTGG
RELB M1_F GACCTCTCCTCACTCTCGCTC exon SLC3A2 Hs00374243_m1 GCCCTTCCTGGACAGCCTATGGAGG
RELB M1_R CCGTTCTCCTTGATGTACTCGT exon PSMB6 Hs00382586_m1 GAACAACCACTGGGTCCTACATCGC
RELB M2_F TCCAGTGTGTGAGGAAGAAGG exon MYLK Hs00364926_m1 TGCAAGATTGAAGGATACCCAGACC
RELB M2_R CAGCTCTGATGTGTTTGTGGAT exon CFLAR Hs00153439_m1 GCAATGAGACAGAGCTTCTTCGAGA
RELB J1_F AGCCACTCCCTGAGAACAGA intron SRXN1 Hs00607800_m1 GACACGATCCGGGAGGACCCAGACA
RELB J1_R AGAATCACACAGCAACGGAA intron BCL2L11 Hs00708019_s1 AGGTAGACAATTGCAGCCTGCGGAG
RELB J5_F CCGTCACCCCCTCAGTTTTA intron TNFAIP3 Hs00234713_m1 GAAAACGAACGGTGACGGCAATTGC
RELB J5_R CACGGAAGTCAAGGGGTTTG exon BAX Hs00180269_m1 CTGGTGCTCAAGGCCCTGTGCACCA
SLC2A6 M4_F GTCCCTCTACGCCCTTGG exon PPARGC1A Hs01016719_m1 AAGGCAATTGAAGAGCGCCGTGTGA
SLC2A6 M4_R AAGCTGAGCAGCAGGATCA exon LCN2 Hs01008571_m1 TCGTCTTCCCTGTCCCAATCGACCA
SLC2A6 M5_F ACCAAATCCCAGGCATCC exon TBP Hs00427620_m1 GCAGCTGCAAAATATTGTATCCACA
SLC2A6 M5_R ACGGCACAGCTGAGAACAT exon CCL20 Hs01011368_m1 ATATTGTGCGTCTCCTCAGTAAAAA
SLC2A6 J1_F GCAATTTCAGCTTTGGGTATG exon TLR2 Hs01872448_s1 GTTGGGATCTTTATGTCACTAGTTA
SLC2A6 J1_R CAAGGTGGAGAATTTGGGAG	 intron TRAF1 Hs01090170_m1 CCCTTCCGGAACAAGGTCACCTTCA
SLC2A6 J5_F AGGCTCCCTGTTTCAAGTGC intron STAT5A Hs00234181_m1 TGTTCCAGGTGAAGACTCTGTCCCT
SLC2A6 J5_R CAGGAGGTCGTTGAGGATCA exon NFKBIZ Hs00230071_m1 ATGGTGACACGTTCCTTCATATTGC
CCL5 M5_F TGCCCACATCAAGGAGTCTTT exon IL15 Hs01003716_m1 TCTTCTAATGGGAATGTAACAGAAT





























Compounds cmax (µM) Concentrations RelA (µM) PCR Concentration (µM) 
nefazodone 0,86 8,59 15,27 27,15 48,29 85,87 27,15 
carbamazepine 15,00 150,00 266,74 474,34 500,00 843,51 500,00 
diclofenac 8,10 235,27 418,38 500,00 744,00 1000,00 500,00 
acetaminophen 130,00 2311,76 4110,96 7310,44 10000,00 13000,00 10000,00 
flucloxacillin 31,90 319,00 567,27 1008,77 1793,87 3190,00 3190,00 
metformin 116,00 652,32 1160,00 2062,80 3668,24 6523,16 6523,16 
tolcapone 21,99 21,99 39,10 69,52 123,63 219,85 69,52 
troglitazone 6,39 20,20 35,91 63,87 113,57 201,96 113,57 
entacapone 3,93 22,10 39,30 69,89 124,28 221,00 124,28 
pioglitazone 2,95 29,46 52,39 93,16 165,67 294,60 294,60 
 
Suppl. Table 3 
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gene symbol protein annotation cluster Pearson's correlation 
SLC7A11 anti-apoptotic 3a 0,80 
RELB NFKB subunit 3b 0,76 
MAFF oxidative stress 2b 0,73 
MAFF anti-apoptotic 2b 0,73 
RELA NA NA 0,66 
SDC4 anti-inflammatory 2a 0,61 
IL23A pro-inflammatory 2a 0,56 
NFKB2 NFKB subunit 2a 0,54 
CSF3 pro-inflammatory 1 0,53 
SOD2 oxidative stress 3a 0,51 
CCL20 pro-inflammatory 2a 0,49 
IER3 anti-apoptotic/pro-apoptotic 2b 0,49 
CSF1 pro-inflammatory 2b 0,37 
IL8 pro-inflammatory 2b 0,34 
TNIP1 anti-apoptotic 3b 0,31 
ELF3 pro-inflammatory 2c 0,30 
BCL3 anti-inflammatory 2c 0,26 
BCL3 anti-apoptotic 2c 0,26 
NFKB1 NA NA 0,26 
ICAM1 pro-inflammatory 2a 0,23 
CXCL5 pro-inflammatory 2a 0,20 
CSF2 pro-inflammatory 2c 0,19 
C3 liver recovery 3a 0,11 
PLAU anti-apoptotic 2b 0,08 
CXCL2 pro-inflammatory 2c 0,03 
TNFAIP2 anti-apoptotic 2c 0,03 
TNFRSF9 pro-inflammatory 2a -0,05 
IRF1 pro-inflammatory 1 -0,07 
IRF1 pro-apoptotic 1 -0,07 
CD44 pro-inflammatory 3a -0,10 
IL15 pro-inflammatory 3b -0,11 
NFKBIE NFKB subunit 2a -0,15 
CCL5 pro-inflammatory 3a -0,15 
LTB anti-apoptotic 2a -0,16 
CXCL3 pro-inflammatory 1 -0,16 
CXCL1 pro-inflammatory 1 -0,18 
VCAM1 pro-inflammatory 2a -0,19 
TNFAIP3 anti-apoptotic 2a -0,19 
TNFAIP3 anti-inflammatory 2a -0,19 
LCN2 anti-inflammatory 3a -0,20 
LCN2 anti-apoptotic 3a -0,20 
SELE pro-inflammatory 1 -0,20 
SLC2A6 unknown function 3b -0,22 
BIRC3 anti-apoptotic 2a -0,23 
NFKBIA NFKB subunit 2c -0,23 
BCL2A1 anti-apoptotic 2a -0,25 
CXCL10 pro-inflammatory 2c -0,26 
FSTL3 unknown function 2a -0,29 
NFKBIZ pro-apoptotic 2c -0,32 
TRAF1 anti-apoptotic 2b -0,35 
CX3CL1 pro-inflammatory 2b -0,44 
 







Suppl. Fig. 1: Comparison of TNFα-induced and DILI compound-induced TNFα target gene induction The 
drug-induced expression is visualized as negative deltadelta Ct to DMSO controls. The colors depict the protein 
function of the target genes. The data is the average of three independent experiments and the error bars reflect the 
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Suppl. Fig. 2: Comparison of temporal DILI compound-induced and TNFα-induced responses The temporal 
drug-induced expression is visualised as negative deltadelta Ct to DMSO controls. The grey color shows the TNFα-
induced gene expression, while the colors depict the clustering of the target genes and show drug-induced gene 





Suppl. Fig. 3: Drug-induced oxidative stress and NF-κB family members A) Expression (Fold change of DMSO 
control) of oxidative stress genes upon CDDO (30 nM) and DEM (100uM) exposure for indicated timepoints. B) NF-κB 
family member expression (Fold change of control) with and without TNF stimulation is depicted. C) Drug-induced 
gene expression of oxidative stress target genes with (grey, dashed lines) or without TNF (colored lines and shades) 
are shown. The expression is visualized as negative deltadelta Ct values compared to DMSO controls. D) The 
knockdown efficiency of siRNA mediated controls is shown as a Fold Change to DMSO controls. Colors represent 
drug exposure. E-F) Drug-induced gene expression (Fc to control) is plotted on the x-axis, while the drug-induced 
gene expression with siRNA mediated knockdown is plotted on the y-axis. The colors represent the pre-exposure 
drugs. The y=x line shows that the knockdown has no effect on the drug-induced gene expression. All data is the 
average of three independent experiments and errorbars or shade reflects standard deviation.   
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Suppl. Fig. 4: TNFα-induced RelA translocation in primary human hepatocyte A) Immunofluorescence images of 
TNFα stimulated hepatocytes. The numbers correspond to the donors. Cells were stimulated with 10 ng/mL TNF for 
indicated timepoints. B) Quantification of immunofluorescence image. The ratio of GFP signal in the 
nucleus/cytoplasm ratio has been depicted. Green shading depicts standard deviation of 2 separate wells. C) Table 





Suppl. Fig. 5: Overview of experimental design and key results A) Time schedule and experimental design. 
Colors refer to different experimental designs Bi, ii, iii) Overview of key messages per research question. The figures 
















Identification of TNF receptor signaling 
pathway components that regulate 














This chapter is based on a manuscript in preparation: 
 
Suzanna Huppelschoten1, Matthijs Vlasveld1, Steven Wink1, Steven Hiemstra1, Janna Klip1, 
Wouter den Hollander1, Casper Roosenstein1, Lisa Fredriksson1, Bob van de Water1, 
 
Identification of TNF receptor signaling pathway components that regulate 
hepatotoxic drug/TNFα-induced synergistic apoptosis 
 
1Division of Toxicology, Leiden Academic Centre for Drug Research, 
Leiden University, Leiden, The Netherlands
Chapter 5 
o Combined TNFα and carbamazepine, diclofenac, griseofulvin, colchicine and valproic 
acid exposure induce synergistic apoptosis 
o Synergistic compound/TNFα-induced apoptosis is regulated by both generic and 
compound-specific mechanisms 
o The compound-induced onset of adaptive stress responses is strongly correlated with 
the modulation of TNFα synergism by several candidate genes (e.g PHF5A, CRK7, 
A20 and CARD12) 
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TNFα stimulation of hepatocytes generally induces cell survival. However, when 
cellular homeostasis is skewed by drug exposure, the outcome of TNFα stimulation 
might incline towards cytotoxicity. The mechanistic understanding of this interaction 
remains largely elusive. Previously we demonstrated TNFα-induced apoptotic 
synergy with carbamazepine and diclofenac exposure. In this study, we assessed the 
role of 182 TNFR signaling pathway components on carbamazepine/TNFα-induced 
apoptosis. We identified 19 genes that upon knockdown inhibit apoptosis, including 
EP300, CUL1, CARD12, CYLD and RAPSN, and 5 genes that upon knockdown 
promote apoptosis, including FBXW11, MAP2K7 and PHF5A. We evaluated 124 drugs 
with drug-induced liver injury liability for TNFα synergism and reveal that colchicine, 
griseofulvin and valproic acid synergistically enhance TNFα-induced apoptosis. Both 
A20 (TNFAIP3) and PHF5A were genuine protective genes against TNFα-induced 
apoptosis upon carbamazepine, diclofenac, valproic acid, griseofulvin and colchicine 
treatment. Mechanistically most similar, diclofenac and valproic acid TNFα-induced 
synergistic apoptosis was strongly modulated by knockdown of known apoptotic 
regulators as CYLD, A20 and CASP8, but also by novel regulators including PHF5A 
and CARD12. The modulation of apoptosis by PHF5A, CRK7 (CDK12), A20 and 
CARD12 is strongly correlated to the onset of different branches of oxidative stress 
and DNA damage response signaling. We anticipate that our study provides 
improved mechanistic understanding of DILI compound/TNFα-mediated 
hepatotoxicity and that genetic polymorphisms in the identified candidate genes may 
define individual susceptibility towards DILI.  
 
Keywords: drug-induced liver injury, TNFα, TNFα-induced apoptosis, TNFα synergism, 
cellular stress responses 
 
Introduction 
The enigmatic TNFα signaling pathway has been a field of extensive research for several 
decades. This has led to the development of successful clinical use of specific anti-TNFα 
drugs in various inflammatory disease settings. Idiosyncratic drug-induced liver injury (DILI) 
is a rare and at the moment unpredictable adverse drug response. One of the current 
hypotheses on the mechanism of idiosyncratic DILI implicates an activating immune 
response, acting as danger signal in combination with intracellular drug responses208. 
These combined immune and drug responses could synergistically lead to enhanced 
cytotoxicity. Indeed, several rodent models showed synergism between otherwise non-toxic 
doses of LPS and drugs with hepatotoxic liabilities. For trovafloxacin, this synergism was 
dependent on TNFα11. For diclofenac/LPS synergism, the severity of hepatotoxic symptoms 
was associated to the TNFα expression99. In vitro, TNFα synergism has been observed in 
human HepG2 and HepaRG cell lines as well as primary human hepatocytes16,41,43,130. 
Further mechanistic studies indicate that for diclofenac synergistic toxicity, MAPK signaling 
plays an important role in TNFα synergism in HepG2 cells14. This has been confirmed for 
more drugs, including for trovafloxacin toxicity in primary human hepatocytes130. 
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Interestingly, also the succesfull anti-TNFα biologicals have been associated with an 
increased risk on DILI139. This underlines the urgency for more mechanistic understanding 
of the TNFα signaling pathway in the context of DILI liabilities. 
TNFα binding to the TNFR induces formation of the TNF receptor complex, 
recruiting TRADD, TRAF2, RIP1, A20, the LUBAC complex and TAK1. TAK1 activates 
MAPK signaling and the IKK complex. IKK activity drives phosphorylation of IκBα, marking 
it for proteosomal degradation. IκBα’s dissociation of the cytoplasmic NF-κB causes it to 
translocate into the nucleus and activate gene transcription20. The spatio-temporal nuclear 
translocation dynamics of NF-κB are currently considered as one of the critical 
determinants of target gene expression26,27. Target genes include other NF-κB family 
members as well as members of the IκB family, thus mediating negative feedback 
responses on TNFR signaling and ultimate biological outcome289. Moreover, other target 
genes are part of the apoptosis regulatory machinery, thereby defining susceptibility for the 
onset of cell death17,20. So far it remains unclear how the various molecules that modulate 
the TNFR signaling pathway define DILI compound/ TNFα hepatotoxicity. 
Carbamazepine is one of the strongest TNFα synergistic drugs that we have 
studied16. The anti-epileptic drug is widely prescribed and induces severe hepatitis in a 
small subset of patients. The induction of cholestatic and hepatocellular injury occurs in 
similar rates, but hepatocellular injury is correlated to a negative outcome290. Around 30% 
of the carbamazepine-induced liver injury patients develop an immunoallergic reaction, 
suggesting involvement of the adaptive immune system290. Indeed, very strong HLA allele 
associations have been found in carbamazepine-induced skin injury. However, these were 
not detected in patients suffering from carbamazepine-induced liver injury53. 
Carbamazepine has a complex metabolic profile, producing several reactive metabolites 
and upregulating the expression of several CYPs both in vitro and in patients291,292. 
Surprisingly, a low dose of carbamazepine upregulates CYP expression in HepG2 cells as 
well, already within 24 hours of culture293. Only recently rodent models for carbamazepine-
induced liver injury have been developed, using high repeated dosing regimens in the 
mouse and BSO-depleted GSH levels in the rat. In both mice and rat models metabolic 
capacity and proinflammatory cytokine levels were increased. In the rat, depletion of 
Kupffer cells decreased proinflammatory cytokine expression and carbamazepine 
toxicity294–296. This suggests that Kupffer cell-produced proinflammatory cytokines are 
involved in carbamazepine-induced hepatotoxicity. We have used carbamazepine exposure 
to further understand the interplay between DILI compounds and TNFα in cytotoxic 
outcome.  
Here we systematically determined the role of individual components of the TNFR 
and related Toll-like receptor (TLR) signaling pathway in modulating drug/TNFα cytotoxicity. 
We focused on carbamazepine/TNFα-induced apoptosis in our primary screen, later 
extending these results to a larger panel of TNFα synergistic DILI compounds. We defined 
24 genes that modulate DILI carbamazepine/TNFα synergistic apoptosis effects. This 
includes known modulators of NF-κB activation such as IKBKG (IKKγ or NEMO) and 
TNFAIP3 (A20) as well as novel players, such as CARD12 (Ipaf, NLRC4) and PHF5A. 
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Drug-specific and generic candidate gene functions were correlated to several drug-
induced stress responses. Our results provide a refined mechanistic understanding of the 
different TNFR signaling pathway components that control DILI compound-induced 
adversity outcome. 
 
Material and Methods 
Cells and reagents 
HepG2 cells were acquired from ATCC (clone HB8065). The cells were maintained and 
exposed to the various chemicals in DMEM high glucose supplemented with 10% (v/v) 
FBS, 25 U/mL penicillin and 25 µg/mL streptomycin. The cells were used between passage 
5 and 20. For the compound screen, all reference compound (diclofenac, carbamazepine 
and DMSO) were acquired from Sigma-Aldrich and freshly dissolved in DMSO. The DILI 
compound library was a kind gift from the Weida Tong, NCTR-FDA. All compounds were 
dissolved in DMSO, except for metformin, fluphenazine, buthionine sulfoxamine, 
bromoethlyamine (all PBS), acetaminophen and phenobarbital (all DMEM). All compounds 
are listed in Suppl. Table 2 together with their respective cmax values. TNFα was acquired 
from R&D Systems (Abingdon, UK). For the siRNA knockdown experiments, the 
compounds were resolved fresh from stock in DMSO to a 500-fold DMSO dilution at the 
intended concentration. Valproic acid was dissolved directly into the medium and spiked 
with DMSO (final concentration 0.2% v/v). Recombinant AnnexinV labeled with Alexa633 
(AnV) was prepared in house as described before42. All siRNAs were purchased at 
Dharmacon GE Healthcare (Lafayette, US). All sequences are listed in Suppl. Table 1. 
 
siRNA screens 
Cells were plated and transfected with INTERFERin (Polyplus Transfection) in a 96-well 
plate. Transfection medium was changed 16-24 hours after transfection. Approximately 72 
hours after transfection, the cells were exposed to compounds for 8 hours. For the primary 
screen, the cells were stimulated with TNFα (1:20 dilution, final concentration 10 ng/mL) 
and directly live imaged for 24 hours with a BD Pathway TM 855 microscope (Becton 
Dickinson). For the deconvolution screen and further DILI compound/siRNA experiments, 
the cells were stimulated with TNFα and imaged for the first time point (t1) on a Nikon 
TiE2000 confocal laser microscope; after incubation for 24 hours, another image was taken 
(t24). For an overview of the time scale, see Suppl. Fig 4. 
 
Compound screen 
Cells were seeded in 384-well plates and exposed to 24 hours compound, after which the 
cells were imaged. Next, culture medium (vehicle control) or TNFα (1:10 dilution, final 
concentration 10 ng/mL) was added and cells were further cultured for another 24 hours, 
after which the cells were again imaged. Nuclei were stained with Hoechst for live cell 
imaging, PI and AnnexinV-633 were used to measure cell death. Cell death was quantified 
using Cell Profiler and R (see image analysis). To calculate the synergistic value, the 
conditions exposed to TNFα and compound (TNFα + compound) in the same well were 
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subtracted from the sum of the single exposures in different wells (TNFα) + (compound); (a) 
+ (b) – (a + b) = synergistic value. The synergistic compounds selected for further research 
did not increase AnV or PI values under compound conditions and did not show increased 
PI staining upon TNFα exposure. Significance was calculated by Anova and subsequent t-
tests with correction for multiple testing with the “fdr” option in the stats package in R220. 
 
BAC-GFP cell stress reporters 
We used BAC-GFP cellular stress reporter data for oxidative stress, ER stress, DNA 
damage and heat shock response. All data for the BAC-GFP reporter cell lines and DILI 
compound treatments has been collected previously (Hollander et al., manuscript in 
preparation). In short, the GFP-reporter cell lines were generated as described previously 44 
and maintained in culture as wild-type HepG2 cells. Cells were plated in 384-well plates 
and exposed for 24 hours. Cells were then imaged with a Nikon TiE2000 confocal laser 
microscope and analysed as described previously44. For this analysis, the mean value of 
control stimulation (DMSO vehicle 0.2%) was calculated. All cells with GFP levels above 
this value were counted and a fraction above 1* or 2* mean was calculated. 
 
Image analysis 
AnV and propidium iodide (PI) staining was analysed using CellProfiler version 2.1.1158. 
Nuclei were segmented using an in-house watershed module. AnV was imaged using an 
open pinhole, allowing detection of all AnV staining in a larger focal plane. The total image 
area positive for AnV and nuclei was measured. For PI, the staining segmentation was 
masked with the nuclear staining and then measured. Segmentation images were stored for 
control and data was stored as HDF5 file. The apoptosis is expressed as a fold change 
over control; general cell death is expressed as percentage PI positive nuclei.  
 
Data analysis 
Data analysis and quality control was performed using the in house developed R package 
H5CellProfiler (Wink et al. 2017, manuscript in preparation). Data was further managed with 
R, using packages plyr, dplyr, tidyr and reshape2217,218. For the primary screen, the z-score 
was calculated. All knockdowns that altered synergism more than 1 z-score value or less 
than -1 z-score value were included in the validation screen. For the validation screen, the 
siRNA-mediated knockdowns that altered expression more than 3 times the standard 
deviation of the control were considered a hit. Hits were considered a candidate gene when 
more than 2 single siRNA’s were a hit in the same direction and the smartpool was also 
acting in the same direction. Data visualization was performed with ImageJ and R, using 
the package ggplot219.  
  
Statistics 
Data is the mean of three independent experiments, unless stated different. Significance 
has been calculated using two-sided t-test with a Welch approximation of the variance, 
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adjusting the p-value for the false discovery rate as indicated in the figures. A p-value < 
0.05 = *, p-value < 0.01 = ** and a p-value < 0.001 = ***. 
 
Results 
Identification of TNFR signaling components that regulate DILI compound/TNFα synergy 
towards apoptosis 
To determine both the general and compound specific TNFα signaling pathway 
components that are involved in compound/TNFα-induced synergistic cell death, we 
performed a siRNA-mediated knockdown screen. The siRNA library consisted of 163 genes 
involved in TNFα/Toll-like receptor signaling pathways (see Suppl. Table 1). 
Carbamazepine was used as exemplary DILI compound for primary screening, since it 
gives strong synergy with TNFα, inducing apoptosis16. HepG2 cells were exposed to 
carbamazepine for 8 hours and next stimulated with TNFα for 24 hours (Fig. 1A, Suppl. Fig. 
4). Live cell imaging revealed 15 genes that affected carbamazepine/TNFα-induced 
cytotoxicity (Fig. 1D and Suppl. Fig. 1A). In addition, a previously large systematic siRNA 
screen targeting kinases, ubiquitin editing enzymes and TNFα/Toll-like receptor signaling 
components identified 19 genes that affect TNFα-induced NF-κB nuclear translocation 
dynamics (Herpers et al. 2017, manuscript in preparation). For validation screening we 
used early time point (1st hour; siRNA and 8 hours carbamazepine effect) and endpoint 
measurements (24 hours; carbamazepine and 24 hours TNFα effect) (Fig. 1A and 1C). We 
validated the knockdown effect of 24 candidate genes on carbamazepine/TNFα-induced 
synergistic cytotoxicity (Fig. 1E). Knockdown of control caspase-8 and TNF receptor 
(TNFRSF1A), but also CUL1 and CYLD were among the strongest protectors, while 
knockdown of PHF5A, FBWX11, TNFAIP3 and IKBKG were the strongest enhancers of 










Fig. 1: siRNA screen to detect known TNFR/TLR signaling genes involved in carbamazepine/TNFα synergism 
A-B) Overview of experimental setups of the primary and validation screen. C) Representative images and 
quantification of mock conditions and siRNA-mediated control knockdowns. D) Primary screen data as standard score 
(Z-score). A Z-score > 1 and < -1 indicates more than a standard deviation difference of the mean and is considered a 
hit, indicated in red. E) siRNA knockdown effects in carbamazepine/TNFα treated cells were normalized to mock. 
Visualized are the stacked values of the hits from the primary screen, that also did meet the requirements of the 
validation screen and were marked as validated candidate gene. Green reflects values lower than, and red reflects 
values higher than mock minus or plus 3 times the standard deviation of mock. All data is the mean of three 
independent experiments, error bars reflecting standard deviation. 
  

















































































































































































































































































Fig. 2: DILI compounds that synergize with TNFα towards apoptosis. Synergism has been calculated by 
subtracting the conditions exposed to TNFα and compound (TNFα + compound) in the same well from the sum of the 
single exposures in different wells (TNFα) + (compound). Compound (single exposure) + TNFα (single exposure) - 
Compound + TNFα (double exposure) = synergistic value. A) An overview of the synergistic value of the compounds 
in combination with TNFα exposure compared to the cell death induced by compound and TNFα single exposures. 
Vehicle control DMSO is blue, positive controls are green and all concentrations of compounds that induce significant 
synergism are red. The concentrations on which there are significant effects of these compounds are indicated with 
asterixes. B) An overview of the experimental setup of the synergism screen. C) Example images of the compounds 
chosen from the significantly synergistic compounds in D. Hoechst staining and AnnexinV staining reflects nuclear 
and apoptosis staining respectively. D) Data of compounds of which at least 1 concentration was significantly 
synergistic and PI negative. All data is the mean of three independent experiments, error bars reflect standard 
deviation and * indicates an adjusted p-value < 0.05.   
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Identification of DILI compounds that synergize with TNFα 
To further investigate the signaling components that mediate generic drug/TNFα synergistic 
effects, we assessed other DILI compounds that could synergize with TNFα. For this, 
HepG2 cells were exposed for 24 hours to each of 124 DILI compounds at 6 different 
concentrations and subsequently stimulated with TNFα or control medium (Fig. 2B, Suppl. 
Table 2). After 48 hours, cell death in compound/TNFα and compound-only treated 
conditions was determined and synergistic values were calculated (Fig. 2A). Nine DILI 
compounds showed significant synergistic apoptosis, combined with not significant PI 
staining. For colchicine, griseofulvin and valproic acid synergism this occurred in a 
(partially) dose-dependent fashion (Fig. 2C and 2D). At the concentration of 25*cmax, all 
three compounds did induce significant synergistic apoptosis; this concentration was used 
for further experiments (Fig. 2D). 
 
TNFR signaling components that generally affect DILI compound/TNFα synergy 
We hypothesized that candidate genes that modulate carbamazepine/TNFα synergism 
could be general TNFα signaling components that define DILI compound/TNFα synergism. 
To test this, we assessed the effect of siRNA-mediated knockdown of the candidate genes 
for other synergistic compounds. As we and others have shown diclofenac/TNFα 
synergistic apoptosis in HepG2 cells, we also included diclofenac16,42. After a pre-exposure 
of 8 hours the accumulation of cell death markers before and after 24 hr TNFα stimulation 
was determined by time point imaging, in a similar way as the carbamazepine validation 
screen (Fig. 1A and Suppl. Fig. 4). Quantification of the AnV labeling indicated DILI 
compound/TNFα-induced apoptosis (Fig.3A).  
Most of the candidate gene knockdowns did not affect DILI compound treatment 
alone; only TNFRSF1A and PHF5A knockdown compared to mock treatment caused a 
modest increase of apoptosis for all DILI compounds (Suppl. Fig. 2). For all compounds 
tested, TNFα-induced synergism could be induced by knockdown of A20 (TNFAIP3) (Fig. 
3A and 3B). Unexpectedly, our control siRNA against caspase 8 (CASP8) did not protect 
against colchicine/TNFα-induced synergism (Fig. 3A and 3B), implying that colchicine-
mediated TNFα-induced apoptosis has a diverging mechanism independent of TNFR-
mediated caspase-8 activation. Interestingly, most candidate genes that upon knockdown 
enhanced carbamazepine/TNFα-induced synergism, showed a similar response for the 
other DILI compound/TNFα synergisms (Fig. 3C). The effect level of knockdown of the 
different candidate genes was compound-specific. For example griseofulvin showed 
modest effects, in contrast to valproic acid which showed major enhancement of its already 
high levels of synergism (Fig. 3B). For the candidate genes that upon knockdown inhibited 
apoptosis, diverse effects were observed for the different DILI compound/TNFα treatments. 
Strikingly, whereas knockdown of the candidate genes did generally protect against 
griseofulvin/TNFα-induced cell death, it did induce extra colchicine/TNFα-induced 




Knockdown of TNFAIP3 (A20), PHF5A, MAP2K7, IKBKG, CYLD and TNFRSF1A (TNFR) 
showed the same effect direction for all DILI compounds (Fig. 3Cii), making these genes 
generic modulators of the drug/TNFα signaling interaction. Since TNFRSF1A (TNFR), A20, 
CYLD and IKBKG are extremely well-characterized modulators of TNFR signaling, this 
indicates that the observed compound/TNFα synergistic apoptosis is based on TNFα-
induced cell death141.  
 
 
Fig. 3: Knockdown of TNFα signaling pathway component effects diverge between TNFα synergism by 
different compound A) Representative images of AnV staining upon 32 hr of compound exposure together with 24 
hours of TNFα stimulation. B) Quantification of the AnV response in A, visualized as AnV/Nuclei area. Ci) Control-
normalized values of synergistic apoptosis (AnV/Nuclei) upon knockdown. Cii) Heatmaps of the control-normalized 
values of synergistic genes in carbamazepine/TNFα-induced synergistic apoptosis. The color reflects the control-
normalized effect of the knockdown. All data is the mean of three independent experiments, error bars reflecting 
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Fig. 4: DILI compound specific candidate gene effects on TNFα synergism Knockdown effects of candidate 
genes on synergistic apoptosis have been plotted compound versus compound. The Pearson correlation coefficient 
has been calculated and is displayed in the graphs in text. The colors and shapes reflect the effect of the knockdown 
in the carbamazepine/TNFα condition. Green (round) are carbamazepine/TNFα synergism inhibiting knockdowns, red 
(triangle) are carbamazepine/TNFα synergism enhancing knockdowns. All data is the mean of three independent 
experiments, error bars reflecting standard deviation. 
 
Next, we determined which compounds demonstrate the highest similarity for facilitating 
TNFα-induced apoptosis, based on the effects of the respective knockdowns. Therefore, 
we correlated the compound/TNFα synergism effects between the different compounds. 
Interestingly, valproic acid/TNFα synergism showed strongest correlation with diclofenac 
and only a modest correlation with carbamazepine (Fig. 4). In general, all compound 
knockdown effects did correlate mildly with each other, suggesting involvement of both 
general and compound-specific TNFα pathway characteristics in all drug/TNFα synergism 
responses. 
 
Association with DILI compound/TNFα synergy mechanisms with cellular stress response 
activation 
To interpret the function of candidate genes in compound-specific interaction with TNFα, we 
studied specific compound-induced cellular stress responses. In another study we mapped 
the activation of cellular stress responses using BAC-GFP HepG2 reporter cell lines. 
SRXN1 and HMOX1 are target genes of Nrf2, and their expression is regulated by oxidative 
















































































stress; p21 and BTG2 are both regulated by p53 activity and represent DNA damage; BiP 
and CHOP are activated upon ER stress; and HSPA1B is a heat shock family member and 
its expression is regulated by HSF1 and activated during protein unfolding135,297–299. 
Exposure to carbamazepine, colchicine, diclofenac, griseofulvin and valproic acid for 24 
hours induced unique stress response activation profiles of one or more reporters (Suppl. 
Fig. 3). The strongest responses were observed for SRXN1-GFP, p21-GFP, CHOP-GFP 
and HSPA1B-GFP reporters. BTG2-GFP and HMOX1-GFP showed some mild responses. 
BiP-GFP levels were hardly increased and even showed a dose-dependent decrease for 
some compounds (Suppl. Fig. 3).  
To link these stress response profiles to the effect of knockdown in DILI 
compound/TNFα synergism, we correlated the stress response induction to the effects of 
the knock down of the candidate genes. A high positive correlation with a stress response 
means that as the stress response shows more activation by a certain compound, the 
synergism with this compound and TNFα is stronger under knockdown condition. In 
contrast, a negative correlation indicates that the knockdown-induced protection against 
compound/TNFα synergism is stronger when a particular cellular stress reponse is higher. 
A strong positive or negative correlation suggests that the function of this candidate gene in 
compound/TNFα synergism is associated to the compound-induced stress response. In 
both cases, this could lead to altered TNFα-induced apoptosis.  
Strikingly, we observed a pattern of two alternating stress response profiles that 
correlate strongly with the synergistic effect of knockdown of different candidate genes. The 
effects of knockdown of one candidate gene group correlates with the expression of SRXN1 
and P21 (CASP8, CRK7, CUL1, MAP2K7, MAP3K14, NFKBIB, PHF5A, TNFRSF11, 
TNFRSF18, TRIM8, and UFD1L) and others with HMOX1 and BTG2 (CARD12, PIK3R3, 
RAPSN, and TNFAIP3; see Fig. 5B). This suggests that although correlated to the same 
stress responses (oxidative stress and DNA damage), at least two major, different branches 
of these stress responses attribute to the synergistic DILI compound/TNFα cytotoxicity. An 











Fig. 5: Correlation of compound effects on TNFα synergism with DILI compound-induced stress responses A) 
Compound-induced stress responses are plotted versus the compound/TNFα synergism effects per siRNA. Colors 
reflect different compounds. A linear relation is plotted with the 95% confidence interval as grey shaded area. B) The 
Pearson’s correlation coefficient is calculated of the conditions shown in A. Correlations higher than 0.6 and lower 
than -0.6 are colored green and orange respectively. All data is the mean of three independent experiments. 
  






In the current study we have systematically determined DILI compounds that synergize with 
TNFα and several individual signaling components of the TNFR/TLR signaling pathways 
that are required in this process. Out of 124 DILI compounds we observed strongest 
synergistic activity for valproic acid, griseofulvin, and colchine. Out of in total 182 candidate 
genes involved in TNFR/TLR signaling we identified 24 genes that are genuinely involved in 
DILI compound/TNFα synergy. Of the generic TNFα toxicity regulators, TNFAIP3 (A20) and 
PHF5A are strongly involved in suppressing TNFα-mediated cell death, while TNFRSF1A 
(TNF receptor), CYLD and ACDK2 are generally involved in promoting TNFα-induced 
apoptosis. In addition, we detected several genes that affected TNFα synergy in a more or 
less compound-specific manner. Altogether, our data suggest that drugs synergize with 
TNFα towards cytotoxicity in both compound specific and general ways. Given the overall 
involvement of inflammatory responses in DILI, we anticipate that screening for TNFα 
synergy would be relevant in DILI liability assessment. Also, mechanistic insight in generic 
compound/TNFα synergism regulators could be directly used to increase test sensitivity, for 
instance by using TNFAIP3 or PHF5A knockout/diminished expression cell lines. 
Our data indicate a very strong synergistic interaction between valproic acid and 
TNFα-mediated pro-apoptotic signaling in liver cells. Hepatotoxicity of the anti-epileptic, 
HDAC inhibiting drug valproic acid is so far mainly associated with its metabolites and the 
onset of mitochondrial injury290. Indeed, valproic acid-induced liver toxicity is most of the 
time dose-dependent and not idiosyncratic. This argues against an important role of 
proinflammatory signaling in the etiology of valproic acid-induced liver inury. However, rare 
cases of severe idiosyncratic acute liver injury have been detected and their etiology is 
currently unkown290,300. In vitro, valproic acid synergizes towards apoptosis with TNFα 
exposure in U937 cells301 and induces mitochondrial dysfunction in HepG2 cells302. 
Lymphocytes exposed to a dose range of valproic acid secrete TNFα in a dose-dependent 
fashion303. We show that valproic acid/TNFα synergy is remarkable similar to the much 
better characterized diclofenac/TNFα synergy. The strong correlation suggests a similar 
mechanism by which these compounds affect TNFα signaling outcome.  
Here, we demonstrate that valproic acid/TNFα synergy towards apoptosis is fully 
dependent on caspase 8 and can be very strongly enhanced by knockdown of CARD12, 
TNFAIP3 (A20) and PHF5A. Of these, knockdown of CARD12 and TNFAIP3 effects were 
strongly associated with the onset of the stress response reflected by HMOX1, BTG2 and 
HSPA1B upregulation (Fig. 5). Diclofenac and valproic acid differ greatly in their stress 
reporter activation profile (Suppl. Fig. 3), in stark contrast to the high similarity in drug/TNFα 
cytotoxic synergism. This suggests that TNFα synergism is not fully determined by the 
drug-induced cellular stress response pathways, but relies on drug-induced alterations in 
the TNFα pathway itself. The exact interaction between the candidate genes and valproic 
acid or diclofenac-induced stress response activation warrants further research.   
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Griseofulvin is an antifungal agent that inhibits fungal replication and microtubule formation. 
Very rare cases of hepatotoxicity have been related to griseofulvin use304. In vivo rat 
experiments showed mild liver injury upon repeated griseofulvin exposure with inflammation 
and leukocyte infiltration305. In this study, we show for the first time that griseofulvin 
synergizes with TNFα towards apoptosis and that candidate gene knockdown in general 
inhibits this synergism. Griseofulvin does not induce many cellular stress responses, 
making the drug-induced liver injury hazard, although very low, unexpected. The synergistic 
TNFα/griseofulvin hepatotoxicity in vitro provides insight into griseofulvin-induced liver injury 
in humans. 
The anti-gout therapy colchicine was also detected as synergistically inducing 
TNFα-induced apoptosis. Colchicine binds to the alpha and beta subunit of tubulin, has a 
weak anti-inflammatory effect and disturbs many cellular signaling pathways in various cell 
types. Colchicine-induced toxicity is uncommon, but when it occurs it is severe and is 
characterized by multi-organ toxicity306. In a study using precision-cut liver slices, super-
pharmacological exposures with cholchicine (2.5 – 5 mM) did induce transcriptomic 
changes that correctly classified colchicine toxicity as a necrotic damage inducing 
compound. These changes included upregulation of genes involved in the heatshock, ER 
stress, oxidative stress responses and lipid metabolism133. Indeed, we also see 
upregulation of oxidative stress response (SRXN1), in combination with upregulation of the 
DNA damage response (p21) by colchicine exposure (Suppl. Fig. 3). Knockdown of 
candidate genes in colchicine/TNFα treated cells in general enhance the synergistic 
response (Fig. 3). This effect is a stark contrast to the generally inhibiting effect of 
candidate gene knockdown in griseofulvin/TNFα-induced toxicity.. Interestingly, we show 
that colchicine/TNFα-induced toxicity is not caspase-8 dependent. This is similar to the well-
characterized synergistically trovafloxacin/TNFα-induced apoptosis. Trovafloxacin induces 
strong p21 activation and cell death via caspase 9 activation120. More research is necessary 
to show if colchicine and trovafloxacin induce TNFα toxicity in a similar manner. 
Unexpectedly, CHOP expression does not show correlation with the effect of 
candidate gene knockdown on compound/TNFα-induced apoptosis. Previously, we have 
shown that CHOP expression is necessary for carbamazepine and diclofenac-mediated 
TNFα-induced apoptosis16. However, CHOP induction is a relatively late event in the 
process of apoptosis and our candidate genes are acting more upstream in the 
compound/TNFα interaction. In addition, we did not see strong concentration-dependent 
effects on CHOP induction by compounds other than diclofenac and carbamazepine, which 
suggests strong compound-specific effects (Suppl. Fig. 3). 
Inhibited expression of some candidate genes affected compound/TNFα 
synergism very strongly. For instance, knockdown of the key inflammasome subunit 
CARD12 (Ipaf, NLRC4) induced strong effects upon most DILI compound/TNFα conditions. 
Such a role of CARD12 has not been described previously.   
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CARD12 is involved in IL1β processing307. Also knockdown of TNFAIP3 (A20) 
strongly promoted DILI compound/TNFα synergistic apoptosis, as expected. Both 
siCARD12 and siA20 effects correlated with a similar cellular stress response profile, 
including the induction of HMOX1, BTG2, HSPA1B and the reduction of BIP expression 
(Fig. 5B). In vivo, both proteins activate regenerative or protective responses upon liver 
damage upon carbon tetrachloride or partial hepatectomy141,308,309. In vitro, CARD12 is a 
target gene of p53 activity while A20 regulates the expression of p21, independently of p53 
activity309,310. However, A20 knockout has no effect on LPS-induced CARD12 
inflammasome formation in macrophages311. As the function of A20 and CARD12 are likely 
very cell type and context dependent, it would be very interesting to see their role and 
interaction in drug and TNFα -treated hepatocytes.  
The strongest enhancer of synergistic compound/TNFα-induced apoptosis 
determined in this study is knockdown of PHF5A. The overall function of PHF5A is not well-
described. PHF5A is essential for maintaining pluripotency in different types of stem cells 
by regulating Ser2 phosphorylation of RNA polymerase II and thereby inducing 
transcriptional elongation of certain gene targets312. Interestingly, CRK7 (CDK12), another 
candidate gene modulating TNFα responses detected in this study, is has a similar 
function. CRK7 also regulates Ser2 RNA polymerase II phosphorylation, regulating the 
expression of DNA damage and oxidative stress target genes198,199. We assessed that 
effects of both siCRK7 and siPHF5A on compound/TNFα-induced cytotoxicity correlate 
strongly with SRXN1-GFP and p21-GFP induction, two stress responses induced by almost 
all our compounds at varying levels (Suppl. Fig. 3). Therefore, we anticipate that PHF5A, 
similar to CRK7, regulates transcriptional elongation and is a novel regulator of specific 
subsets of stress-regulated target genes, including SRXN1 and P21. We show that CRK7 
and PHF5A knockdown have opposite effects on compound/TNFα synergism. This 
suggests that both PHF5A and CRK7 regulate separate subsets of Nrf2 and p53 target 
gene expression. The subsequent different activity of these adaptive cellular stress 
responses could well lead to the partially opposing effects upon PHF5A and CRK7 
knockdown on synergistic compound/TNFα-induced cytotoxicity. 
 The TNFα signaling pathway has long been an area of great interest and anti-
TNFα therapies are a great improvement in the treatment of many immune-related 
diseases. However, their efficacy cannot always be predicted or explained. Furthermore, 
TNFα inhibitors have been associated with an increased risk on drug-induced liver injury139. 
In addition, excessive TNFα signaling is implicated in many liver disease states. To be able 
to treat inflammation driven diseases, an improved understanding of the TNFα signaling 
pathway in a cell and context specific manner is essential. In this study, we identified critical 
modulators of TNFα-mediated hepatocyte death, including PHF5A, CRK7 (CDK12), 
TNFAIP3 (A20) and CARD12. We anticipate this will contribute to alternative therapeutic 
approaches for treatment of TNFα-dependent inflammatory disease states, including 
adverse drug reactions.  
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Suppl. Fig. 1: Data of the primary and validation siRNA screen A) Visualization of the control-normalized 
visualization of all data. Mean are reflected as bar graphs and separate experiments as black dots. Hits with a Z-score 
of higher than 1 or lower than -1 are visualized in red. B) Control-normalized data, of which the mean is reflected as 
bar graphs and separate experiments as black dots. Hits that alter synergism with more than 3 times the standard 
deviation of mock control are red and green for increasing and decreasing apoptosis respectively. All data is the mean 







Suppl. Fig. 2: Effect of knockdowns on DILI compound cytotoxicity A) Apoptosis reflected as non-normalized 
AnV/Nuclei ratios. Different compounds are visualized in different colors. B) PI staining is shown as the fraction of 
cells that is considered PI positive. Different compounds are visualized in different colors. All data is the mean of three 




Suppl. Fig. 3: DILI compound-induced cellular stress responses The fraction of cells that has GFP levels higher 
than 1*mean (upper panel) or 2*mean (lower panel) of the control condition at 24 hours of exposure is visualized in 
bar graphs. Color reflects the concentration of exposure. All data is the mean of three independent experiments and 
error bars reflect standard deviation.  






















































Supplementary Figure 3 
DILI compound-induced cellular stress responses
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Suppl. Fig. 4: Schematic overview of experimental design and key results A) Overview of time lines in different 
experimental designs (indicated by colors). B) Experimental workflow of this study. Colored text refers back to time 





Suppl. Table 1 
 
  
Gene Symbol Pool Number Duplex Number Gene Id Accession Number Gene Symbol Pool Number Duplex Number Gene Id Accession Number
AKT1 M-003000-03 D-003000-05 207 NM_001014431 MAP3K1 M-003575-02 D-003575-02 4214 NM_005921
AKT1 M-003000-03 D-003000-07 207 NM_001014431 MAP3K1 M-003575-02 D-003575-04 4214 NM_005921
AKT1 M-003000-03 D-003000-22 207 NM_001014431 MAP3K1 M-003575-02 D-003575-05 4214 NM_005921
AKT1 M-003000-03 D-003000-08 207 NM_001014431 MAP3K1 M-003575-02 D-003575-03 4214 NM_005921
AKT2 M-003001-02 D-003001-05 208 NM_001626 MAP3K14 M-003580-04 D-003580-10 9020 NM_003954
AKT2 M-003001-02 D-003001-21 208 NM_001626 MAP3K14 M-003580-04 D-003580-11 9020 NM_003954
AKT2 M-003001-02 D-003001-07 208 NM_001626 MAP3K14 M-003580-04 D-003580-12 9020 NM_003954
AKT2 M-003001-02 D-003001-08 208 NM_001626 MAP3K14 M-003580-04 D-003580-26 9020 NM_003954
ASC M-004378-01 D-004378-03 29108 NM_013258 MAP3K5 M-003584-02 D-003584-01 4217 NM_005923
ASC M-004378-01 D-004378-04 29108 NM_013258 MAP3K5 M-003584-02 D-003584-04 4217 NM_005923
ASC M-004378-01 D-004378-05 29108 NM_013258 MAP3K5 M-003584-02 D-003584-09 4217 NM_005923
ASC M-004378-01 D-004378-01 29108 NM_013258 MAP3K5 M-003584-02 D-003584-03 4217 NM_005923
ATM M-003201-04 D-003201-28 472 NM_138292 MAP3K7 M-003790-06 D-003790-17 6885 NM_145333
ATM M-003201-04 D-003201-27 472 NM_138292 MAP3K7 M-003790-06 D-003790-31 6885 NM_145333
ATM M-003201-04 D-003201-29 472 NM_138292 MAP3K7 M-003790-06 D-003790-16 6885 NM_145333
ATM M-003201-04 D-003201-30 472 NM_138292 MAP3K7 M-003790-06 D-003790-18 6885 NM_145333
AZ2 M-014092-00 D-014092-03 64343 NM_022461 MAP3K7IP1 M-004770-02 D-004770-02 10454 NM_153497
AZ2 M-014092-00 D-014092-04 64343 NM_022461 MAP3K7IP1 M-004770-02 D-004770-03 10454 NM_153497
AZ2 M-014092-00 D-014092-01 64343 NM_022461 MAP3K7IP1 M-004770-02 D-004770-18 10454 NM_153497
AZ2 M-014092-00 D-014092-02 64343 NM_022461 MAP3K7IP1 M-004770-02 D-004770-01 10454 NM_153497
BCL3 M-003874-02 D-003874-12 602 NM_005178 MAP3K7IP2 M-004771-01 D-004771-02 23118 NM_015093
BCL3 M-003874-02 D-003874-10 602 NM_005178 MAP3K7IP2 M-004771-01 D-004771-03 23118 NM_015093
BCL3 M-003874-02 D-003874-11 602 NM_005178 MAP3K7IP2 M-004771-01 D-004771-17 23118 NM_015093
BCL3 M-003874-02 D-003874-09 602 NM_005178 MAP3K7IP2 M-004771-01 D-004771-04 23118 NM_015093
BIRC1 M-004389-02 D-004389-01 4671 NM_022892 MAP3K8 M-003511-03 D-003511-07 1326 NM_005204
BIRC1 M-004389-02 D-004389-04 4671 NM_022892 MAP3K8 M-003511-03 D-003511-08 1326 NM_005204
BIRC1 M-004389-02 D-004389-05 4671 NM_022892 MAP3K8 M-003511-03 D-003511-10 1326 NM_005204
BIRC1 M-004389-02 D-004389-02 4671 NM_022892 MAP3K8 M-003511-03 D-003511-09 1326 NM_005204
BIRC2 M-004390-02 D-004390-08 329 NM_001166 MAPK1 M-003555-04 D-003555-01 5594 NM_138957
BIRC2 M-004390-02 D-004390-10 329 NM_001166 MAPK1 M-003555-04 D-003555-04 5594 NM_138957
BIRC2 M-004390-02 D-004390-09 329 NM_001166 MAPK1 M-003555-04 D-003555-03 5594 NM_138957
BIRC2 M-004390-02 D-004390-11 329 NM_001166 MAPK1 M-003555-04 D-003555-09 5594 NM_138957
BIRC3 M-004099-02 D-004099-02 330 NM_001165 MAPK9 M-003505-02 D-003505-05 5601 NM_002752
BIRC3 M-004099-02 D-004099-08 330 NM_001165 MAPK9 M-003505-02 D-003505-09 5601 NM_002752
BIRC3 M-004099-02 D-004099-09 330 NM_001165 MAPK9 M-003505-02 D-003505-06 5601 NM_002752
BIRC3 M-004099-02 D-004099-10 330 NM_001165 MAPK9 M-003505-02 D-003505-07 5601 NM_002752
BTRC M-003463-01 D-003463-02 8945 NM_003939 MEFV M-011081-00 D-011081-01 4210 NM_000243
BTRC M-003463-01 D-003463-04 8945 NM_003939 MEFV M-011081-00 D-011081-02 4210 NM_000243
BTRC M-003463-01 D-003463-01 8945 NM_003939 MEFV M-011081-00 D-011081-04 4210 NM_000243
BTRC M-003463-01 D-003463-03 8945 NM_003939 MEFV M-011081-00 D-011081-03 4210 NM_000243
C6ORF166 M-031863-00 D-031863-02 55122 NM_018064 MYD88 M-004769-01 D-004769-02 4615 NM_002468
C6ORF166 M-031863-00 D-031863-01 55122 NM_018064 MYD88 M-004769-01 D-004769-04 4615 NM_002468
C6ORF166 M-031863-00 D-031863-03 55122 NM_018064 MYD88 M-004769-01 D-004769-01 4615 NM_002468
C6ORF166 M-031863-00 D-031863-04 55122 NM_018064 MYD88 M-004769-01 D-004769-03 4615 NM_002468
CARD12 M-004396-00 D-004396-01 58484 NM_021209 NALP1 M-004423-02 D-004423-05 22861 NM_001033053
CARD12 M-004396-00 D-004396-02 58484 NM_021209 NALP1 M-004423-02 D-004423-02 22861 NM_001033053
CARD12 M-004396-00 D-004396-04 58484 NM_021209 NALP1 M-004423-02 D-004423-04 22861 NM_001033053
CARD12 M-004396-00 D-004396-03 58484 NM_021209 NALP1 M-004423-02 D-004423-03 22861 NM_001033053
CARD15 M-003464-01 D-003464-01 64127 NM_022162 NALP10 M-019113-01 D-019113-01 338322 NM_176821
CARD15 M-003464-01 D-003464-02 64127 NM_022162 NALP10 M-019113-01 D-019113-03 338322 NM_176821
CARD15 M-003464-01 D-003464-04 64127 NM_022162 NALP10 M-019113-01 D-019113-02 338322 NM_176821
CARD15 M-003464-01 D-003464-07 64127 NM_022162 NALP10 M-019113-01 D-019113-04 338322 NM_176821
CARD4 M-004398-00 D-004398-03 10392 NM_006092 NALP11 M-009033-01 D-009033-01 204801 NM_145007
CARD4 M-004398-00 D-004398-04 10392 NM_006092 NALP11 M-009033-01 D-009033-02 204801 NM_145007
CARD4 M-004398-00 D-004398-02 10392 NM_006092 NALP11 M-009033-01 D-009033-04 204801 NM_145007
CARD4 M-004398-00 D-004398-01 10392 NM_006092 NALP11 M-009033-01 D-009033-03 204801 NM_145007
CARD8 M-004454-00 D-004454-04 22900 NM_014959 NALP12 M-015092-00 D-015092-01 91662 NM_033297
CARD8 M-004454-00 D-004454-02 22900 NM_014959 NALP12 M-015092-00 D-015092-03 91662 NM_033297
CARD8 M-004454-00 D-004454-01 22900 NM_014959 NALP12 M-015092-00 D-015092-04 91662 NM_033297
CARD8 M-004454-00 D-004454-03 22900 NM_014959 NALP12 M-015092-00 D-015092-02 91662 NM_033297
CASP1 M-004401-03 D-004401-18 834 NM_033295 NALP13 M-018073-01 D-018073-03 126204 NM_176810
CASP1 M-004401-03 D-004401-03 834 NM_033295 NALP13 M-018073-01 D-018073-02 126204 NM_176810
CASP1 M-004401-03 D-004401-02 834 NM_033295 NALP13 M-018073-01 D-018073-01 126204 NM_176810
CASP1 M-004401-03 D-004401-05 834 NM_033295 NALP13 M-018073-01 D-018073-04 126204 NM_176810
CASP5 M-004405-01 D-004405-02 838 NM_004347 NALP14 M-019075-01 D-019075-02 338323 NM_176822
CASP5 M-004405-01 D-004405-03 838 NM_004347 NALP14 M-019075-01 D-019075-03 338323 NM_176822
CASP5 M-004405-01 D-004405-05 838 NM_004347 NALP14 M-019075-01 D-019075-04 338323 NM_176822
CASP5 M-004405-01 D-004405-04 838 NM_004347 NALP14 M-019075-01 D-019075-01 338323 NM_176822
CD14 M-011121-02 D-011121-18 929 NM_001040021 NALP2 M-020253-01 D-020253-01 55655 NM_017852
CD14 M-011121-02 D-011121-03 929 NM_001040021 NALP2 M-020253-01 D-020253-03 55655 NM_017852
CD14 M-011121-02 D-011121-02 929 NM_001040021 NALP2 M-020253-01 D-020253-02 55655 NM_017852
CD14 M-011121-02 D-011121-04 929 NM_001040021 NALP2 M-020253-01 D-020253-04 55655 NM_017852
CDC37 M-003231-01 D-003231-07 11140 NM_007065 NALP4 M-015351-01 D-015351-03 147945 NM_134444
CDC37 M-003231-01 D-003231-06 11140 NM_007065 NALP4 M-015351-01 D-015351-01 147945 NM_134444
CDC37 M-003231-01 D-003231-05 11140 NM_007065 NALP4 M-015351-01 D-015351-04 147945 NM_134444
CDC37 M-003231-01 D-003231-08 11140 NM_007065 NALP4 M-015351-01 D-015351-02 147945 NM_134444
CHUK M-003473-02 D-003473-05 1147 NM_001278 NALP5 M-019146-01 D-019146-01 126206 NM_153447
CHUK M-003473-02 D-003473-04 1147 NM_001278 NALP5 M-019146-01 D-019146-03 126206 NM_153447
CHUK M-003473-02 D-003473-03 1147 NM_001278 NALP5 M-019146-01 D-019146-02 126206 NM_153447
CHUK M-003473-02 D-003473-06 1147 NM_001278 NALP5 M-019146-01 D-019146-04 126206 NM_153447
CIAS1 M-017367-00 D-017367-01 114548 NM_004895 NALP6 M-015334-00 D-015334-01 171389 NM_138329
CIAS1 M-017367-00 D-017367-04 114548 NM_004895 NALP6 M-015334-00 D-015334-04 171389 NM_138329
CIAS1 M-017367-00 D-017367-02 114548 NM_004895 NALP6 M-015334-00 D-015334-03 171389 NM_138329
CIAS1 M-017367-00 D-017367-03 114548 NM_004895 NALP6 M-015334-00 D-015334-02 171389 NM_138329
COMMD1 M-007264-01 D-007264-03 150684 NM_152516 NALP7 M-016890-01 D-016890-01 199713 NM_206828
COMMD1 M-007264-01 D-007264-01 150684 NM_152516 NALP7 M-016890-01 D-016890-02 199713 NM_206828
COMMD1 M-007264-01 D-007264-02 150684 NM_152516 NALP7 M-016890-01 D-016890-04 199713 NM_206828
COMMD1 M-007264-01 D-007264-04 150684 NM_152516 NALP7 M-016890-01 D-016890-17 199713 NM_206828
CREBBP M-003477-02 D-003477-19 1387 NM_001079846 NALP8 M-019472-00 D-019472-01 126205 NM_176811
CREBBP M-003477-02 D-003477-20 1387 NM_001079846 NALP8 M-019472-00 D-019472-04 126205 NM_176811
CREBBP M-003477-02 D-003477-18 1387 NM_001079846 NALP8 M-019472-00 D-019472-02 126205 NM_176811
CREBBP M-003477-02 D-003477-21 1387 NM_001079846 NALP8 M-019472-00 D-019472-03 126205 NM_176811
CSNK2A1 M-003475-03 D-003475-01 1457 NM_177560 NALP9 M-019254-00 D-019254-02 338321 NM_176820
CSNK2A1 M-003475-03 D-003475-24 1457 NM_177560 NALP9 M-019254-00 D-019254-04 338321 NM_176820
CSNK2A1 M-003475-03 D-003475-02 1457 NM_177560 NALP9 M-019254-00 D-019254-01 338321 NM_176820
CSNK2A1 M-003475-03 D-003475-23 1457 NM_177560 NALP9 M-019254-00 D-019254-03 338321 NM_176820
CSNK2A2 M-004752-00 D-004752-04 1459 NM_001896 NCOR2 M-020145-02 D-020145-03 9612 NM_001077261
CSNK2A2 M-004752-00 D-004752-03 1459 NM_001896 NCOR2 M-020145-02 D-020145-01 9612 NM_001077261
CSNK2A2 M-004752-00 D-004752-01 1459 NM_001896 NCOR2 M-020145-02 D-020145-04 9612 NM_001077261
CSNK2A2 M-004752-00 D-004752-02 1459 NM_001896 NCOR2 M-020145-02 D-020145-05 9612 NM_001077261
CSNK2B M-007679-00 D-007679-03 1460 NM_001320 NFKB1 M-003520-01 D-003520-02 4790 NM_003998
CSNK2B M-007679-00 D-007679-01 1460 NM_001320 NFKB1 M-003520-01 D-003520-01 4790 NM_003998
CSNK2B M-007679-00 D-007679-02 1460 NM_001320 NFKB1 M-003520-01 D-003520-03 4790 NM_003998
CSNK2B M-007679-00 D-007679-04 1460 NM_001320 NFKB1 M-003520-01 D-003520-05 4790 NM_003998
CUL2 M-007277-00 D-007277-01 8453 NM_003591 NFKB2 M-003918-02 D-003918-02 4791 NM_002502
CUL2 M-007277-00 D-007277-04 8453 NM_003591 NFKB2 M-003918-02 D-003918-01 4791 NM_002502
CUL2 M-007277-00 D-007277-02 8453 NM_003591 NFKB2 M-003918-02 D-003918-18 4791 NM_002502
CUL2 M-007277-00 D-007277-03 8453 NM_003591 NFKB2 M-003918-02 D-003918-03 4791 NM_002502
CYLD M-004609-01 D-004609-01 1540 NM_001042355 NFKBIA M-004765-00 D-004765-01 4792 NM_020529
CYLD M-004609-01 D-004609-03 1540 NM_001042355 NFKBIA M-004765-00 D-004765-04 4792 NM_020529
CYLD M-004609-01 D-004609-02 1540 NM_001042355 NFKBIA M-004765-00 D-004765-02 4792 NM_020529
CYLD M-004609-01 D-004609-04 1540 NM_001042355 NFKBIA M-004765-00 D-004765-03 4792 NM_020529
DAPK1 M-004417-03 D-004417-02 1612 NM_004938 NFKBIB M-015757-00 D-015757-02 4793 NM_001001716
DAPK1 M-004417-03 D-004417-21 1612 NM_004938 NFKBIB M-015757-00 D-015757-01 4793 NM_001001716
DAPK1 M-004417-03 D-004417-04 1612 NM_004938 NFKBIB M-015757-00 D-015757-03 4793 NM_001001716
Genes regulating hepatotoxic drug/TNFα-induced synergistic apoptosis 
	 99	
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DAPK1 M-004417-03 D-004417-07 1612 NM_004938 NFKBIB M-015757-00 D-015757-04 4793 NM_001001716
ELKS M-010942-00 D-010942-03 23085 NM_015064 NFKBIE M-004766-01 D-004766-03 4794 NM_004556
ELKS M-010942-00 D-010942-01 23085 NM_015064 NFKBIE M-004766-01 D-004766-04 4794 NM_004556
ELKS M-010942-00 D-010942-02 23085 NM_015064 NFKBIE M-004766-01 D-004766-01 4794 NM_004556
ELKS M-010942-00 D-010942-04 23085 NM_015064 NFKBIE M-004766-01 D-004766-02 4794 NM_004556
EP300 M-003486-04 D-003486-10 2033 NM_001429 NFKBIZ M-013497-01 D-013497-01 64332 NM_001005474
EP300 M-003486-04 D-003486-01 2033 NM_001429 NFKBIZ M-013497-01 D-013497-02 64332 NM_001005474
EP300 M-003486-04 D-003486-02 2033 NM_001429 NFKBIZ M-013497-01 D-013497-03 64332 NM_001005474
EP300 M-003486-04 D-003486-03 2033 NM_001429 NFKBIZ M-013497-01 D-013497-04 64332 NM_001005474
FADD M-003800-03 D-003800-02 8772 NM_003824 NGFR M-009340-02 D-009340-05 4804 NM_002507
FADD M-003800-03 D-003800-19 8772 NM_003824 NGFR M-009340-02 D-009340-04 4804 NM_002507
FADD M-003800-03 D-003800-01 8772 NM_003824 NGFR M-009340-02 D-009340-06 4804 NM_002507
FADD M-003800-03 D-003800-04 8772 NM_003824 NGFR M-009340-02 D-009340-19 4804 NM_002507
FAS M-003776-04 D-003776-01 355 NM_152876 P2RX7 M-003728-01 D-003728-01 5027 NM_002562
FAS M-003776-04 D-003776-21 355 NM_152876 P2RX7 M-003728-01 D-003728-03 5027 NM_002562
FAS M-003776-04 D-003776-20 355 NM_152876 P2RX7 M-003728-01 D-003728-05 5027 NM_002562
FAS M-003776-04 D-003776-02 355 NM_152876 P2RX7 M-003728-01 D-003728-04 5027 NM_002562
GSK3B M-003010-03 D-003010-08 2932 NM_002093 PANX1 M-018253-00 D-018253-01 24145 NM_015368
GSK3B M-003010-03 D-003010-05 2932 NM_002093 PANX1 M-018253-00 D-018253-02 24145 NM_015368
GSK3B M-003010-03 D-003010-06 2932 NM_002093 PANX1 M-018253-00 D-018253-03 24145 NM_015368
GSK3B M-003010-03 D-003010-09 2932 NM_002093 PANX1 M-018253-00 D-018253-04 24145 NM_015368
HDAC3 M-003496-02 D-003496-02 8841 NM_003883 PCAF M-005055-00 D-005055-04 8850 NM_003884
HDAC3 M-003496-02 D-003496-01 8841 NM_003883 PCAF M-005055-00 D-005055-03 8850 NM_003884
HDAC3 M-003496-02 D-003496-03 8841 NM_003883 PCAF M-005055-00 D-005055-01 8850 NM_003884
HDAC3 M-003496-02 D-003496-04 8841 NM_003883 PCAF M-005055-00 D-005055-02 8850 NM_003884
HSPCA M-005186-02 D-005186-01 3320 NM_005348 PDLIM2 M-010731-02 D-010731-01 64236 NM_198042
HSPCA M-005186-02 D-005186-02 3320 NM_005348 PDLIM2 M-010731-02 D-010731-04 64236 NM_198042
HSPCA M-005186-02 D-005186-05 3320 NM_005348 PDLIM2 M-010731-02 D-010731-14 64236 NM_198042
HSPCA M-005186-02 D-005186-03 3320 NM_005348 PDLIM2 M-010731-02 D-010731-02 64236 NM_198042
HSPCB M-005187-02 D-005187-05 3326 NM_007355 PIAS1 M-008167-01 D-008167-05 8554 NM_016166
HSPCB M-005187-02 D-005187-01 3326 NM_007355 PIAS1 M-008167-01 D-008167-01 8554 NM_016166
HSPCB M-005187-02 D-005187-02 3326 NM_007355 PIAS1 M-008167-01 D-008167-02 8554 NM_016166
HSPCB M-005187-02 D-005187-18 3326 NM_007355 PIAS1 M-008167-01 D-008167-03 8554 NM_016166
IKBKB M-003503-03 D-003503-01 3551 NM_001556 PIAS4 M-006445-00 D-006445-01 51588 NM_015897
IKBKB M-003503-03 D-003503-03 3551 NM_001556 PIAS4 M-006445-00 D-006445-04 51588 NM_015897
IKBKB M-003503-03 D-003503-04 3551 NM_001556 PIAS4 M-006445-00 D-006445-02 51588 NM_015897
IKBKB M-003503-03 D-003503-02 3551 NM_001556 PIAS4 M-006445-00 D-006445-03 51588 NM_015897
IKBKE M-003723-02 D-003723-06 9641 NM_014002 PIK3CA M-003018-03 D-003018-25 5290 NM_006218
IKBKE M-003723-02 D-003723-03 9641 NM_014002 PIK3CA M-003018-03 D-003018-07 5290 NM_006218
IKBKE M-003723-02 D-003723-04 9641 NM_014002 PIK3CA M-003018-03 D-003018-08 5290 NM_006218
IKBKE M-003723-02 D-003723-07 9641 NM_014002 PIK3CA M-003018-03 D-003018-24 5290 NM_006218
IKBKG M-003767-02 D-003767-01 8517 NM_001099856 PIK3CB M-003019-02 D-003019-09 5291 NM_006219
IKBKG M-003767-02 D-003767-04 8517 NM_001099856 PIK3CB M-003019-02 D-003019-05 5291 NM_006219
IKBKG M-003767-02 D-003767-03 8517 NM_001099856 PIK3CB M-003019-02 D-003019-06 5291 NM_006219
IKBKG M-003767-02 D-003767-02 8517 NM_001099856 PIK3CB M-003019-02 D-003019-07 5291 NM_006219
IL1R1 M-005188-00 D-005188-04 3554 NM_000877 PIK3R1 M-003020-04 D-003020-26 5295 NM_181504
IL1R1 M-005188-00 D-005188-01 3554 NM_000877 PIK3R1 M-003020-04 D-003020-10 5295 NM_181504
IL1R1 M-005188-00 D-005188-03 3554 NM_000877 PIK3R1 M-003020-04 D-003020-27 5295 NM_181504
IL1R1 M-005188-00 D-005188-02 3554 NM_000877 PIK3R1 M-003020-04 D-003020-11 5295 NM_181504
IL1R2 M-007960-01 D-007960-05 7850 NM_004633 PIK3R2 M-003021-03 D-003021-07 5296 NM_005027
IL1R2 M-007960-01 D-007960-01 7850 NM_004633 PIK3R2 M-003021-03 D-003021-26 5296 NM_005027
IL1R2 M-007960-01 D-007960-03 7850 NM_004633 PIK3R2 M-003021-03 D-003021-05 5296 NM_005027
IL1R2 M-007960-01 D-007960-02 7850 NM_004633 PIK3R2 M-003021-03 D-003021-08 5296 NM_005027
IL1RAP M-003504-00 D-003504-02 3556 NM_002182 PIK3R3 M-019546-00 D-019546-01 8503 NM_003629
IL1RAP M-003504-00 D-003504-04 3556 NM_002182 PIK3R3 M-019546-00 D-019546-04 8503 NM_003629
IL1RAP M-003504-00 D-003504-01 3556 NM_002182 PIK3R3 M-019546-00 D-019546-02 8503 NM_003629
IL1RAP M-003504-00 D-003504-03 3556 NM_002182 PIK3R3 M-019546-00 D-019546-03 8503 NM_003629
IRAK1 M-004760-03 D-004760-04 3654 NM_001569 PPP2R4 M-005214-01 D-005214-01 5524 NM_178003
IRAK1 M-004760-03 D-004760-07 3654 NM_001569 PPP2R4 M-005214-01 D-005214-02 5524 NM_178003
IRAK1 M-004760-03 D-004760-01 3654 NM_001569 PPP2R4 M-005214-01 D-005214-04 5524 NM_178003
IRAK1 M-004760-03 D-004760-03 3654 NM_001569 PPP2R4 M-005214-01 D-005214-17 5524 NM_178003
IRAK2 M-004761-01 D-004761-03 3656 NM_001570 PRKACA M-004649-01 D-004649-17 5566 NM_207518
IRAK2 M-004761-01 D-004761-17 3656 NM_001570 PRKACA M-004649-01 D-004649-03 5566 NM_207518
IRAK2 M-004761-01 D-004761-04 3656 NM_001570 PRKACA M-004649-01 D-004649-01 5566 NM_207518
IRAK2 M-004761-01 D-004761-01 3656 NM_001570 PRKACA M-004649-01 D-004649-02 5566 NM_207518
IRAK3 M-004762-00 D-004762-03 11213 NM_007199 PRKACB M-004650-00 D-004650-04 5567 NM_002731
IRAK3 M-004762-00 D-004762-04 11213 NM_007199 PRKACB M-004650-00 D-004650-02 5567 NM_002731
IRAK3 M-004762-00 D-004762-01 11213 NM_007199 PRKACB M-004650-00 D-004650-03 5567 NM_002731
IRAK3 M-004762-00 D-004762-02 11213 NM_007199 PRKACB M-004650-00 D-004650-01 5567 NM_002731
IRAK4 M-003302-01 D-003302-02 51135 NM_016123 PRKCZ M-003526-04 D-003526-10 5590 NM_002744
IRAK4 M-003302-01 D-003302-05 51135 NM_016123 PRKCZ M-003526-04 D-003526-12 5590 NM_002744
IRAK4 M-003302-01 D-003302-01 51135 NM_016123 PRKCZ M-003526-04 D-003526-11 5590 NM_002744
IRAK4 M-003302-01 D-003302-06 51135 NM_016123 PRKCZ M-003526-04 D-003526-13 5590 NM_002744
IRF3 M-006875-02 D-006875-01 3661 NM_001571 PRKR M-003527-00 D-003527-02 5610 NM_002759
IRF3 M-006875-02 D-006875-03 3661 NM_001571 PRKR M-003527-00 D-003527-04 5610 NM_002759
IRF3 M-006875-02 D-006875-04 3661 NM_001571 PRKR M-003527-00 D-003527-01 5610 NM_002759
IRF3 M-006875-02 D-006875-05 3661 NM_001571 PRKR M-003527-00 D-003527-03 5610 NM_002759
LBP M-010128-00 D-010128-01 3929 NM_004139 REL M-004768-01 D-004768-03 5966 NM_002908
LBP M-010128-00 D-010128-02 3929 NM_004139 REL M-004768-01 D-004768-04 5966 NM_002908
LBP M-010128-00 D-010128-04 3929 NM_004139 REL M-004768-01 D-004768-01 5966 NM_002908
LBP M-010128-00 D-010128-03 3929 NM_004139 REL M-004768-01 D-004768-02 5966 NM_002908
LTBR M-008023-01 D-008023-02 4055 NM_002342 RELA M-003533-02 D-003533-03 5970 NM_021975
LTBR M-008023-01 D-008023-03 4055 NM_002342 RELA M-003533-02 D-003533-04 5970 NM_021975
LTBR M-008023-01 D-008023-04 4055 NM_002342 RELA M-003533-02 D-003533-05 5970 NM_021975
LTBR M-008023-01 D-008023-05 4055 NM_002342 RELA M-003533-02 D-003533-18 5970 NM_021975
LY96 M-020298-00 D-020298-01 23643 NM_015364 RELB M-004767-02 D-004767-04 5971 NM_006509
LY96 M-020298-00 D-020298-02 23643 NM_015364 RELB M-004767-02 D-004767-01 5971 NM_006509
LY96 M-020298-00 D-020298-04 23643 NM_015364 RELB M-004767-02 D-004767-05 5971 NM_006509
LY96 M-020298-00 D-020298-03 23643 NM_015364 RELB M-004767-02 D-004767-18 5971 NM_006509
MAP2K3 M-003509-03 D-003509-04 5606 NM_002756 RIPK1 M-004445-02 D-004445-04 8737 NM_003804
MAP2K3 M-003509-03 D-003509-05 5606 NM_002756 RIPK1 M-004445-02 D-004445-05 8737 NM_003804
MAP2K3 M-003509-03 D-003509-02 5606 NM_002756 RIPK1 M-004445-02 D-004445-06 8737 NM_003804
MAP2K3 M-003509-03 D-003509-06 5606 NM_002756 RIPK1 M-004445-02 D-004445-03 8737 NM_003804
MAP2K4 M-003574-02 D-003574-03 6416 NM_003010 RIPK2 M-003602-02 D-003602-02 8767 NM_003821
MAP2K4 M-003574-02 D-003574-05 6416 NM_003010 RIPK2 M-003602-02 D-003602-04 8767 NM_003821
MAP2K4 M-003574-02 D-003574-06 6416 NM_003010 RIPK2 M-003602-02 D-003602-01 8767 NM_003821
MAP2K4 M-003574-02 D-003574-01 6416 NM_003010 RIPK2 M-003602-02 D-003602-03 8767 NM_003821
MAP2K6 M-003967-01 D-003967-01 5608 NM_002758 RIPK3 M-003534-01 D-003534-02 11035 NM_006871
MAP2K6 M-003967-01 D-003967-17 5608 NM_002758 RIPK3 M-003534-01 D-003534-01 11035 NM_006871
MAP2K6 M-003967-01 D-003967-04 5608 NM_002758 RIPK3 M-003534-01 D-003534-03 11035 NM_006871
MAP2K6 M-003967-01 D-003967-03 5608 NM_002758 RIPK3 M-003534-01 D-003534-04 11035 NM_006871
MAP2K7 M-004016-01 D-004016-04 5609 NM_145185 RPS6KA1 M-003025-04 D-003025-12 6195 NM_001006665
MAP2K7 M-004016-01 D-004016-06 5609 NM_145185 RPS6KA1 M-003025-04 D-003025-07 6195 NM_001006665
MAP2K7 M-004016-01 D-004016-05 5609 NM_145185 RPS6KA1 M-003025-04 D-003025-06 6195 NM_001006665
MAP2K7 M-004016-01 D-004016-02 5609 NM_145185 RPS6KA1 M-003025-04 D-003025-08 6195 NM_001006665
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Gene Symbol Pool Number Duplex Number Gene Id Accession Number Gene Symbol Pool Number Duplex Number Gene Id Accession Number
RPS6KA4 M-004664-01 D-004664-01 8986 NM_001006944 TNFRSF13C M-013424-00 D-013424-04 115650 NM_052945
RPS6KA4 M-004664-01 D-004664-03 8986 NM_001006944 TNFRSF14 M-008096-00 D-008096-02 8764 NM_003820
RPS6KA4 M-004664-01 D-004664-04 8986 NM_001006944 TNFRSF14 M-008096-00 D-008096-03 8764 NM_003820
RPS6KA4 M-004664-01 D-004664-02 8986 NM_001006944 TNFRSF14 M-008096-00 D-008096-04 8764 NM_003820
RPS6KA5 M-004665-02 D-004665-04 9252 NM_182398 TNFRSF14 M-008096-00 D-008096-01 8764 NM_003820
RPS6KA5 M-004665-02 D-004665-06 9252 NM_182398 TNFRSF17 M-011217-02 D-011217-01 608 NM_001192
RPS6KA5 M-004665-02 D-004665-01 9252 NM_182398 TNFRSF17 M-011217-02 D-011217-04 608 NM_001192
RPS6KA5 M-004665-02 D-004665-19 9252 NM_182398 TNFRSF17 M-011217-02 D-011217-03 608 NM_001192
SITPEC M-010826-00 D-010826-03 51295 NM_016581 TNFRSF17 M-011217-02 D-011217-18 608 NM_001192
SITPEC M-010826-00 D-010826-01 51295 NM_016581 TNFRSF18 M-006449-02 D-006449-05 8784 NM_148901
SITPEC M-010826-00 D-010826-02 51295 NM_016581 TNFRSF18 M-006449-02 D-006449-06 8784 NM_148901
SITPEC M-010826-00 D-010826-04 51295 NM_016581 TNFRSF18 M-006449-02 D-006449-07 8784 NM_148901
SOCS1 M-011511-04 D-011511-09 8651 NM_003745 TNFRSF18 M-006449-02 D-006449-17 8784 NM_148901
SOCS1 M-011511-04 D-011511-07 8651 NM_003745 TNFRSF19 M-008098-00 D-008098-01 55504 NM_018647
SOCS1 M-011511-04 D-011511-08 8651 NM_003745 TNFRSF19 M-008098-00 D-008098-02 55504 NM_018647
SOCS1 M-011511-04 D-011511-23 8651 NM_003745 TNFRSF19 M-008098-00 D-008098-04 55504 NM_018647
SUGT1 M-012877-00 D-012877-03 10910 NM_006704 TNFRSF19 M-008098-00 D-008098-03 55504 NM_018647
SUGT1 M-012877-00 D-012877-04 10910 NM_006704 TNFRSF1A M-005197-00 D-005197-02 7132 NM_001065
SUGT1 M-012877-00 D-012877-02 10910 NM_006704 TNFRSF1A M-005197-00 D-005197-03 7132 NM_001065
SUGT1 M-012877-00 D-012877-01 10910 NM_006704 TNFRSF1A M-005197-00 D-005197-04 7132 NM_001065
TBK1 M-003788-02 D-003788-07 29110 NM_013254 TNFRSF1A M-005197-00 D-005197-01 7132 NM_001065
TBK1 M-003788-02 D-003788-02 29110 NM_013254 TNFRSF1B M-003934-00 D-003934-02 7133 NM_001066
TBK1 M-003788-02 D-003788-01 29110 NM_013254 TNFRSF1B M-003934-00 D-003934-01 7133 NM_001066
TBK1 M-003788-02 D-003788-06 29110 NM_013254 TNFRSF1B M-003934-00 D-003934-03 7133 NM_001066
TCEB1 M-010541-01 D-010541-06 6921 NM_005648 TNFRSF1B M-003934-00 D-003934-04 7133 NM_001066
TCEB1 M-010541-01 D-010541-01 6921 NM_005648 TNFRSF21 M-004450-01 D-004450-02 27242 NM_014452
TCEB1 M-010541-01 D-010541-02 6921 NM_005648 TNFRSF21 M-004450-01 D-004450-05 27242 NM_014452
TCEB1 M-010541-01 D-010541-05 6921 NM_005648 TNFRSF21 M-004450-01 D-004450-01 27242 NM_014452
TCEB2 M-012376-02 D-012376-07 6923 NM_207013 TNFRSF21 M-004450-01 D-004450-04 27242 NM_014452
TCEB2 M-012376-02 D-012376-20 6923 NM_207013 TNFRSF25 M-004449-02 D-004449-16 8718 NM_001039664
TCEB2 M-012376-02 D-012376-01 6923 NM_207013 TNFRSF25 M-004449-02 D-004449-14 8718 NM_001039664
TCEB2 M-012376-02 D-012376-21 6923 NM_207013 TNFRSF25 M-004449-02 D-004449-15 8718 NM_001039664
TIRAP M-004713-02 D-004713-03 114609 NM_148910 TNFRSF25 M-004449-02 D-004449-17 8718 NM_001039664
TIRAP M-004713-02 D-004713-04 114609 NM_148910 TNFRSF4 M-008100-00 D-008100-02 7293 NM_003327
TIRAP M-004713-02 D-004713-02 114609 NM_148910 TNFRSF4 M-008100-00 D-008100-04 7293 NM_003327
TIRAP M-004713-02 D-004713-18 114609 NM_148910 TNFRSF4 M-008100-00 D-008100-03 7293 NM_003327
TLR1 M-008086-01 D-008086-17 7096 NM_003263 TNFRSF4 M-008100-00 D-008100-01 7293 NM_003327
TLR1 M-008086-01 D-008086-01 7096 NM_003263 TNFRSF5 M-008101-02 D-008101-02 958 NM_152854
TLR1 M-008086-01 D-008086-04 7096 NM_003263 TNFRSF5 M-008101-02 D-008101-04 958 NM_152854
TLR1 M-008086-01 D-008086-03 7096 NM_003263 TNFRSF5 M-008101-02 D-008101-01 958 NM_152854
TLR10 M-008087-01 D-008087-03 81793 NM_001017388 TNFRSF5 M-008101-02 D-008101-05 958 NM_152854
TLR10 M-008087-01 D-008087-02 81793 NM_001017388 TNFRSF7 M-008103-01 D-008103-03 939 NM_001242
TLR10 M-008087-01 D-008087-04 81793 NM_001017388 TNFRSF7 M-008103-01 D-008103-02 939 NM_001242
TLR10 M-008087-01 D-008087-01 81793 NM_001017388 TNFRSF7 M-008103-01 D-008103-01 939 NM_001242
TLR2 M-005120-03 D-005120-09 7097 NM_003264 TNFRSF7 M-008103-01 D-008103-04 939 NM_001242
TLR2 M-005120-03 D-005120-06 7097 NM_003264 TNFRSF8 M-008104-01 D-008104-03 943 NM_152942
TLR2 M-005120-03 D-005120-07 7097 NM_003264 TNFRSF8 M-008104-01 D-008104-04 943 NM_152942
TLR2 M-005120-03 D-005120-08 7097 NM_003264 TNFRSF8 M-008104-01 D-008104-17 943 NM_152942
TLR3 M-007745-00 D-007745-01 7098 NM_003265 TNFRSF8 M-008104-01 D-008104-02 943 NM_152942
TLR3 M-007745-00 D-007745-04 7098 NM_003265 TNFRSF9 M-008105-02 D-008105-04 3604 NM_001561
TLR3 M-007745-00 D-007745-03 7098 NM_003265 TNFRSF9 M-008105-02 D-008105-19 3604 NM_001561
TLR3 M-007745-00 D-007745-02 7098 NM_003265 TNFRSF9 M-008105-02 D-008105-05 3604 NM_001561
TLR4 M-008088-01 D-008088-02 7099 NM_138554 TNFRSF9 M-008105-02 D-008105-06 3604 NM_001561
TLR4 M-008088-01 D-008088-03 7099 NM_138554 TOLLIP M-016930-01 D-016930-01 54472 NM_019009
TLR4 M-008088-01 D-008088-01 7099 NM_138554 TOLLIP M-016930-01 D-016930-17 54472 NM_019009
TLR4 M-008088-01 D-008088-04 7099 NM_138554 TOLLIP M-016930-01 D-016930-02 54472 NM_019009
TLR5 M-008089-01 D-008089-01 7100 NM_003268 TOLLIP M-016930-01 D-016930-04 54472 NM_019009
TLR5 M-008089-01 D-008089-02 7100 NM_003268 TRADD M-004452-01 D-004452-02 8717 NM_003789
TLR5 M-008089-01 D-008089-04 7100 NM_003268 TRADD M-004452-01 D-004452-04 8717 NM_003789
TLR5 M-008089-01 D-008089-17 7100 NM_003268 TRADD M-004452-01 D-004452-01 8717 NM_003789
TLR6 M-005156-01 D-005156-02 10333 NM_006068 TRADD M-004452-01 D-004452-03 8717 NM_003789
TLR6 M-005156-01 D-005156-03 10333 NM_006068 TRAF2 M-005198-00 D-005198-02 7186 NM_021138
TLR6 M-005156-01 D-005156-05 10333 NM_006068 TRAF2 M-005198-00 D-005198-04 7186 NM_021138
TLR6 M-005156-01 D-005156-01 10333 NM_006068 TRAF2 M-005198-00 D-005198-01 7186 NM_021138
TLR7 M-004714-01 D-004714-02 51284 NM_016562 TRAF2 M-005198-00 D-005198-03 7186 NM_021138
TLR7 M-004714-01 D-004714-03 51284 NM_016562 TRAF3 M-005252-02 D-005252-03 7187 NM_003300
TLR7 M-004714-01 D-004714-01 51284 NM_016562 TRAF3 M-005252-02 D-005252-21 7187 NM_003300
TLR7 M-004714-01 D-004714-04 51284 NM_016562 TRAF3 M-005252-02 D-005252-01 7187 NM_003300
TLR8 M-004715-01 D-004715-04 51311 NM_138636 TRAF3 M-005252-02 D-005252-04 7187 NM_003300
TLR8 M-004715-01 D-004715-02 51311 NM_138636 TRAF5 M-006568-01 D-006568-01 7188 NM_001033910
TLR8 M-004715-01 D-004715-01 51311 NM_138636 TRAF5 M-006568-01 D-006568-02 7188 NM_001033910
TLR8 M-004715-01 D-004715-03 51311 NM_138636 TRAF5 M-006568-01 D-006568-04 7188 NM_001033910
TLR9 M-004066-01 D-004066-02 54106 NM_017442 TRAF5 M-006568-01 D-006568-03 7188 NM_001033910
TLR9 M-004066-01 D-004066-04 54106 NM_017442 TRAF6 M-004712-00 D-004712-02 7189 NM_004620
TLR9 M-004066-01 D-004066-05 54106 NM_017442 TRAF6 M-004712-00 D-004712-03 7189 NM_004620
TLR9 M-004066-01 D-004066-03 54106 NM_017442 TRAF6 M-004712-00 D-004712-01 7189 NM_004620
TNFAIP3 M-009919-00 D-009919-03 7128 NM_006290 TRAF6 M-004712-00 D-004712-04 7189 NM_004620
TNFAIP3 M-009919-00 D-009919-04 7128 NM_006290 TRAM1 M-018676-01 D-018676-02 23471 NM_014294
TNFAIP3 M-009919-00 D-009919-01 7128 NM_006290 TRAM1 M-018676-01 D-018676-03 23471 NM_014294
TNFAIP3 M-009919-00 D-009919-02 7128 NM_006290 TRAM1 M-018676-01 D-018676-04 23471 NM_014294
TNFRSF10A M-008090-02 D-008090-15 8797 NM_003844 TRAM1 M-018676-01 D-018676-01 23471 NM_014294
TNFRSF10A M-008090-02 D-008090-16 8797 NM_003844 TRIF M-012833-02 D-012833-02 148022 NM_182919
TNFRSF10A M-008090-02 D-008090-06 8797 NM_003844 TRIF M-012833-02 D-012833-04 148022 NM_182919
TNFRSF10A M-008090-02 D-008090-17 8797 NM_003844 TRIF M-012833-02 D-012833-01 148022 NM_182919
TNFRSF10B M-004448-00 D-004448-01 8795 NM_003842 TRIF M-012833-02 D-012833-21 148022 NM_182919
TNFRSF10B M-004448-00 D-004448-02 8795 NM_003842 UBE2N M-003920-01 D-003920-04 7334 NM_003348
TNFRSF10B M-004448-00 D-004448-03 8795 NM_003842 UBE2N M-003920-01 D-003920-02 7334 NM_003348
TNFRSF10B M-004448-00 D-004448-04 8795 NM_003842 UBE2N M-003920-01 D-003920-05 7334 NM_003348
TNFRSF10C M-008091-00 D-008091-01 8794 NM_003841 UBE2N M-003920-01 D-003920-01 7334 NM_003348
TNFRSF10C M-008091-00 D-008091-02 8794 NM_003841 UBE2V1 M-010064-03 D-010064-21 7335 NM_001032288
TNFRSF10C M-008091-00 D-008091-03 8794 NM_003841 UBE2V1 M-010064-03 D-010064-23 7335 NM_001032288
TNFRSF10C M-008091-00 D-008091-04 8794 NM_003841 UBE2V1 M-010064-03 D-010064-02 7335 NM_001032288
TNFRSF10D M-008092-01 D-008092-03 8793 NM_003840 UBE2V1 M-010064-03 D-010064-22 7335 NM_001032288
TNFRSF10D M-008092-01 D-008092-05 8793 NM_003840 XEDAR M-008044-01 D-008044-06 60401 NM_021783
TNFRSF10D M-008092-01 D-008092-01 8793 NM_003840 XEDAR M-008044-01 D-008044-05 60401 NM_021783
TNFRSF10D M-008092-01 D-008092-02 8793 NM_003840 XEDAR M-008044-01 D-008044-07 60401 NM_021783
TNFRSF11A M-008093-01 D-008093-01 8792 NM_003839 XEDAR M-008044-01 D-008044-08 60401 NM_021783
TNFRSF11A M-008093-01 D-008093-04 8792 NM_003839
TNFRSF11A M-008093-01 D-008093-05 8792 NM_003839
TNFRSF11A M-008093-01 D-008093-06 8792 NM_003839
TNFRSF11B M-008094-01 D-008094-01 4982 NM_002546
TNFRSF11B M-008094-01 D-008094-04 4982 NM_002546
TNFRSF11B M-008094-01 D-008094-02 4982 NM_002546
TNFRSF11B M-008094-01 D-008094-03 4982 NM_002546
TNFRSF12A M-010661-01 D-010661-04 51330 NM_016639
TNFRSF12A M-010661-01 D-010661-05 51330 NM_016639
TNFRSF12A M-010661-01 D-010661-03 51330 NM_016639
TNFRSF12A M-010661-01 D-010661-01 51330 NM_016639
TNFRSF13B M-008095-00 D-008095-01 23495 NM_012452
TNFRSF13B M-008095-00 D-008095-02 23495 NM_012452
TNFRSF13B M-008095-00 D-008095-04 23495 NM_012452
TNFRSF13B M-008095-00 D-008095-03 23495 NM_012452
TNFRSF13C M-013424-00 D-013424-01 115650 NM_052945
TNFRSF13C M-013424-00 D-013424-02 115650 NM_052945
TNFRSF13C M-013424-00 D-013424-03 115650 NM_052945
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Suppl. Table 2 
 
compound cmax	(μM) compound cmax	(μM) compound cmax	(μM) compound cmax	(μM)
acarbose 0,15 dexamethasone 0,224 indomethacin 5,59 phenytoin 21,72
acetaminophen 139 dextromethorphan	HBr 0,022 isoniazid 76,56 pioglitazone 2,946
adefovir 0,085 diclofenac 10,1 isoproterenol 2,02 prednisolone 0,68
allopurinol 13,81 didanosine 9,83 kanamycin 60,1 primaquine 0,615
altretamine 3,76 diethylmaleate NA ketoconazole 6,59 primidone 4,67
amiodarone 0,807 digoxin 0,003 ketorolac 3,53 procyclidine 0,404
amoxicillin 22,3 diltiazem 0,356 labetalol 2,68 propranolol 0,201
azathioprine 0,34 disulfiram 5,4 maprotiline 0,18 propylthiouracil 9,1
benzbromarone 4,339 DMSO 0,2 mebendazole 0,13 ranitidine 1,79
betaine 940 edrophonium 60,2 meclizine 0,026 ribavirin 2,61
bicalutamide 1,97 enalapril 0,4 mercaptopurine 0,48 rifampicin 15
bosentan 7,4 entacapone 3,93 metformin 7,78 simvastatin 0,082
bromfenac 17,96 epinephrine 0,002 methimazole 2,62 succinylcholine 137,74
buspirone 0,016 erythromycin 11 methotrexate 0,77 sulindac 31,985
busulfan 0,277 ethambutol 24,47 methyldopa 18,94 tacrolimus 0,037
captopril 8,882 etodolac 68,49 metoprolol 0,56 tamoxifen 0,162
carbamazepine 50,79 etoposide NA mexiletine 3,83 terbinafine 4
chloramphenicol 46,36 famotidine 0,308 moxisylyte 0,16 thapsigargin NA
chlormezanone 10,59 fenofibrate 4,1 naproxen 0,2 thioridazine 0,55
chlorpromazine 0,94 fenoprofen 58,2 nefazodone 3,95 ticlopidine 8,075
chlorpropamide 130,1 fialuridine 1 neomycin 0,44 tnfα NA
cimetidine 11,89 fluoxetine 0,05 nifedipine 0,43 tolbutamide 233,03
ciprofloxacin 6,58 flurbiprofen 57,32 nimesulide 21,082 tolcapone 21,99
clofibrate 470 folic	acid 0,043 nitrofurantoin 6 trazodone 5,056
clotrimazole 0,087 furosemide 3,29 nizatidine 4 troglitazone 6,39
clozapine 2,44 ganciclovir 4,62 ofloxacin 9,96 valproic	acid 243,	08
colchicine 0,016 glimepiride 1,12 omeprazole 4,7 verapamil 0,5
cyclosporin	A 0,2 griseofulvin 4,54 oxytetracycline 3,26 warfarin 4,86
dacarbazine 20,64 haloperidol 0,005 paroxetine 0,061 ximelagatran 0,3
danazol 0,109 hydroxyzine 0,27 perhexiline 2,16 zafirlukast 1,21
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Chapter 6 
o DILI compound exposure induces specific adaptive stress reporter activation with 
distinct time dynamics and magnitude  
o Quantitative data analysis and hierarchical clustering reveals both mechanistic and 
predictive inshight into mechanisms of toxicity 
o Feature selection and SVM classification show predictive power of a diverse and 
complex set of biologically interpretable features 
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Drug-induced liver injury remains a major concern during drug development. There 
is an urgent need for improved mechanistic understanding and prediction of DILI 
liabilities from in vitro approaches. Previously, we have reported a high content live 
cell microscopy platform containing mechanism-based fluorescent protein toxicity 
pathway reporters to detect cellular stress responses reflecting primary human 
hepatocyte drug responses. Here, we have systematically evaluated the application 
of integrated stress pathway target gene activation of four key adaptive stress 
pathways: oxidative stress, ER stress, DNA damage stress and inflammatory stress. 
More than 118 FDA-labeled drugs in 5 concentrations based on human plasma 
maximum concentration levels were screened for reporter activation, using live cell 
confocal imaging. Quantitative data analysis revealed activation of single or multiple 
reporters by most drugs in a concentration and time dependent manner. Hierarchical 
clustering of time course dynamics and refined single cell analysis allowed the 
allusion of key events in toxicity. Concentration response modeling was performed 
to calculate benchmark concentrations (BMCs). Extracted temporal dynamic 
parameters and BMCs were used to assess the predictive power of sublethal 
adaptive stress pathway activation. Although cellular adaptive responses were 
activated by non-DILI and severe-DILI compounds alike, dynamic behavior and lower 
BMCs of pathway activation were sufficiently distinct between these compound 
classes as shown by unsupervised hierarchical clustering and their combined high 
correct classification. The high level detailed temporal and concentration-dependent 
dynamics of adaptive stress pathway activation by exposure with compounds with 
DILI liabilities add to the overall understanding and prediction of drug-induced liver 
toxicities 
 




Despite major efforts to understand and predict drug-induced liver injury (DILI), unpredicted 
liver failure upon drug use remains an important problem both in the clinic and during drug 
development313. In general, various chemical, genetic, and life style factors can contribute 
to the development of DILI. To be able to improve prediction of DILI liabilities of new 
molecular entities it is essential to understand how currently known compounds induce 
injury. Of most interest are the idiosyncratic DILI compounds, inducing unpredicted results 
at a normal dose, and only in a very small group of patients.  
Gene expression analysis has contributed significantly to our understanding of 
DILI314,315 . This has led to the identification of specific signaling pathways that are activated 
during DILI and are possibly predictive for chemical-induced liver injury. Key among these 
are classic stress responses activated to maintain cellular homeostasis, including the 
oxidative stress response, the ER stress response and the DNA damage response314, 
together with inflammatory stress208. We have established fluorescent protein reporter 
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hepatoma cell lines using bacterial artificial chromosome (BAC) GFP tagging, that capture 
each of these four pathways using SRXN1, CHOP, p21 and ICAM1 as biomarkers44. 
For the oxidative stress pathway we have established a SRXN1-GFP reporter44. 
Parent compounds or their metabolites can oxidize, reduce or alkylate cellular components, 
thereby directly inducing oxidative stress or indirectly for example via disruption of essential 
mitochondrial functioning. The activation of transcription factor Nrf2 together with AP1 is 
dependent on the redox sensor Kelch-like ECH-associated protein 1 (Keap1), and induces 
expression of antioxidants among which the small redox protein (SRXN1)316,317. SRXN1, 
conserved in all eukaryotes, is best characterized for its ATP-dependent reduction of the 
hyperoxidized form of peroxiredoxin317. Peroxiredoxin (Prx) is an enigmatic protein, its 
reversible inactivation caused by its own substrate. However, it is hypothesized that SRXN1 
activity is the essential switch between Prx either acting as chaperone of the intracellular 
messenger peroxides and its usual peroxidase function, protecting the cell against oxidative 
damage317. Furthermore, deglutathionylation of s-glutathionylated cysteins by SRXN1 has 
been shown to be essential for the functioning of phosphatases318. In vivo studies show that 
in the liver, upregulation of SRXN1 via Nrf2 activation, upon either cadmium-induced heavy 
metal stress and Pyrazole exposure or alcohol-induced CYP2E1 related toxicity, is vital for 
protection against fulminant oxidative stress and subsequent organ failure319–321.  
To monitor ER stress we have established a CHOP-GFP reporter44. ER stress is a 
protective response upon the accumulation of untranslated proteins in the endoplasmic 
reticulum (ER). This can be induced by compound or metabolite-induced disruption of for 
example N-linked glycosylation, disulfide bond formation, transport of folded proteins from 
the ER, protein folding, calcium homeostasis, or ER stress response components itself. The 
outcome of the compound-induced ER stress response, cell survival or cell death, is 
dependent both on the strength and duration of the response322. Upon ER stress, three 
classical signaling pathways are activated via the sensor proteins PKR-like ER kinase 
(PERK), activating transcription factor 6 (Atf6), and inositol-requiring enzyme 1 (Ire1). 
Activation of PERK leads to arrested protein translation by phosphorylation of the 
eukaryotic transcription factor 2, in order to diminish the flux of unfolded proteins into the 
ER. Permitted translation of activating transcription factor 4 (Atf4) and results in the specific 
expression of ER function-related proteins and the transcription factor C/EBP homologous 
protein (CHOP). Activation of the Ire1 and Atf6 pathways can also induce CHOP 
expression, although with lower efficiency323. CHOP activity induces or represses the 
expression and function of many proteins, including proapoptotic proteins like Bcl-X, BAX 
and caspase3, and the suppression of antiapoptotic proteins as Bcl2. In the liver, CHOP 
expression is not conclusively linked to protection or increased drug-induced injury. In vitro 
as well as in vivo studies have detected CHOP induction upon drug exposure, however, at 
this moment a causal relationship with cell death or protection against cell death cannot be 
drawn324. 
DNA damage can be monitored by a fluorescent protein reporter for the p53 
downstream target gene p21, as shown previously44. The cellular protective response upon 
DNA damage induces cell cycle arrest and subsequent senescence, to prevent genomic 
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instability during replication. DNA damage can be induced either directly by chemical 
mutagens, usually electrophiles that directly interact with DNA and form covalent bonds, or 
indirectly by the formation of ROS that can interact with DNA135. The key transcription factor 
p53 is activated upon DNA damage and induces expression of its many target genes, 
among which is p21325. The best-characterized function of p21 is its effective inhibition of 
cyclin-dependent kinases (CDK), which halts the progression of the cell cycle in the G1 or 
G2/M phase. Localization of p21 has been found both in the nucleus and the cytoplasm, 
reflecting different roles in both cell cycle arrest and antiapoptosis signaling respectively326. 
In the liver, in vivo studies show upregulated p21 nuclear expression upon drug exposure, 
mostly via p53 activation327,328.  
Finally, a fluorescent reporter for ICAM1 allows the monitoring of the cytokine-
mediated activation of NF-κB signaling28. Besides intrinsic drug qualities as dose and 
lipophilicity, several host factors have been described to be involved in the development of 
idiosyncratic DILI. Among these, inflammatory processes have been known to be 
detrimental in the process of liver injury, but are also known to be essential for recovery 
after injury208. Inflammatory cytokine excretion firstly activates and recruits innate as well as 
adaptive immune cells, and secondly activates the hepatocytes and non-parenchymal cells 
themselves. In in vivo studies, the production of proinflammatory cytokine TNFα upon 
lipopolysaccharide exposure in combination with drugs is strongly suggested to increase 
toxicity10. TNFα stimulation of endothelial cells as hepatocytes has been known to induce 
both adaptive, pro-survival, and adverse, pro-death, cellular signaling. The activation of the 
key transcription factor nuclear factor kB (NF-κB) ensures the expression of several pro-
survival genes, but also enhances the proinflammatory gene expression20. One of the 
proinflammatory genes induced by NF-κB activation is intercellular adhesion molecule 1 
(ICAM1). ICAM1 is expressed at the membrane of TNFα-activated hepatocytes, aiding in 
the adherence and transendothelial migration of leukocytes from the blood stream329. 
ICAM1 is widely used as a marker for inflammation and ICAM1 expression is also 
increased upon inflammation in the liver330. 
Given the central role of the above pathways in liver injury and DILI specifically, 
our objective was to evaluate the application of our panel of target gene BAC-GFP reporter 
cell lines that represent these four major adaptive stress response pathways to predict DILI 
liability. Previously, we demonstrated that the BAC-GFP reporters allow the quantification of 
the chemical-induced stress responses similar to primary human hepatocytes44. Here we 
systematically determined the application of the BAC GFP-SRXN1, GFP-CHOP, GFP-p21 
and GFP-ICAM1 reporters for the assessment of DILI using a set of 118 FDA-labeled drugs 
with DILI drug label classification. The concentration- and time-dependent GFP responses 
were determined in association with several cytotoxicity parameters. In this study, we 
provide quantitative information of the dynamic adaptive stress response activation for all 
118 drugs allowing detailed mode-of-action assessment. Mechanism-based temporal 
dynamic data together with concentration response modeling was used for prediction of 
DILI outcome.  
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Materials and methods 
Cell culture 
Human hepatoma HepG2 cells were acquired from ATCC (clone HB8065). HepG2 SRXN1, 
DDIT3 (CHOP), CDKN1A (p21) and ICAM1 BAC GFP reporter cell lines were generated 
and characterized as described previously44. HepG2 BAC-GFP reporters were maintained 
and exposed to drugs in DMEM high glucose supplemented with 10% (v/v) FBS, 25 U/mL 
penicillin and 25 µg/mL streptomycin. The cell lines were used between passage 5 and 25. 
For live cell imaging, the cells were seeded in Greiner black µ-clear 384 wells plates, at 
8,000 cells per well. 
 
Reagents 
All reference compound chemicals were acquired from Sigma-Aldrich and freshly dissolved 
in DMSO; except for metformin, fluphenazine, buthionine sulfoxamine, bromoethlyamine (all 
PBS), acetaminophen and phenobarbital (all DMEM). TNFα was acquired from R&D 
Systems (Abingdon, UK). DILI compounds were a kind gift from the Dr. Weida Tong, 
NCTR-FDA331. All compounds were maintained as 500-fold stock such that final treatments 
did not exceed 0.2 % v/v DMSO. 
 
Microscopy 
Accumulation of GFP levels, propidium iodide (PI) and Hoechst staining was monitored 
using a Nikon TiE2000 confocal laser microscope (lasers: 540nm, 488nm and 408nm), 
equipped with an automated stage and perfect focus system at 37 degrees Celsius with 
humidified atmosphere and 5% CO2/air mixture. Prior to imaging at 20x magnification, 
HepG2 cells were loaded for 45 minutes with 100 ng/mL Hoechst33342 to visualize the 
nuclei, upon which the Hoechst-containing medium was washed away to avoid Hoechst 
phototoxicity332 and replaced with medium containing PI to monitor cell death. Each 384-
well plate contained one reporter cell line, which was exposed to all the compounds used in 
the screen at one certain concentration (1, 5, 10, 50 or 100 C-max); for each concentration 
at least two replicates were imaged per reporter cell line. For the ICAM1-GFP reporter 
experiments, cells were first exposed for 8 hours to compound only. Next, TNFα was added 
to all wells, up to a final concentration of 10 ng/mL, which diluted the compound 
concentration ten times. Upon TNFα exposure, imaging was started. 
 
Reporter response quantification 
Quantitative image analysis was performed with CellProfiler version 2.1.1158 with an in 
house developed CellProfiler module implementing the watershed masked algorithm for 
segmentation44,159. Image analysis results were stored as HDF5 files. Data analysis, quality 
control and graphics was performed using the in house developed R package h5CellProfiler 
(manuscript in preparation). For each reporter hourly intensity levels of the GFP signal, the 
nuclear Hoechst33342 intensity levels and at 24 hours the PI staining were measured at the 





GFP intensity cell population means were calculated. In addition, for each plate the cell 
population mean GFP intensity of the DMSO treated cells was calculated to determine 
background control values. Per plate, the single cells that had values above the 2X mean, 
3X mean were counted. For ICAM1, the background control values consisted of DMSO 
conditions treated with TNFα, and the single cells with values above, as well as below 
background values were counted. Due to the non-symmetric distribution of ICAM1 cell 
population GFP intensities, the interquartile range (IQR) was used to count the number of 
cells 1.5X, 2X and 3X above and below the TNFα IQR control values (Suppl. Fig. 1). To 
account for PI background staining noise the PI segmentations were masked by a 2 pixel 
dilated nuclei. The area of these nuclei and the PI objects were divided to obtain a PI/nuclei 
ratio. These ratios were filtered to be at least 10 % of the cell size and following this 
procedure each cell was either flagged as alive or dead in the final time point of the 24 live 
imaging session. PI positive fraction were normalized to DMSO (or TNFα for ICAM1) by 
subtracting the control PI positive fractions. Linear regression was applied with time as 
independent variable to quantify treatment effects on a plate to plate basis of cell speed, 
nuclear size, Hoechst33342 nuclear intensity cell numbers. The slope coefficient mean over 
all plates was used to obtain a compound-concentration specific summary feature. All 
summary features were scaled between 0 and 1 with the formula (x-xmin_replicate) / 
(xmax_replicate – xmin_replicate), with the exception of 1) the cell count features which were scaled 
between 0 and 1 by calculating cell fractions and 2) the ICAM1-GFP intensity features 
which were scaled between -1 and 1 to account for up or down regulation of the TNFα-
induced ICAM1 expression (Suppl. Fig. 1). 
 
Concentration response data transformation and Benchmark Concentration (BMC) 
modeling 
The maximum values over time of the scaled intensity levels and positive GFP fractions 
were selected for the concentration response curves. These values were fit to a 4 
parameter log-logistic model using the drc package333. BMC values were calculated as the 
concentration at which +0.25 (and – 0.25 for ICAM1) absolute increase from the initial 
response values occurred (Fig. 4A). The replicate means of the maximum over-time 
features were calculated for each compound-concentration preceding unsupervised 
hierarchical clustering. For the time courses (Fig. 3) natural cubic splines with 8 degrees of 
freedom were fit after which 24 discrete equidistant time points were selected to calculate 
per-time point replicate means. The time course hierarchical clustering was performed by 
first calculating Manhattan-based distances between all time course vectors. The mean 
Manhattan-based distances over all reporters were used as inputs for the Ward-based 
clustering. This ensured the temporal dynamics were also clustered appropriately. 
 
Data representation  
All HCI data representations were generated or modified with Illustrator CS6, Fiji, 
ggplot2219, the `aheatmap` function of the NMF package334.  
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Severe vs non-Severe DILI prediction with Support vector machine 
FDA DILI-annotation was used as ‘ground truth’ with non-DILI (n=16), less-severe DILI 
(n=36) and ambiguous DILI (n=12) grouped as `nonSevere DILI` and severe-DILI (n=54) as 
`severe DILI` resulting in a two-classification problem. Features were obtained by time 
dynamic feature extraction of time courses using functional data analysis using the in house 
developed R-package `celloscillate` and the BMC and cmax normalized BMC values (Fig. 
6). Feature selection and SVM model tuning was performed in an 200 times iterative 
process with randomly selected 80/20 – equal class distributed training/test set procedure. 
The training phase included a first feature selection step using a Kolmogorov-Smirnov test 
for equal distributions between the two classes followed by pair-wise correlation filter step 
(>0.8 or <-08). After the feature selection step the training phase. The second step in the 
training phase consisted of the SVM model tuning with 10 repeats of 10-fold cross-
validation. The test phase on 20% of the compounds was performed using the selected 
features and tuned SVM model. Reported prediction results are the average of the 200 test-
set runs (Fig. 6), the ROC distribution of the test-runs are displayed in Fig. 6A. Hierarchical 
clustering of the 20 selected features (Fig. 6) correspond to the features selected >150 
times through the 200 iterations.  
 
Gene expression analysis 
CEL files were downloaded from the Open TG-GATEs database: “Toxicogenomics Project 
and Toxicogenomics Informatics Project under CC Attribution-Share Alike 2.1 Japan” 




For statistical significance of all time courses first linear interpolation was applied for each 
separate time course using the `approx` function from the R-stats package to obtain 100 
equal discretized time points for each replicate. The high number of linear interpolations 
was required to retain the original noise in the time course data. Following this step, a one-
way ANOVA for functional data method was applied using the `anova.onefactor` function of 
the R-package fda.usc to determine significant difference in time-curves compared to 
DMSO for SRXN1/CHOP/p21 or TNFα for ICAM1. Multiple testing correction was applied 
using the fdr-method (Benjamini & Hochberg). SRXN1/CHOP/p21 were assessed for 
significant upregulation and ICAM1 for significant down- or up-regulation. For the log-BMC 
values a linear model with the BMC as explanatory and C-max as explanatory variable was 
fit as null-model. The null-model was compared in an anova to a model containing DILI-
class as additional additive explanatory variable. The models were compared in an anova 
for significant effect of DILI-class. For the C-max normalized BMC a Welch two-sample t-







High content adaptive stress response screen with DILI compounds 
To assess the application of adaptive stress response pathway activation for the 
assessment of DILI liabilities we screened 123 compounds, of which 118 with known DILI 
liabilities (Fig. 1 and Table 1). As an adaptive stress response read-out, HepG2 BAC-GFP 
reporter cell lines for oxidative stress (SRXN1-GFP), DNA damage (p21-GFP), ER-stress 
(CHOP-GFP) and inflammatory cytokine signaling stress (ICAM1-GFP) were used (28 and 
see Suppl. Fig. 2). Stress response activation following drug exposure was monitored with 
live cell confocal microscopy for a period of 24 hours. The time-resolved single cell data 
was quantified using an established image analysis pipeline44. For labeling DILI compounds 
we used the FDA DILI labeling, which labels drugs either as no-DILI-concern, ambiguous 
DILI-concern, less-DILI concern or most-DILI-concern335. Most-DILI-concern drugs are 
highly associated with DILI and represent multiple specialist verified cases of DILI. Less-
DILI-concern drugs represent few verified cases of DILI. If drugs are suspected to cause 
most- or less-DILI-concern, but the presented cases cannot be conclusively validated by 
experts, drugs received the ambiguous DILI-concern label. No-DILI-concern drugs are on 
the market for decades and are never associated with DILI. In order to separate out clear 
examples of DILI, we made two classes: non-severe and severe DILI, where the most-DILI-
concern drugs are in the severe DILI group and all others are in the non-severe DILI group. 
In addition, we included FDA labeling in eight separate classes of hepatotoxicity ranging 
from no hepatotoxicity to fatal hepatotoxicity (Table 1). The screen also included control 
reference compounds included negative controls (DMSO and medium) and positive 
controls (i.e. DNA damage inducers, alkylating agents, ER stress inducers etc.) (Table 1 
and Fig. 2). 
 
Single cell analysis allows fine tuning of sensitivity versus dynamic range of BAC-GFP 
reporter responses 
All reporters were exposed to five concentrations: 1, 5, 10, 50 and 100 C-max followed by 
automated live cell imaging and multiparametric image analysis (Fig. 1). C-max values and 
drug metabolite formation were obtained either from FDA or from literature (see Table 1). 
For all images single cell analysis was performed to extract a diverse set of quantitative 
data, including GFP reporter activity, cell number and cytotoxicity (Suppl. Fig. 1). SRXN1-
GFP, p21-GFP and CHOP-GFP reporter single cell data was used to derive quantitative 
data for four different determinants of reporter activity: intensity, fraction of cells with GFP 
intensity levels above control values. All ICAM1-GFP reporter drug exposures were primed 
with TNFα exposure; likewise, ICAM1-GFP shows a gradual increase over 24 hour time 
period in the vehicle control. Therefore drug treatment can lead to an up- or downregulation 
of the ICAM1-GFP response. Systematic evaluation of these descriptors for the least and 
strongest responding compound for each individual reporter allowed fine tuning of the 
sensitivity versus the dynamic range (Fig. 2).   
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For example, based on the SRXN1-GFP intensity over the single cell population 
chlorpromazine would not have been defined as positive in the SRXN1-GFP reporter cell 
line, because only in a small proportion of cells that contain a higher level of SRXN1-GFP 
the signal was detected. Yet, the GFP_pos.2m and GFP_pos.3m responses of 
chlorpromazine were more sensitive descriptors that also allowed evaluation of the time 
course dynamics. Similar observations were made for nitrofurantoin and clozapine for the 
CHOP-GFP and p21-GFP reporters, respectively. However for strong inducers of oxidative 
stress (diethylmaleate; DEM), UPR (thapsigargin) and DNA damage (etoposide), GFP 
mean intensity already allowed detection of the reporter responses, while GFP_pos.2m 
caused an early saturation, thereby lowering the information value of the temporal 
dynamics. Further, well-known inflammatory stress modulating compounds diclofenac 




Fig. 1: BAC cloning, BAC reporter DILI screen and analysis pipeline Left panel) BAC cloning technology is used 
to maintain endogenously regulated reporter protein levels and regulation. Monoclonal reporter selection from a high 
number of clones to ensure endogenous response to positive control stimuli and suitability of reporter for imaging. 
Middle panel) High content live cell screen of 123 compound at 1, 5, 10, 50 and 100 C-max at 2 or 3 replicates. Right 
panel) Image and data analysis is performed with CellProfiler/Fiji and R, respectively. Some in-house tools were 
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Fig. 2: Dynamics of SRXN1-GFP, CHOP-GFP, p21-GFP and ICAM1-GFP reporter activation Left panel) Time 
lapse images of the reporters exemplifying the importance of single cell analysis which allows fine tuning sensitivity 
versus dynamic range of BAC-reporter read-out. Right panel) Quantification of GFP signal of the SRXN1-GFP, p21-
GFP and CHOP-GFP reporters from a control, a weak reporter-activating compound and a strong reporter-activating 
compound. For ICAM1-GFP the TNFα control was accompanied by a compound which induced the TNFα induced 
response and by a compound which reduced the TNFα response. Intensity, GFP_pos.2m, GFP_pos.3m and 
GFP_pos.m3sd are shown for SRXN1-GFP, CHOP-GFP and p21-GFP. For ICAM1-GFP, Intensity, GFP_dif.1m, 
GFP_dif.2m and GFP_dif.3m are shown.  
 
DILI compounds show specific reporter activation with distinct time dynamics and 
magnitude 
For evaluation of the reporter activation for the entire compound screen GFP_pos.2m was 
selected as the most sensitive initial readout. The GFP_pos.2m time courses were used to 
calculate the mean of the replicates for SRXN1-GFP, CHOP-GFP, p21-GFP and ICAM1-
GFP reporter responses for all compounds (Fig. 3A and Suppl. Fig. 3). Some compounds 
showed a response in all four reporters, where ICAM1-GFP can be increased or decreased 
due to compound exposure. Methyldopa (MD) for example shows an increase in SRXN1-
GFP, CHOP-GFP and p21-GFP and a clear decrease in ICAM1-GFP. Mercaptopurine 
(6MP) induced all four reporters. The data also allowed discrimination of specific time 
dynamics of stress pathway activation. Thus, for nimesulide (NMS), rifampicin (RFP) and 
oxytetracycline (OXY) an initial CHOP-GFP response at 100x C-max and a delayed 
SRXN1-GFP response was observed. In contrast, for the azathioprine (AZA), colchicine 
(CLC) and dacarbazine (DTIC) an SRXN1-GFP response was followed by CHOP-GFP, 
eluding to the primary mode of action or type of cellular stress. As a next step we performed 
hierarchical clustering of the time courses from all 118 compounds representing the 
reporter activities from all BAC-GFP reporter cell lines (Suppl. Fig. 4). We observed a 
cluster with strong modulation of stress responses containing mostly the higher C-max 
treatment conditions (Fig. 3B). This highly active cluster showed an overrepresentation of 
severe DILI drugs as well as more severe classes of hepatotoxicity (liver necrosis, acute 
liver failure and fatal hepatotoxicity). Clusters with activation of all four reporters were 
present, with ICAM1-GFP either up- or downregulated. p21-GFP did show few responses 
and did not contribute much to the DILI compound clustering. The time response clearly 
demonstrated the dynamics of the various stress response programs and allowed 
discrimination between primary stress type and subsequent secondary responses. 
Strikingly, suppression by DILI compounds of the cytokine-induced ICAM1-GFP expression 
was highly correlated with activation of the CHOP-GFP reporter, which in a few cases was 
co-occurring with SRXN1-GFP activation. In conclusion, time resolved clustering results in 







Fig.3: Time dynamics of a subset of the screened drugs A) GFP responses over time of GFP_pos.2m of SRXN1-
GFP, CHOP-GFP and p21-GFP and of GFP_dif.2m of ICAM1-GFP. Statistics are performed as described in the 
material and methods section and represent *<0.01 with the corresponding color to dissect between the different 
reporter lines. B) Zoom of hierarchical clustering of time dynamic responses. Red is an upregulation and blue is a 
downregulation. On the left the severe/non-severe (purple) and the hepatotoxicity class (grey) labeling are indicated 
as well as the C-max values (green).  
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Clustering of compounds concentration relationships reveals strong clustering towards 
severe DILI 
Next, we summarized time course data by extracting the time point at which the reporter 
expression reached a peak response using the various quantitative GFP reporter activity 
descriptors as well as cytotoxicity measurements, including PI and cell number. Hierarchical 
clustering revealed one large non activate cluster (compound names in red) and one 
activated group divided over three clusters (compound names in green, blue and purple) 
(Fig.4). The purple cluster is marked by an increase in SRXN1-GFP, CHOP-GFP and (for 
some compounds) p21-GFP in combination with a decrease in ICAM1-GFP. The blue 
cluster is characterized by a strong increase in CHOP-GFP and cytotoxicity and a strong 
decrease in ICAM1-GFP, also in lower concentrations. In the green cluster SRXN1-GFP 
and ICAM1-GFP both show a clear increase. Most severe drugs are in one of the activated 
clusters, as well as the black and dark grey hepatotoxicity classes. The C-max value for 
magnitude of activation could be discerned through the column wise increasing C-max level 
and corresponding maximum response level and increased sensitivity features within each 
reporter, respectively. For example, the fatal hepatotoxicity compound mercaptopurine 
showed a relatively strong activation of both the oxidative and inflammatory stress 
pathways, yet, the point-of-departure for inflammatory stress was at a lower Cmax than for 
the onset of oxidative stress. In contrast, the fatal hepatotoxicity compound ketoconazole 
showed no SRXN1-GFP response at the intensity feature level but only at the more 
sensitive GFP positive cell counts starting earliest at 50 C-max and as the primary and only 
stress-type. Thus, the current high content data analysis revealed the value of measuring 
quantitative adaptive stress responses for the different DILI classes with a clear distinction 
in primary stress responses for individual DILI compounds.  
 
Benchmark concentrations reveal low point of departure for SRXN1-GFP and CHOP-GFP 
in the severe DILI group 
Based on the concentration response curves extracted from the peak response in 
GFP_pos.2m (SRXN1-GFP, CHOP-GFP and p21-GFP) and GFP_dif.m2 (ICAM1-GFP) we 
were able to calculate the benchmark concentration (BMC) (Fig. 5A). We defined the BMC 
as the concentration where at least 25% of the cells reach the two times average threshold 
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Fig.4: Hierarchical clustering of peak GFP response in tims Hierarchical clustering of responses of intensity and 
count related GFP responses in dose response fashion. Cell death measurements cell number and PI staining are in 
the right bar. On the left side DILI labeling is depicted in three bars: severe/non-severe, DILI-concern labeling and 





Fig. 5: Benchmark concentration (BMC) versus the absolute C-max values per reporter A) Explanation of how 
we extract BMC from the fitted dose ranges from different GFP reporters. B) For each reporter the absolute BMC (y-
axis) is plotted against the absolute C-max (x-axis), each dot represents a compound which reached the 0.25 
threshold. Purple indicates a severe DILI drug, Light blue indicates a non-severe drug; * = p<0.05 and ** = p<0.01. C) 
The BMC is divided by the absolute C-max value per compound and represented in the severe/non-severe DILI 
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Fig. 6: Prediction of severe versus non-severe DILI groups.A) Explanation of temporal feature extraction. B) 
Feature selection by Kolmogorov Smirnov test and pairwise correlation filter. Followed by unsupervised hierarchical 
clustering of the most often selected features from the 200 feature selection iterations. C) ROC curves from 200 test 
data runs and average prediction results (left); Fraction of correct prediction for each drug 
 
 
This BMC can function as an indicator for the point of departure for further risk assessment 
modeling. The C-max values for the screened compounds show a large concentration 
range which ranges from 1.7 nM to 0.94 mM. To correct for this difference we plotted the 
BMC against the absolute C-max value (Fig. 5B) and we divided the BMC by the absolute 
C-max (Fig. 5C). After this correction, we are able to observe a lower BMC in SRXN1-GFP, 
CHOP-GFP and ICAM1-GFP for severe DILI drugs, compared to non-severe drugs. In 
SRXN1-GFP and CHOP-GFP this difference is statistically significant (p < 0.001 for CHOP 
& p < 0.05 for SRXN1 for both methods), indicating severe DILI drugs have a lower point of 
departure and are therefore more potent to induce adaptive stress responses. 
 
Feature selection and SVM classification show predictive power of a diverse and complex 
set of biologically interpretable features 
Time dynamic features and BMC values were extracted as described in the material and 
methods section (Fig. 6). The resultant table of 273 variables corresponding to the total set 
of features and 118 observations corresponding to the compounds was subjected to 
machine learning to asses temporal stress pathway activation and concentration–response 
relations for predictive power and feature importance.  
Feature selection and support vector machine (SVM) model tuning was performed 
over 200 iterations of random training/test dataset sampling (Suppl. Fig. 1), as described in 
detail in the material and methods. The features selected more than 150 times in the 200 
iterations were subjected to unsupervised hierarchical clustering (Fig. 6B). Interestingly a 
diverse set of features, encompassing all reporters, BMC, C-max and also toxicity features 
including cell death with TNFα at 10 C-max, cell death at 100 C-max and cell speed at 50 
C-max. Early and late slope features from the reporters seem to be preferred over the max 
magnitude values. The resulting clustering with these features shows 3 dominant clusters 
with enriched severe DILI compounds (purple, blue and green clusters, Fig. 6B). 
The 200 independent test-set prediction validations with the tuned SVM model 
resulted in an average ROC of 0.73 (Fig. 6C, left panel) and a sensitivity of 0.60 and 
specificity of 0.75 with ‘positive’ being the severe-DILI group. Over the 200 runs the correct 
prediction rates for each compound was calculated (Fig. 6C, right panel), clearly a subset of 
30 compounds have some uncertainty as to being predicted correctly. The remaining 
compounds are all either predicted correctly, or predicted falsely. No enrichment for DILI-
class can be seen for these prediction rates.  




Here we investigated the integrated application of a panel of four adaptive stress response 
BAC reporters in high content high throughput screening as a method for DILI liability 
assessment. We focused on adaptive stress pathway signaling as these defense programs 
are a universal theme in all life forms and respond before the onset of overt toxicity. We 
monitored four downstream target genes for oxidative stress (Srnx1), ER-stress/UPR 
(CHOP), DNA damage (p21) and inflammation (ICAM1); these are selective targets for 
these pathways. Using CellProfiler and R-package h5CellProfiler we quantified all images 
and summarized the responses in a time- and concentration dependent relationship. 
Concentration information was used to extract the benchmark concentration for each 
compound-reporter combination. This revealed significant changes between the severe and 
non-severe DILI classes for SRXN1-GFP and p21-GFP. Furthermore, a non-significant yet 
similar trend was observed for ICAM1-GFP. To perform detailed analysis on the 
contribution of time and concentration based features to DILI classification, we extracted 20 
features and assed these data for predictive power using support vector machine 
approaches. Using these features we are able to classify severe versus non-severe DILI 
classes with a sensitivity of 60% and a specificity of 75%. We demonstrate how advanced 
analysis of live-single cell data can provide key information on the concentration-time 
course reporter responses that can be applied for DILI liability evaluation. We showed that 
integration of such mode-of-action assessment using different reporters increases our 
mechanistic understanding of severe DILI concern compounds.  
By using adaptive stress response measurements we are able to dissect detailed 
information on the mode-of-action of different drugs (Fig. 4). Three differently activated 
clusters are clearly visible. Strikingly, SRXN1-GFP is often not activated without the 
activation of other responses (CHOP-GFP, ICAM1-GFP). This indicates oxidative stress is 
either occurring as a secondary effect after cellular stress induction or as a primary cause 
which also disturbs other systems as protein folding or inflammation20.Since we also 
capture the time dependent adaptive stress activation dynamics, we are able to make a 
distinction between these two possibilities (Fig. 3, Suppl. Fig. 2 and 3). Interestingly, the 
blue colored compound cluster with strong decrease in ICAM1-GFP show also strong 
increase in CHOP-GFP, but no or minor activation of SRXN1-GFP, meaning that a specific 
mode-of-action regulates both the inflammation and the ER-stress pathways. Previously, 
we demonstrated this dual role for diclofenac221. Furthermore, for two other members of this 
cluster, nefazodone and clozapine, this dual activation has been illustrated before130,336–338. 
An increase in ICAM1-GFP is often accompanied with an increase in SRXN1-GFP (green 
cluster). Interestingly, also a decrease in cell number is observed in these drugs, indicating 
a role for ICAM1-GFP in cell cycle arrest. No major increase of p21-GFP is seen for most 
compounds, this is probably due to the fact that genotoxicity is thoroughly checked during 
drug development.  
The minor role of p21-GFP is especially visible when looking at the benchmark 
concentration. No difference is observed between the severe and non-severe DILI groups, 
but this is mainly due to a low amount of compounds (19) that reach the 25% positively 
Dynamic stress response pathway evaluation for drug safety assement 
	 121	
activated cell threshold in p21-GFP. In contrast, SRXN1-GFP, CHOP-GFP and ICAM1-GFP 
show lower benchmark concentrations at the C-max value, indicating that the severe DILI 
group are already activating stress responses at lower concentrations. This is especially 
pronounced in SRXN1-GFP and CHOP-GFP, where the BMCs of the severe DILI group are 
significantly lower than the BMCs of the non-severe group after C-max correction. For 
CHOP-GFP this is expected, since CHOP is an important adaptation-adversity-switch in ER 
stress signaling and therefore activated when the system is more perturbed and closer to 
cytotoxicity339. For SRXN1-GFP this is less obvious since multiple drugs cause oxidative 
stress, often followed by adaptation340. Yet, we are able to distinguish the severe from the 
non-severe DILI group.  
The screen was performed in a time-resolved live single cell setting. To date, 
toxicity screening efforts using high content imaging have mostly focused on single time 
point fluorescent dyes or anti-bodies341 with several real-time based toxicity screening 
efforts342. However, the use of dyes and anti-bodies brings additional noise to already very 
noisy systems as fixation and anti-body binding are likely additional sources of variability; 
this is not an issue using our reporter models. With the use of our reporter cell lines 
biological signaling can be visualized with a high time resolution to more accurately pinpoint 
the primary mode-of-action in relation to cellular stress. Time course signaling data also 
greatly benefits computational modeling efforts as these require detailed time and dose 
response dynamics, this is only feasible using live cell imaging data. Furthermore, we were 
able to extract features based on this time and dose response dynamics. These features 
were used in support vector machine approach to assess possible differences in cellular 
adaptive signaling between less- severe and severe DILI. Due to the limited number of no-
DILI compounds (n = 16) and the total of 118 compounds tested we had obtained a limited 
set of observations for building predictive models. However by combining the less-Severe 
DILI and ambiguous DILI cases together with the no-DILI compounds we were still able to 
show significant predictivity with an independent subset of our data not used in the SVM 
tuning process. This promising result indicates the importance of adaptive signaling 
dynamics in DILI. However exact pinpointing of key-features remains difficult without a 
significantly larger dataset containing a more balanced safe versus unsafe labeled 
compound annotation. We anticipate the development of an ever increasing database 
containing such detailed signaling based features linked to chemical exposure, i.e. 
compound specific biological fingerprints, will ultimately aid in the safety evaluation and 
early (DILI) prediction of new drugs and chemicals. 
In addition to screening more DILI related drugs, more adaptive stress response 
pathways (heat shock response, mitochondrial toxicity, hypoxia) or reporters (Hmox1-GFP, 
A20-GFP, Btg2-GFP, BiP-GFP) can be screened. Another issue which affected the result of 
the prediction is labeling of the drugs in different DILI-concern categories. The labeling of 
these drugs changes over time, making it difficult to establish a balanced set of most-DILI-
concern drugs versus no-DILI-concern drugs331,335. Separating the most-DILI-concern drugs 
from all other drugs allows classification, however at a cost of including drugs with 
ambiguous nature related to DILI-severity. This led to poor prediction of several less-DILI 
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drugs (glimepiride, cimetidine, metformin, omeprazole, tacrolimus, clofibrate, entacapone, 
phenobarbital, pioglitazone and verapamil) (Fig. 6C, right panel). Some of them are known 
to induce adaptive stress responses (verapamil and metformin)343,344. In addition, all most-
DILI-concern drugs are or have been on the market, meaning they passed toxicity testing 
stages of drug development. Therefore, when these reporters are to be used in drug 
development with new chemicals prediction is expected to perform better.  
We performed the screen using the HepG2 cell line. Although HepG2 has several 
advantages for in vitro screening (unlimited lifespan, cheap, easy to culture), the major 
setback is their lack of metabolic capacity. However, several compounds that involve 
biotransformation-dependent toxicity do show a SRXN1-GFP oxidative stress response 
(e.g. acetaminophen and sulindac). To test whether there is a concordance between the 
HepG2 BAC-GFP reporters and the transcript levels in primary human hepatocytes we 
used the TG-GATES dataset to calculate the correlation of the activity of the reporters 
genes between TG-GATES and the current BAC-GFP HepG2 DILI screen (Suppl. Fig. 5). 
This indicates a significant overlap for SRXN1 responses of transcript levels in primary 
human hepatocyte and BAC-GFP HepG2, indicating a minor role for drug metabolism in the 
DILI prediction. Still, some of the drugs in the poorly predicted set are supposed to be 
metabolized (zafirlukast, troglitazone, methimazole, mexilitine). It is noteworthy to mention a 
large cloud of points exists in the top left (boxed area, Suppl. Fig. 5) demonstrating mainly 
enhanced SRXN1 protein activation in comparison to PHH transcript levels indicating 
increased oxidative stress detection sensitivity. Previously, we optimized a HepG2 3D 
spheroid protocol to enhance liver like properties and to enable chronic exposures129. In 
future research we can test whether this would increase prediction of DILI drugs.  
In conclusion, we have shown that BAC-GFP reporter cell lines are a sensitive tool 
to provide detailed mechanistic information regarding the adaptive stress response 
activation in a broad compound screening setting using high-content live single cell 
imaging. Such detailed insights in the perturbations of signaling pathways after chemical 
exposure provides key information for safety assessment and possibly predictive purposes. 
We anticipate that our BAC-GFP reporter platform will contribute to the early pre-clinical 
screening for DILI liabilities and possibly also other chemical safety assessment paradigms.  
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Table 1: Test compound set Alphabetically sorted list of screened compounds in this study including their c-max 
values, abbreviations, DILI-concern labeling, severity class, hepatotoxicity class (1 = no hepatotoxicity, 2 = 
cholestasis/steatohepatitis, 3 = liver aminotransferases increase, 4 = hyperbilirubumenia, 5 = jaundice, 6 = liver 
necrosis, 7 = acute liver failure, 8 = fatal hepatotoxicity), C-max reference and metabolic potential based on the 







Suppl. Fig. 1: Data analysis workflow The features in red are displayed in the figures of the results section.  
  





Suppl. Fig. 2: ICAM1-GFP characterization A) Time lapse images with and without TNFα. B) Comparison BAC-GFP 
ICAM1-GFP and wildtype HepG2 with western blotting after induction with TNFα and stained with ICAM1, GFP and 
tubulin antibodies. C) Time lapse images of ICAM1-GFP after knock down of caspase 8 and NF-κB subunit RelA and 
TNFα exposure.  
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Suppl. Fig. 3: Time course graphs of all treatments and concentrations. For all compounds the reporter activity is 
shown for GFP_pos.2m (SRXN1-GFP, CHOP-GFP and p21-GFP) and GFP_dif.m2 (ICAM1-GFP). Statistics were 
performed as described in the material and methods section: * = p<0.01   
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Suppl. Fig. 4: Hierarchical clustering of time course summarized in a heatmap. Red depicts an upregulation and 
blue a downregulation. On the left the severe/non-severe (purple) and the hepatotoxicity class (grey) labeling are 









Suppl. Fig. 5: Correlation of TG GATES primary human hepatocytes transcript levels versus BAC-HepG2 
SRXN1-GFP (blue), CHOP-GFP (green) and p21-GFP (red) BAC-GFP reporter values are plotted against the TG-
GATES fold changes, correlation has been depicted next to the graph. Boxed cloud depicts BAC-GFP reporter 
activated compounds only. Correlation has been calculated using 61 degrees of freedom, *** = pvalue < 0.005. 
  


























o The importance of inflammatory stress on the etiology of drug-induced liver injury is 
increasingly recognized 
o Current in vitro models do not capture hepatocyte specific immune signaling 
o In this thesis, I report both mechanistic insight into hepatocyte specific immune 
signaling and application for prediction modeling 
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Idiosyncratic DILI remains an important problem in drug development and safety 
assessment, since it is difficult to predict DILI liability. Inflammatory stress is considered as 
an important host factor involved in DILI208. Several in vivo and in vitro models show that 
inflammatory stress induced by pathogenic or sterile inflammation decreases the toxicity 
threshold of certain drugs, as discussed in Chapter 28,16,41,72. Toxicity is correlated to TNFα 
levels for diclofenac/LPS-induced hepatotoxicity, and for trovafloxacin proven to be TNFα 
and TNFR dependent11,99. At this moment, several mechanisms of TNFα-induced cell death 
in different cell types have been recognized20. Also drug-induced cell death mechanisms 
have been extensively investigated, implicating activation of cellular adaptive stress 
responses as one of the key events135. In this thesis, I focused on drug-induced cellular 
stress responses and their relation to TNFα-induced hepatotoxicity. The interaction 
between these cellular stress responses and TNFα signaling has been studied previously, 
by us and others15,16,43,345.  
Although significant studies on drugs and inflammatory stress have shown that 
drug/cytokine interaction play an important role in DILI, we do not know how drugs interact 
with signaling downstream of the TNF receptor complex. Furthermore, it has been 
suggested that the activation of NF-κB and its target genes play an important role in TNFα-
induced cytotoxicity17,42. The precise process and role of NF-κB activation in drug/TNF-
induced hepatotoxicity is unknown. Moreover, it has been shown that also other TNFα-
induced pathways play roles in inducing a synergistic drug/TNF apoptosis, including MAP 
kinases14. Drug/TNFα synergistic toxicity has been detected in both PHHs and HepG2 
cultures16,41,120. In the studies that are presented in this thesis, we thrived to characterize 
drug-induced skewed TNFα signaling in HepG2 cells (Chapter 3-5). Furthermore, in 
Chapter 6 we used our inflammatory stress reporter in addition to our previously 
characterized fluorescent reporter platform to predict drug-induced liver injury hazard44. 
 
TNFα-induced NF-κB signaling 
One of the best-characterized results of TNFα stimulation is the nuclear translocation of the 
RelA subunit of the NF-κB protein family. Previously, our lab has shown that this 
translocation phenotype can be disrupted by diclofenac pre-exposure42. To investigate how 
this phenotype is induced, we generated a stable CMV-driven RelA-GFP reporter. In 
Chapter 3, we used this reporter cell line for live cellular imaging-based siRNA screening, 
to determine signaling molecules that are involved in the creation of the typical oscillatory 
phenotype. We focused mainly on the role of kinases and ubiquitinases, both under control 
as well as drug-exposed conditions. As expected, we determined that various genes that 
are involved in ubiquitination processes play an essential role in TNFα-induced NF-κB 
activation144. Intriguingly, many candidate genes that delayed the oscillatory phenotype 
upon knockdown did not increase the toxicity upon drug exposure only, but decreased the 
cytotoxic potential of TNFα/diclofenac exposure. This underlines the complex relationship 
between NF-κB activation and cytotoxicity. We identified knockdown of UFD1L and CDK12 
(CRK7) as strong inhibitors of the cytotoxic response and delaying RelA translocation under 
control and drug exposure conditions. Interestingly, CDK12, but not UFD1L knockdown did 
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increase the TNFα-induced A20 expression massively. UFD1L had already been described 
as part of the proteosomal targeting complex of IκBα182. However, we show here that 
UFD1L is not involved in IκBα breakdown in TNFα-stimulated HepG2 cells. This 
emphasizes the importance of cell type specific experiments and cautions against drawing 
conclusions based on literature in different cell types. CDK12 is known as RNA pol II kinase 
that phosphorylates Ser2 on the C-terminal domain, leading to improved elongation of RNA 
transcripts. Remarkably, CDK12 is specifically involved in the induction of stress-induced 
gene sets, for example upon oxidative and DNA damage stress198,199. Here, we suggest 
that CDK12 is also involved in NF-κB-mediated transcriptional programs. Whether 
diclofenac/TNFα cytotoxicity is induced by generally skewed CDK12-mediated gene 
expression or via specific CDK12-mediated inhibition of A20 expression requires more 
research. As CDK12 is involved in oxidative stress, inflammatory stress and DNA-damage 
responses, it is a most promising candidate gene to study in relation to iDILI. Especially 
since CDK12 knockout/knockdown affects gene transcription efficiency only during stress 
responses199, CDK12 polymorphisms could form a genetic basis in which certain individuals 
could be more sensitive to specific drug-induced stress responses. 
As shown in Chapter 3, delayed TNFα-induced RelA nuclear translocation is not 
always associated with increased drug/TNFα cytotoxicity. To determine the physiological 
effects of drug-delayed RelA responses, we tested compound effects on TNFα-induced 
RelA translocation, target gene induction and cytotoxicity in Chapter 4. The compounds 
chosen were part of the training compound set defined by IMI MIP-DILI212, plus 
carbamazepine, a drug we studied extensively previously16. Of these compounds, some 
delayed TNFα-induced translocation (metformin, nefazodone, diclofenac, tolcapone, 
troglitazone, carbamazepine), while others did not (acetaminophen, flucloxacillin, 
pioglitazone and entacapone). To investigate TNFα target gene induction, we chose 45 
target genes and determined the effect of drug exposure on their TNFα-induced expression 
kinetics. In general, drug exposure increased TNFα-induced expression of most target 
genes, not related to a specific kinetic or functional group of target genes. In addition, this 
increase was not defined by drug-induced delayed TNFα-induced RelA nuclear 
translocation.  
As expected, TNFα-induced target genes that regulate oxidative stress, including 
SLC7A11, SOD2 and MAFF, were enhanced upon concurrent drug exposure. However, 
also proinflammatory cytokine and chemokine signaling target genes, including CCL20, IL8, 
CXCL3, CSF2, CSF3 and CCL5, were generally increased upon combined drug/TNFα 
exposure compared to TNFα exposure only. The increased expression of these cytokines 
could influence nearby liver cell populations, but also hepatocytes in an autocrine feedback 
loop. While the induction of inflammatory molecules has been studied in several 
experimental models including KCs and other resident immune cells, the excretion by 
hepatocytes has not been well characterized. In addition, we determined that expression of 
transcription regulating proteins including IER3, ELF3 and NFKB2 were increased upon 
drug exposure. The increased expression of these transcription factors complicates the 
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overall expected physiological outcome, since the hepatocyte-specific role of these 
transcription factors is currently not entirely clear263,346.  
In other models, combined drug/inflammatory regulator exposure was often 
directed at KC activation. Direct co-exposure with drug/LPS of human liver slices generally 
decreased the overall proinflammatory cytokine secretion113, which was not entirely similar 
to the results in mouse liver slices112. However, as resident immune cells are present in this 
model, it is likely that the proinflammatory modulator production is at a different scale 
compared to hepatocyte only produced cytokines. Indeed, no increased cytokine secretion 
upon compound-only exposure was detectable in mouse or human slices112,113, in contrast 
to our results. In a rat KC study, drug-treated KCs increased proinflammatory gene 
expression upon LPS stimulation, in contrast to LPS stimulation alone347. This is more 
similar to our result in hepatocytes. However, these contradictory outcomes show that it is 
difficult to extrapolate results between species and models.  
It becomes more and more accepted that also hepatocytes are involved in immune 
regulation on organ and systemic levels58. Mice hepatocyte-specific knockout of A20 seem 
healthy when unchallenged, whit only slightly increased chronic inflammation levels in the 
liver. However, when challenged with LPS, LPS-induced NF-κB-dependent responses, 
including expression of IL6 and CCL2 expression are severely enhanced192. Thus, altered 
hepatocyte NF-κB signaling can enhance liver wide inflammatory responses. Therefore, we 
anticipate that enhanced TNFα-induced NF-κB target gene expression upon drug exposure 
as shown in this manuscript, could have severe physiological results.  
 
Drug-induced NF-κB signaling  
In Chapter 4 we show that drug exposure by itself also induces TNFα target gene induction 
in HepG2 cells. Although this induction is partially regulated by RelB and cREL, the 
induction of target gene expression mainly depends on RelA expression. Interestingly, IL8 
(CXCL8) and CCL5 are well-described chemokines, recruiting macrophages and 
neutrophils (Fig.1). Macrophage and neutrophil recruitment is considered a key event in the 
etiology of drug-induced liver injury116,235. By our knowledge, the regulation of these target 
genes by drug-induced activity of the whole NF-κB family in hepatocytes has not been 
described before.  
Here, we show that drug-induced RelB expression is independent of RelA 
transcriptional activity and is strongly associated, and thus likely induced, by oxidative 
stress. The role of the non-canonical pathway in liver injury is not well characterized, 
although key protein MAP3K14 (NIK) activity aggravates (TNFα-mediated) liver injury in 
vivo348,349. In addition, inhibition of MAP3K14 decreased oxidative stress generation349. 
Indeed, in Chapter 5 we show that knockdown of MAP3K14 affects drug/TNFα synergism 
in a drug-specific way. This effect correlates with drug-induced SRXN1 induction. 
Intriguingly, intricate connections between the classical (RelA) and alternative (RelB) NF-κB 
pathways exist, also upon TNFα exposure21,350. MAP3K14 activity and RelB are not 
interacting directly, but via several intermediate signalling proteins. Therefore, these results 
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do not define whether the effect of MAP3K14 knockdown on drug/ TNFα synergism is 
related to RelB involvement.  
Interestingly, Willy et al. did also see a NF-κB target gene induction response upon 
palmitic acid exposure of HepG2 cells, leading to increased cytotoxicity. The cytotoxicity 
was dependent on the activation of CHOP via IRAK2, which lead to expression of 
inflammatory regulators, including IL8 and TNFα itself. While IL8 was mainly involved in 
macrophage recruitment, the CHOP-mediated secretion of TNFα was essential for palmitic 
acid cytotoxicity. Importantly, this response was not seen in primary mouse hepatocytes, 
underlining the species-specific regulation of NF-κB activation345. Here, we describe drug-
induced regulation of NF-κB target gene induction as well. Although we previously and in 
this thesis showed that CHOP is activated by several drug exposures16, we do not anticpate 
CHOP-mediated cytokine secretion. Our drugs are not cytotoxic upon drug only exposure 
and could not induce detectable TNFα mRNA expression upon drug exposure (data not 
shown). Therefore, we assume that there is no TNFα excretion by our HepG2 cells upon 
exposure of drugs alone. However, we anticipate that the increased secretion of 
inflammatory regulators as we have detected, demonstrate a subtle modulation of the 
inflammatory response upon drug exposure in vivo. 
 
Drug/TNFα-induced cytotoxicity 
Already a decade ago, the groups of Roth and Ganey were one of the first to 
describe synergistic responses in rodents upon low doses drug and LPS8,72. Since then, 
they and others have developed several models to detect inflammatory stress and drug 
synergistic hepatotoxicity. Roth and colleagues have also demonstrated that TNFα is an 
essential cytokine in the LPS/drug-induced liver injury in vivo11. We and others have shown 
that HepG2 cells also show TNFα/drug synergistic cell death42,120. This synergistic cell 
death is dependent on CHOP expression, MAPK function and the regulation of general 
protein translation machinery components14,16. However, it is still unknown how TNFα 
stimulation can interact with drug-induced cellular stress responses to increase cytotoxicity. 
In this thesis we studied both regulators of TNFα-induced RelA nuclear translocation in 
Chapter 3 and regulators TNFα/drug synergism in Chapter 5. Synergistic cell death seems 
not strictly correlated with a delayed RelA translocation phenotype, as knockdown of 
candidate genes can both delay TNFα-induced RelA translocation and inhibit cytotoxicity. 
Therefore, in Chapter 5, we studied several candidate genes that affected TNFα/drug 
synergistic toxicity with different drug exposures. We detected both generic and compound 
specific characteristics of the candidate gene effects. Strong generic TNFα/drug synergistic 
toxicity regulators (A20 and PHF5A) increased cytotoxicity upon knockdown. This 
knowledge could be used in the development of sensitive safety testing approaches to 
detect inflammatory cytotoxicity.  
The correlation between candidate gene effects under diclofenac and valproic acid 
exposure suggests a similar mechanism of TNFα toxicity. However, the compound-induced 
stress responses show stark differences. In conclusion, there must be other, yet unknown, 
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mechanisms involved in both valproic acid and diclofenac toxicity that synergize with TNFα 
signaling and affect our candidate gene function.  
The effect of candidate gene knockdown on drug/TNFα toxicity was correlated to 
the drug-induced onset of several stress responses. This effect was most strongly seen 
with two separate branches of oxidative stress and the DNA damage response 
(SRXN1/P21 and HMOX1/BTG2). Both branches of these stress responses interact with 
TNFα and NF-κB signaling differently, according to literature19,121,351. Remarkably, both the 
oxidative stress and DNA damage response are related to target gene expression regulated 






Fig. 1: Overview of drug-induced mechanisms Hepatocytes exposed to drugs induce several responses. In the 
first panel, hepatocytes are in homeostasis. In the second panel, drugs induce the activation of cellular stress 
responses. This includes swollen or perturbed mitochondria, increased levels of unfolded/misfolded proteins inside 
and outside of the endoplasmic reticulum and DNA damage occurring. CDK12 and PHF5A start elongating mRNA 
transcripts of specific stress-related target genes. The hepatocytes start producing damage associated molecular 
patterns (DAMPs) and chemokines, including CCL5 and IL8 (as described in this thesis). The DAMPs activate the 
Kupffer cell, which start to produce high amounts of proinflammatory cytokines, including TNFα. The chemokines start 
attracting immune cells, including monocytes and neutrophils. In the last panel, the TNFα in combination with the 
drug-induced responses has led to increased levels of hepatocyte apoptosis. Specific cell types and responses are 
indicated. KC is Kupffer cell, LSEC is liver sinusoidal endothelial cell, SC is stellate cell, HC is hepatocyte. DAMPs are 
damage associated molecular patterns. MC is monocyte, N is neutrophil.  
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This protein function of CDK12 is similar to the RNA pol II Ser2 kinase function of PHF5A, 
the strongest generic regulator of drug/TNFα toxicity in our study. We determined that the 
drug/TNFα toxicity effect of both kinases correlated strongly with the SRXN1/P21 branch of 
stress responses. We anticipate that both CDK12 and PHF5A are essential regulators of 
drug/TNFα toxicity in hepatocytes and control specific stress-induced transcription 
programs (Fig.1). 
 
Assessing TNFα signaling in toxicity screening approaches 
As discussed in Chapter 2, screening approaches that involve addition of TNFα can add 
valuable information for safety assessment. In Chapter 6, we applied a high throughput 
approach in which we used the previously described BAC-GFP HepG2 reporter platform44, 
complemented with the ICAM1-GFP cell line and manual addition of TNFα. Addition of the 
TNFα-treated ICAM1 reporter increased the mechanistic and predictive power of our stress 
response reporter platform. The effects of drug exposure on TNFα-induced ICAM1 
expression reflects some of the distortion of the inflammatory stress response in 
hepatocytes by the drug in vivo. Clusters of compounds that decrease or increase TNFα-
induced ICAM1 expression concurrent with SRXN1 and/or CHOP expression indicate 
diverse toxicity mechanisms. Furthermore, we show that severe DILI compounds did in 
general increase adaptive stress responses at a lower exposure concentration than non-
severe DILI compounds. Time dynamic, single cell features were distracted for support 
vector machine-based prediction of liver injury liability. To our best knowledge, this is the 
first time that high density dynamic temporal data for actual toxicity screening and 
prediction approaches is used. We anticipate that the detection of more adaptive stress 
responses, tested with and without inflammatory mediators, will increase the predictive 
power during in vitro safety assessment approaches.  
As described in Chapter 5, separate branches of individual adaptive stress 
response pathway correlated strongly with the effects of individual candidate gene 
knockdowns on drug/TNFα synergism. Therefore, we anticipate that the inclusion of more 
reporters of the same stress response pathways also improves predictive power. 
Furthermore we recommend the optimization of the cellular model, for instance by 3D 
culture, co-culture or the use of stem-cell derived hepatocytes/primary human hepatocytes. 
To improve the detection of drug-induced immune-related toxicity, culture methods of all of 
these models should be adjusted to improve the resemblance to liver immunotolerant 
environment1. Furthermore, we anticipate that including hepatocyte-produced pro- and anti-
inflammatory factors detection methods in early drug discovery toxicity screening increases 
the predictive power of in vitro safety assessment.  
 
Conclusion and future perspectives 
In this thesis I describe the drug-induced perturbations of TNFα signaling in 
HepG2 cells. The findings in this thesis report several novel processes and candidate 
genes that were not previously implicated in drug-induced liver injury (some are 
summarized in Fig. 1). Overall, the importance of inflammatory stress and its detection in 
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drug toxicity screens for safety assessment is emphasized. The findings in this thesis can 
be used to develop better predictive models for drug toxicity in early drug development. 
Furthermore, the knowledge that specific genes are involved in drug/TNFα interactions 
may, in the end, lead to more specific prescription practice in a personalized medicine 
approach.  
The HepG2 cell line is still one of the most widely used in vitro methods in 
predictive toxicology to test hepatocyte toxicity. The detection of inflammation-induced drug 
hepatotoxicity is usually not incorporated in the early in vitro studies and only detected in 
animal studies. To lower animal burden and increase early detection of drug-interaction with 
inflammatory stress signaling pathways, we hypothesized in this thesis that HepG2 cells 
could be used as an adequate model to study inflammatory stress and drug toxicity. The 
outcome of these studies show that HepG2 cells are able to reflect many inflammatory 
signaling characteristics and can be used in predictive screening approaches.  
The development of both inflammatory hepatocyte-only and co-culture models 
would increase our knowledge on inflammatory signaling in the liver substantially. Although 
primary hepatocytes are currently unsuitable for studying inflammatory signaling37, evolving 
isolation and culture methods could increase the usability of this cell type. Furthermore, the 
development of induced pluripotent stem cells holds the most promising possibilities in the 
future, for both toxicity testing and personalized medicine strategies. This thesis contributes 
to the development of inflammatory stress models in the current, but also future testing 
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Een bekende bijwerking van medicijnen is leverschade (in het engels Drug-Induced Liver 
Injury, afgekort tot DILI). DILI is de meest voorkomende oorzaak van opname in het 
ziekenhuis voor acuut leverfalen. De meeste DILI ontstaat door een overdosis, bijvoorbeeld 
van acetaminophen (paracetamol). Er zijn echter ook medicijnen die bij een normale dosis 
in een paar patienten DILI veroorzaken. Doordat deze idiosyncratische DILI (iDILI) 
onafhankelijk is van de dosis en een erg lage incidentie heeft is het lastig te voorspellen 
welk medicijn iDILI gaat veroorzaken, en in welke patienten. Deze op zichzelf effectieve 
medicijnen krijgen vaak een “black box warning” (de zwaarste vorm van een waarschuwing 
in een bijsluiter) en worden minder voorgeschreven aan patienten. Ook worden medicijnen 
soms van de markt gehaald of in een van de laatste fases van ontwikkeling gestopt. De 
farmaceutische industrie is erg gemotiveerd om in een vroeg stadium in de ontwikkeling 
van een nieuw medicijn het risico op iDILI te bepalen. Daarnaast zou de herkenning van 
personen die gevoelig zijn voor deze bijwerkingen de effectief behandelde patientpopulatie 
vergroten. 
De oorzaak van iDILI is momenteel onbekend. Onderzoek laat zien dat er 
specifieke interacties zijn tussen de eigenschappen van het medicijn (lipofiliciteit, 
metabolisme, transport en dosis) en patient-gebonden factoren. De patient-gebonden 
factoren bestaan onder andere uit variatie in metabole competentie en expressie van 
transporter eiwitten, (toxicologische) stress responsen, ontstekingsreacties en de 
mogelijkheid tot herstel na schade. De schade die een medicijn uiteindelijk toebrengt aan 
de lever is een som van al deze processen. 
De meeste medicijnen induceren adaptieve stress responsen in levercellen, die de cel 
beschermen tegen schade. Als de schade een drempelwaarde bereikt, gaan deze 
responsen over in het activeren van specifieke celdood programma’s. Stress, celdood, of 
een infectie kan de lever residente macrofagen activeren. Geactiveerde macrofagen gaan 
een ontstekingsbevorderend cytokine, TNFα, uitscheiden. De levercel is dan dus 
blootgesteld aan zowel het medicijn als TNFα. 
TNFα is een enigmatisch cytokine. Het kan zowel overleving van de cel bevorderen (via de 
activatie van transcriptie factor NF-κB) als celdood induceren (via de activatie van caspase 
8 of RIPK3). In een gezonde levercel induceert stimulatie met TNFα geen celdood. Echter, 
als de levercel gestresst is door medicijngebruik kan de balans omslaan en kan TNFα 
stimulatie leiden tot synergistisch meer celdood. 
In dit proefschrift bestuderen we specifieke stress responsen die ontstaan na 
medicijngebruik, en hoe deze interacteren met TNFα signalering. Voor dit onderzoek 
gebruiken we een HepG2 levercellijn, die we behandelen met medicijnen en TNFα. In 
hoofdstuk 2 vatten we samen wat er op dit moment bekend is over TNFα in iDILI. Als 
voorbeeldmedicijn gebruiken we diclofenac, waarvan wij en anderen al eerder hebben laten 
zien dat leverceldood synergistisch verhoogd wordt als levercellen gestimuleerd worden 
door diclofenac in combinatie met TNFα. We bespreken de mogelijkheden om 
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inflammatoire stress (zoals TNFα) te gebruiken als test in de ontwikkeling van nieuwe 
medicijnen.  
Zoals eerder gezegd, TNFα induceert NF-κB transcriptie factor activatie en dat 
leidt tot celgroei en het voortbestaan van de levercel. In hoofdstuk 3 hebben we de 
regulering van NF-κB activatie na TNFα stimulatie onderzocht. Hiervoor hebben we aan 
een onderdeel van NF-κB (RelA) een fluorescent label geplakt, dat we kunnen volgen in 
levende cellen met confocale microscopie. TNFα stimulatie induceert translocatie van NF-
κB vanuit het cytoplasma naar de celkern, waar NF-κB pas actief kan zijn. In de celkern 
activeert NF-κB de expressie van specifieke genen, waaronder genen die NF-κB uit de kern 
halen (bijvoorbeeld IκBα) en genen die activatie van het receptor complex negatief 
beinvloeden (bijvoorbeeld A20). Hierdoor ontstaat een typisch kern/cytoplasma oscillatie 
patroon. De kwantificatie van dit patroon laat zien dat NF-κB translocatie vertraagd is als 
levercellen behandeld zijn met diclofenac. Om te bepalen welke eiwitten betrokken zijn in 
de totstandkoming van het oscillatie patroon en dus NF-κB activatie, hebben we een siRNA 
screen uitgevoerd. Behandeling met siRNA vermindert de expressie van een specifiek 
eiwit. Van de 1567 geteste eiwitten bleken uiteindelijk 46 betrokken te zijn bij de regulatie 
van door TNFα gestimuleerde NF-κB oscillatie. Verlaagde expressie van sommige genen 
vertraagde NF-κB translocatie, net zoals diclofenac, maar beschermden in het algemeen 
tegen de synergistische celdood door TNFα en diclofenac of carbamazepine. De verlaagde 
expressie van een aantal van deze genen had ook een groot effect op de expressie van 
A20. Een van de sterkste effecten had de RNA polymerase II kinase CDK12. Wij laten hier 
voor het eerst zien dat CDK12 betrokken is bij de regulering van NF-κB translocatie, A20 
expressie en celdood inductie door TNFα stimulatie.  
In hoofdstuk 4 hebben we meerdere, door het MIP-DILI consortium 
geselecteerde medicijnen getest op hun effect op TNFα signalering in HepG2 cellen. TNFα 
signalering in HepG2 cellen lijkt veel op de meest gebruikte, niet-immuun cellen voor TNFα 
onderzoek: muis embryonale fibroblasten (MEFs). We hebben hier aangetoond dat TNFα 
de expressie van groepen genen induceert die een verschillende kinetiek vertonen: vroege 
expressie, gemiddelde expressie en late expressie. Dit wordt in HepG2s, net zoals in 
MEFs, onder andere gereguleerd door splicing; het splitsen van boodschapper RNA 
moleculen vlak na de transcriptie vanuit het DNA. We zien hier ook dat de functies van de 
door TNFα geinduceerde genexpressie verschilt in de expressiegroepen. De vroege 
genexpressie groep bevat meer pro-inflammatoire genen, terwijl de late genexpressie 
groep nauwelijks pro-inflammatoire genen bevat en bijvoorbeeld meer genen die bekend 
staan om hun rol in herstel. Blootstelling aan medicijnen verhoogde de TNFα geinduceerde 
expressie van target genen. Dit was niet direct gecorreleerd aan de mate van 
synergistische celdood. Wel was het gedeeltelijk gecorreleerd aan de mate van disruptie 
van NF-κB nucleare translocatie patronen, en dus NF-κB activatie. In een andere 
interessante observatie bleek dat blootstelling aan medicijnen zonder TNFα  al NF-κB 
(RelA) geinduceerde gen expressie te activeren, waaronder chemokines CCL5 en IL8. 
Verschillende andere NF-κB transcriptie factor familieleden (RelB, cREL) reguleerden deze 
expressie. Dit was gedeeltelijk gecorreleerd met de medicijn-geinduceerde activatie van 
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adaptieve oxidatieve stress responsen. Hiermee tonen we aan dat medicijnen intrinsiek 
TNFα genexpressie kunnen induceren, onder andere bekende immunomodulatoren in de 
lever zoals CCL5 (neutrofiel recruterende signaalstof) en IL8 (macrofaag recruterende 
signaalstof). We laten ook zien dat dit gereguleerd wordt door meerdere eiwitten uit de NF-
κB familie en de medicijn geinduceerde oxidatieve stress respons.  
In hoofdstuk 5 hebben we ons geconcentreerd op specifieke compenenten van 
de TNFα signaleringscascade die bijdragen aan de synergistisch verhoogde medicijn/TNFα 
celdood. We hebben een kleine siRNA screen gedaan met 184 bekende TNFα 
signaleringseiweitten. Verlaagde expressie van uiteindelijk 24 genen reguleerde de 
verhoogde celdood met het anti-epileptische medicijn carbamazepine en TNFα. Een screen 
met 124 medicijnen in 6 concentraties identificeerde nog 3 andere medicijnen (colchicine, 
griseofulvine en valproine zuur) die ook in synergie met TNFα celdood veroorzaakten. De 
24 genen die carbamazepine/TNFα synergie reguleerden hebben we getest met de andere 
medicijnen en TNFα. Verlaging van de expressie van de 24 genen en medicijn/TNFα 
blootstelling liet een wisselend beeld zien. Dit betekent dat er genen zijn die in het 
algemeen medicijn/TNFαsynergisme reguleren, maar ook dat sommige genen specifieke 
functies hebben in synergie met een specifiek medicijn. Dit zou kunnen samenhangen met 
de medicijn-specifieke adaptieve stress responsen die geinduceerd worden. In ons lab 
gebruiken we een platform van fluorescente cellijnen, waarmee we de activatie van 
verschillende adaptieve stress responsen kunnen meten met confocale microscopie. De 
synergistische medicijnen in deze studie activeerden allemaal een aantal van deze stress 
responsen, en deze activatie was medicijn-specifiek. De activatie van specifieke stress 
responsen correleerde in veel gevallen met het effect van verminderde genexpressie op 
TNFα/medicijn synergistische celdood. Dit betekent dat deze genen waarschijnlijk een rol 
spelen, of beinvloed worden door deze adaptieve stress responsen. Meer inzicht in het 
functioneren van deze genen zou kunnen leiden tot patientspecifieke behandeling. 
Behalve mechanistisch onderzoek hebben we in hoofdstuk 6 ook de fluorescente 
cellijnen van verschillende stress responsen gebruikt in een nieuw testsysteem, om te 
voorspellen welke medicijnen DILI veroorzaken in patienten. De oxidatieve stress respons 
(SRXN1), endoplasmic reticulum stress respons (CHOP), DNA schade respons (p21) 
werden blootgesteld aan een set van 118 medicijnen. Om inflammatoire stress te kunnen 
meten hebben we NF-κB target gen ICAM1 blootgesteld aan zowel de medicijnen als 
TNFα. Alle responsen zijn gekwantificeerd over tijd en samengebracht in verschillende 
statistische modellen. We laten zien dat de medicijnen verschillende combinaties van stress 
responsen activeren. Verder tonen we aan dat de medicijnen die ernstige DILI veroorzaken, 
in tegenstelling tot diegenen die minder ernstige DILI veroorzaken, bij een lagere absolute 
concentratie van het medicijn al stress responsen activeren. Uiteindelijk hebben we een 
automatische selectie van de belangrijkste karakteristieken van over tijd gemeten activatie 
curves gemaakt. Met deze selectie hebben we machine learning gedaan en konden we 
voorspellen welke compounds DILI in mensen veroorzaken. Dit konden we met een 
sensitiviteit en specificiteit van respectievelijk 0,6 en 0,75. In de toekomst kunnen we dit 
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model gebruiken om zowel mechanistische als voorspellende informatie te verkrijgen over 
de medicijnen voordat ze in mensen of dieren getest worden. 
In hoofdstuk 7 vat ik de resultaten uit dit proefschrift samen en hoe deze 
samenhangen met de huidige literatuur. Inflammatoire stress is inmiddels erkend als een 
belangrijke patientgebonden factor in het onstaan van iDILI. In deze studies laten we zien 
dat de interacties tussen medicijn geinduceerde responsen en inflammatoire stimuli als 
TNFα kunnen leiden tot afwijkende genexpressie en synergistische celdood. We hebben 
verschillende nieuwe eiwitten geidentificeerd (CDK12, PHF5A, CARD12) die een 
belangrijke rol spelen in medicijn/TNFα geinduceerde signalering en synergistische 
celdood. We laten ook zien dat blootstelling aan medicijnen zelf bijdraagt aan inflammatoire 
signalering vanuit levercellen. Dit gebeurt via activatie van de NF-κB familie en 
daaropvolgende expressie van bekende proinflammatoire signaalstoffen zoals CCL5 en 
IL8.  
De identificatie van patienten met polymorfismen in de in dit proefschrift 
beschreven genen zou kunnen bedragen aan het uitsluiten van een kleine patientpopulatie 
waardoor een effectief medicijn weer veilig is voor een grote populatie. Naast een bijdrage 
aan inzicht in door medicijn en TNFα geinduceerde signaleringscascades in HepG2 cellen, 
hebben we deze kennis ook toegepast. We hebben een platform opgezet van cellijnen die 
cellulaire stress responsen detecteren en waarmee nieuwe medicijnen getest kunnen 
worden in een vroeg stadium van medicijnontwikkeling. In dit proefschrift hebben we dus 
bijgedragen aan zowel mechanistische kennis van TNFα signalering in levercellen als aan 
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